var title_f28_29_29136="Mature cataract 2";
var content_f28_29_29136=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mature cataract",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 272px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEQAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxSOTbkAnrn61YXdIuEcnnPBp8UW/J5xk/T6VZgsEaRc8bfTNdMnchNIRQwOyMlpD6HgVejiIjKyBmCjIH9at21kkURKLtXrwOakmiCoCozkdcdKqMTGdUrQMDHvycDkjPNPjjJAK5VmJLN7elWEthISSP3UeFJ9TTLi4jERwSqKO/fNddOFtWck59CtcTBI5GDsqA4cA/pXNapqLSF40dsepGadq18CzRR/dP3sdTWA0jM+ODzmnOdtEXSp31ZMS7c5PPXnNOSR8d+vH1qFWITPPocnNT2MEk0h46nqRXK+52RQ+ENkEFs4/WtWztJbhAOhzyMYz9at6TpBZfmXg85Pauit7QQKy4zzwwrkq11HQ6aVFzZn2mn+Wu59xbHanXDHKqQQQMjBq7Lu8wkZDdelU7oBmMgJB67cGvNqVXLdnp0KKT2Inn3REqSCCuDnrVKTcVZi5C8+2KshDIGXJOe3H4f1rMfUYBK8cMxfYTulHI6chewA9ayinLSKO+TjBXmxz3GwBV3NJgPgnAX0ye3061jXuoFGEayvd3R7g4VOOgA9/5VHLcT6qWjtYo4LYHC47nufc+9bukaDFZR+Yd0tw4+864Cj2Hr71206KguaZ5OJx/2YGTZ6bLdyCe/kZ24wmcKPausgst8HBOcgHnGB/hT47GLYu5WXGTitnTYyFGI89vmHAHrVzqdDynJyd2UobYGKNUBJ3EnAx6f/X/ADq9aWzqWdtwX65NbNrZxu3zK27oNg/PNX2swVxGCpUdD1P/ANauOcykZUEbFztwNxxz9PWppbP5BKW3KW2gA9Pw/rWlFZ4jYk5JHfoDmrgtSTEuOcFmz0BPSudstGCtqVDbQwPuMFTS29sxf7wHoO9dALBiZD5ec9SecmmLahTngY9uKhspGebFZHKuCwzyxqf7MFD/ACNxgKQOK0raEO4OSMc9asNabsHDH5t1F7DRz7WTb1wcZJJxxxV+2smLBUznGcZxj3rQS1LElgeccGrJgVE+RAGb5Sc8gUXGc9rVs140SAyLGo2oo5AXPTFY5tZScrv3gdT2+mK6y7h8tuQAp44HQdvzNZrQBAW25J4PGKxk3c0ijFEBy5kDFjxwv9SauWFlZbJ3uROWZMRNGwG1vcHgjt2q+tsN2SgPoM8VZW3HlgHaH6cDpWsHZbBJ30K1poF3HaR3s0ZFvIdm9cHB9D7VBq/h95rQzRtPZTFSkd5HF8/uuTww9VNblqG2MgeUIeoJOD+FXlnuIlVIp5VAzgBiNoIx9K0i1zXi7EXkkeM6r4VksdhW8tpFeMMTuMQDdwA2fTNZo0q8EcxW3mnEKmSRoVMgVB1YlegHHNe8Lcyy20ls8Vpc2753xz26PnjtkZB9wRXHat4aXT0e60q+MYDfIrs8chLcFc9MfiM1106vI9Xdf1odlGvGppPR/n/wTzNAxXAbI6/TmnrIcEPkc1pajZsGZnQoy9Qy45/zxWdLGQhcjYSQdo9O5ruhiE0aSw12Z1+DhgobPpWbBFKXBbP4+ta0i7pNvPPFWfs64C7c+4rSGIu9Tmq4Sy0MS9jLRnBx04qCLT8licnJ4OTWvJZMJSWGV9aeymPPB9ea7INS1POqQlFWMKTTmaTC7gR1qtcWUsaBmztJwCDXU4GzOM8fnUeBdhoBgYPX1qnBT2MVVlBnLLJJHgtkjpk5qRSXxscjAxjPFddBoqSQlAvzc5rIu9BmtcsoOOoGORWNWg4anTTxMZaGUdx7HB9+1Im4ZxnGfWpwpRiHUZYZIqSKMEHg9ea4pKx3wqHS2tsWfapAOTxWrFb733E4ZRgAnj6VLYQAMxx19q0lQhGLjco4xiuxRuePOZVtwNwI4jxz3pRbtcKCXKJ228E8+tW2gCoIwCN5A6fjUOoSm3jAU5AGTgV004rqcs5lK/kEdviNiUJwcEenT865PWdQyuxMjJxjNXNZuwjMRyWXAAHSuUvJGeQnB468cCtKk7aIKULu7GTS/Mx6kkEHNIADjGfbiolO5uCMYx1rUtrFpOoA9Dg1zu252xRHY2jTyEEfu/511Ol6YMjC8KMn/AVLpunqAMAACt6GOMRYGPl5GOv41w4ivbRHbQpKb1GbFhtw3ZDjA5rOuLvL5B2nphe1aN3kQkJx39azltiZGPGOua85TT1kezClypJEsDh4iCCdp4xSR2rMpIJdiMnn0/wpYVLjAXbngdhx3JrH1fWYXRoYH3WqZD7OHuW7hT2T3rm5ZVJWidN4Uo80ivqkhuVmhtZCtuuVkuFON47hfQep71zlnYS3iFYPktWzjj74z6fyqSeSXU7mO1iGyIfLIEHHH9O1dho+nKCgb5QDgr1x3r1aVN0oHz2NxXtJ36kOjaWkMIEaEYXjNdDZ24eIqyE4wxIHNaOl6dvlAVRhxtUHuavQ2e3zY1ACd3weAKzqTucFzJa2MzgEFcZHPp/Wr1hbsGjQ5Hfk9quCzlZxshY7juBKnpWlZ6cyzky7ztOP6VzuRSILK1Z3AGW65GK2ra3dOANuRyCOPzp8FsU7cbumK0Iofmzz3z3rFmiI2sU8vgfeHp3prwjzC2W7Dk+la0SkxZYcDkf5FUpIud6qN2OpFZy0LiQooWCRkJOR941BsyQTt2jt3P41bjhLowkc5I5/pRHEFA+Xp361DKSsNsrXaGkOMqMYByATVtLYJgkAdifXvUkK7YlUAgMxYge1XETKAkZycnjvVWBFW3tFkZRsP4VYS3UZABIxjPtVtI2jLY6nAH5VLsCQvhMuw2jHYUPYaMG5ty4YH7p6DPQVnCyKblABz1966B0zgFcjqKiWEEksPbgVnypsu5jCyCn1GemOlMa2ySFwvbmt1oMjKlSScYIqOazwCQG3HkkDp7VXKFzLVFIG1TtHUY5qdY97BUBAH3iTkfnV+KzYqACck84B4Hr+NTpEIwYwuUJzjHU01ETZltbg4G4cHkYNNa3SRGDqsiHgoRkN7EHtWo0BG5xtHHJ6fpUaRs5xkYHTNWkQea+LvDclur3NoZGtRy0Kknyx1OB/d+nSuJvMBTlFXd6Ekfn6V9ASwAoxOMA4PtXlXjPQG0+dpYF3QyH92ccqfQj+tZyqOnp0Pby/EKo/Zz3OKCLHESNrFuhxwaWJHZx5iYGevUVLb2ZuDIVJ3j5vQVcWD5T5eCIQMvzg5rug1YqtOSlYSOAvF8w2gYwcDNZt5biIEctnnk1sJIHg7Er1x0//AF1HJB5ijfjGOmOnFb0q8ovQ561GMlqcwxdcjoPrVmzgEbBwcY5NWGtQFIIyV6ZHUetOjGGwcfSvYpTvqeJiKPK7I0YJxIEXO1xgkjpW7b2iXERVlVmcYB9a5RWKOCuBXQx6ggtc8h1GQQea7oVIzi0zzqlOUXocf4msFs7gg/cJIwB/Ws+K1fadoyM8EV0t7/p12jSxny88471D9lSMlQxAB4DLXmTo3O6nVaVjpbGL5mG1sIc4/wDr1oiM7cuuVIG0D2p8UayDg5GcZFLNciJGBGccA9QPxrSKOObvsVr19qqSzALyFzyCRXK6teMhcvnJGOnFbN9OItzzchhyc9+tcRrFyZZSN2QeK3TsjOMeZmXcymVxuPAPFQKhx6A981I67toB/SrkFqZJFIGFPPFc0p3Z3xhZEFhYB5SzjA7DFdLYWQcgLtCjoc1JZ2W1QFUFj074robexNvBnaRuHHGe1c9atym9Gk5akMMCRqApzxyT35q1Gqjhmjx054zThCv8O5OwpkkKh2yTkjkAV5NWomz16NFqw25thzjGOhye3riq04UHcq53dOcVYVmAVdpYDr3/AEqK8nNrCG+X7Q+RAhONzY449B3NcUpNux6lOPu3fQwvEN4ouP7NVyi9bqQHGwH/AJZj/aPf0rmtSP22eGCzjCy42ccCNP8AI5q3dQrpk5WdzPOBvkP95z3/ABOataHZtFMWcCSd2+bP54zXsYajGKTieDj8VJ35y5oGjxW8MahcnGQcgEn1NdbYaeisi5+bjI9feq9nD91kQYXg8V1OkgN8h2gpgKFHUe/9K0qyueLe+pasrIBPM+U5/i28Z9q0LW0CMSQrHII44NWbeAogKnawGSp5q1HGSAy9uK45ForPANitlgfQUiQsjF1B9STWgsRChMdTnkZqaNDwWIGTyPQ1k0aIrpFypYjNW1j4wQQcg1PFHlflGWJ6+lPCHPOPfFZmm5AxALbec4OOlRFNzY2/lV0quMEe+TQsRxkYBOM5qWWiCCNon3Ig3YyAehPpSyQrvYwptUngdcCrH3DleoIPSngEdFBHXk0m7jsVo4QMAgnngirUcXygEY59aUfKSVA59O1OUn2zjNK9irEjYZienOak3DZluM9s1Eo3c8GlHTuW6AGgpIqS5LtgKAOgqFuSMD8RWkIBgM2MCnfZF8oyE4y3H4dqSiMx1Do0jkbkTqD39qmsQ8suEBbcdpBq+LZmjUbVABJGB1JqaC0ljRyiMDgDjtnOT+WKpJ9REBcZwoYL0ye9N2DO7JzjPNP2MuFYH8qVjgbWGT160BYhliDAZYbe4FMWJQwAHJ9e1TOSCWI49KFKnOOc+tTzBYryAZUEH2BrL1fTodQsZYLhSVYY9SD2P1Fbbq2c4G3PAHeoZI+pbA4xiolZrUqN4u63PDtRsJdM1KeC4ypQ89gQf4h7Go5lVkEcbEL12L3Nem+MNEF3aG6jXM0Cng8707j8OteaSRiNwhyQ3U47HkUoVGvce6PocPy4mPP16lCZMoY4s/eznOKuRR/Ls42qNxBGCfxpojVtzZwwOcdqfGACpdCx+vU/1rpjUtoVUoK5WurJ5v38RVSowvXBwKzWi3LvTIbuuehrp4mR4wJGClvujPSsnU7doJGfAKsOo5Jrtw+K+yzhr4RSVzIY9hjcepqOSfDAZPvg1LP5caZXIU+px+lZw3NJyR14r04VtTxqtCz1N+y/1YbOQBnbWlC0bJufbk1h2VykMgB4Pv0zWtAQyncRwfSu26kjzZRszo1V4wWC7I5OBk9D6iq9+djHaQUCjpwB61fuJ8cMCZFbKD19K57V7jy0beRh+cep9KygranO22zD128Dq4Awv1rkHZmZjliM1p6pcKWbcwAXgdxispGzkgH5j6df/rVFSV3odVGFldkltF5kowD6V0djZ7FXd17c9aq6TagMu8DnnJrp7K2JQhgeawnLlR0xXO0kXNJsfNlVv4V/iPY1pXONwABJBIyxHX0q3pyQwRhSo3AdfQ1JJFujzuAIBP4V49eq3I9ajFJWM4RyKCc7sn8BVd1Z3LTKAOBgHHOa0IowRxkAjoTjBJ6ClmtSikujqR3Y8g+1ck+ZandSqQfumUFjUu7kKEBYk9OOprng81xPJqE42B0CQI3BWMcjB9TyTV7xdvGlx2se5WuJAp4ydg5Yn8cVzk9ywjn+dwFHloMZGa6MLQcoufVk4zEJSVJf0zOum+26+XUdxub3Axmuq02JVWMhcnOTxWV4f01jveQlpWOckcn2rrtMsGL4ZWY4yMdq9lRUIKKPl8VW9pNmto9mLpFxuK7snHSuntbTyV+Vc7uuBiodNt/K2hQeuD9cVvxQOApIGD3Pf2rjqMyjqR20ZBIAGRwc+lXVTauCGDduc0qwY65weuKmiQkBsgEc8iueTNkhEjyCOe54qURnf0I9zjmpVQbT8p6+uKcAMdh3PtWLZqkNUDPBb6ZqXGecUxecYJxnrmn45HpWZaE25Izgk8D2oReD7e1SsuePmPHpwacsYwD296TLSISpLcg06JCW6ZHvVjGQOhxTlX5T2pIqwzyRjBH0zSLGqMfUfpUpHHBprYAIBPHPFDLSGSEZJQEAjqT39aReRzknGePWmgFxzjk8e1WEjYKckkn8qlFWAKxQYHtUm3eVRfuLwMd/enBTjbzkVLboFmHPyjvWsNybHU6Rp8axI8iBjjjIrTihT52CjLnnj8Kr6ZKr2aMpBFXFr1VFJaI5r6nOeJLCNYxPGoU5wcVytxBjnBGec12fiO5EcKRqcOTn6VyU5D7jId2BwPU15NdJTaR0U1dGcwZehIPpSBPmDENz71aeMsck5NNCdOK52zXlQ1TnqCKaUO4kYx646VIE9eT6CnqhG5iPl64H8RoTYNEDRBlwfm9j3ry7xdpA07UXNvlYph5ie3qB9K9VP38gn8BWR4nskutKkkAAntwZEbGccc1E/wCfsdWCreyqpdGePPEEYKinPU8feNPdSMevqD0rQWPenDAtnk+tV5wWJypRc9B0qVM99ple2jP3hlh0JP1qS6t0e3zu57kjrSRqE6E8jJPSrKKZAN5BGDlccA81XtGmS4o4HVEMUrAbuapW787XznPBBrrdfsDITtRgSDXLeSI2JJ5ya9nB4lVFqeVjsPZXRbK7GVi2R2x61oW9wNnJLe+T6Vhl1/izgdAeafHOFBCdM16sKuh4FSjqemXmFlm3Ftu7CnOcVxPia5AKAAbRk49D/n+ddXqFyfLkGcjPIGOK8+8Q3PmOcc9jW1tLHlx+IwpZDyuM9+tWrJDJKvcDjGM1RA3t1BPb1rpdHtMIq9wM5rGbsehFaGvZWwVFCR8kAZ966bT7VtyCUFR1z71n6XbPJcR7t3A5/wDr11Gnxn5hu6ZIJrzsTV0sduEpWbkytqAeKAbcshOOBziooJcRc5Azx3zV5IHgQrgsrZ+VjyT7014Y8s6hmB6gHpXnTkrWO6mm5cyK8rFGGEGGG0kf54zVS4jEtxGUcopU5DMTzV54wEJLcH7pHWsvWLxbDTZZCCXlXyolP948Z/CsVObaiup0xpQs5y6HOrf+fJLLNhnZ2VNrcqnT+maxrl1u9UECgGGMBiMdWPTNal7psFtBHOJf3aKAw4+bAz2rD0XzGuZJmG7zHyfUV7mGpRck49DxcVXkoSb3Z2Gj2/yoCh3cc5rtdKtVUYKDJP6Vi6PEHRQjYQrjPBwa6PToWidmYElTtBA61tUPETNWGJNwUbcjvWrEjLjjt+NZ0S4fdgrzzWnACOTlsjp1rimzeL1LUJJXHfofpUvljO5sj3FMiOMelTAF+h4rmkdERBzgLihss2cA47VLtJA5wOOlCx8/MWz3NZSNkhrHBzgDPXmnBTjjg+9SAHbyT7DinqOD1z6etQWkCKDjcefpTwoyRjBNNTg9SKlXODRc0SAKBgE47UhTHTpT16jufTiplj3eoNNRuMrhe4zSFCat+TtxntTSjEHrijlBMhEajp1pQu3nqanCYPrT8YX0z0o5SrkCA53Y5NTbQ3PTtR8wzt64waXd3x780XGWba9ms2+U5XoVI4NaL68dmFhAPrnNY0rDYMHk1AXI4P8AKq+sSirXF7OL3Jry5a4kLynLfyqgwBPNSP8AMcj8+9RsG9ciuWUrs1jGwHpzTcCndsE+9NOc45NRcuwKu5xginnBPB4FNbKrgkgnrxSrnuCKpGbQm1R054qN0A5YZXOMevrUrEjpye1RnnryfT0qrJoh6HlV7aPYXVzbOhC29w8SkD7ycNG3/fJA/Cs6VMSleSCDjNdZ48Xydd0bcW8i/WW2du/moA8f6bxWLFbxC4Pm/M6HAUjGa5lTtLU+io4lTpJ9TLSMIfnHLD/PFTwRqGDOML/OrVzsG5lVd3ovaqckrbcA7QeMdz9KznLXQ3jeS1K2uBHtsIBk8Z9a4TVYPIcmQgMeQortbqVlXy1X5sH5mOcVzGpxCUkEMQeeBXTgqrpyHUpe0hY5V5Tu69OKu22Gizgcn3qldxmKYrjjOM1Paf6n8a+lo1LxufMYilyysdr4huEO5YDtlz0Ycge9cBqbnectnPIHpXXa/M0ksrAkgfLyP8964jUny+c44xXbzHhQjqNslEsw7gGu101cIFGMjt61ymkw5fdjJPTPauu0obpVwPlGB161jLVXOlu2h2mhWvk2rS7cM3rzWzZxssDOCBxjkY59Kq2ceyzyFDKVxnpiroZktkiGD2OemcDivErO8j16OlMswQfutxbaSBgnuabc28e4eVhXB5x3FJFOyIA4Al6AIetCTFsMyZH94due9ck00zWErq6M27tlZAABnPUHg1574tvTLdW9kyECAtI7E9SRjH0HX8a9MvziJvJ2kEevA+grynXvMvPEd++wqgk2YIHAHH866svgpVrvoicVUaoWXVlLVLzfYhVYbM4APBYVa8N2jTAKoOcAADrmqGpQnNrARjILljycdK3dAUwyKFLB8gnHc171GCUW0eDjql1GHY7XQbQIxUny2U4z611cELbuVI9qwtDxv81gQGbDj6jrXT2S5AGCGA6/3hXPVOGDuyxbxrnPAx05q2i7Tx0HvUMQAyVye/NWkAwCBg+lcM2dcCVRyMj8asKCVHOfxpkUZJBPSpwpHrWDOiI4DoD0PFOKcdto6Y70oGaei4Axk+tZM2Qzy8E45p6ryvBzg81KEHp707Ztxik0aIiVWB68elSBeM4pQuTxUyRnHce1CRQ1I+9SBSB1oIJHpTlU4607gOQ5GGFOIOeOlCpTgCM1aGNCcZxQPunipSCByO3Sk4x6UgKxjLc9M9aURjv0qfj0pdvFZ2NExsaLkZUH61FdR/MCMZ7irK/eGabIAc+tVJXViU2mZzL71GVPPTHvV6SPOMZquwIJFckotG6dyqQe3SnhSqnt/Opdg7j9ajfl8AgcVJREV4704cCnryB8ufxpO/8ASqRmxNm4Zzg/SgJycD3zT9rAZbP0o5PXp7VpYzZyfxFsUl8Px6gOJdJuUvsgc+WPlkHt8jE/hXLX8amVnhyFU8jOQwI4YHvmvTry3S5sbm3lVWSWF4yp6EFSMV454IMkmjaf55UCa1B2nPBGQBz3wK5q6+0uh62WydnFj9h8wBUJOD+FQ3CBAQm1pMdfT6VsXEUmNvz5/uqMVkzxttO/Ax1B7VjClJq6PUlWgtLmY6FYpNzMGYZAA6Vj3URfeQPmAHTt9K6JolY4Lsv+70qhIipM4XPKjBB6GhXi9jWlUTTOH1e323DErhTg8+lV4ThSM9+wrc8RRjaG7Hpx1rAiJ2nHTPGDX0GBqKVPU8bMadqmht61IVzjkcndmuOn/eTkLyc4yBXTa9J8zkhhzx0NcxGpaX5vXtXs9D5OG5u6TBx/THf2rrfDEAe7GVbr6cZ61h6XCPKDDoMHiu78NWpjRZHGEc5AJHJx+lY1p8sGjenHmkdA4ZolXBD8c4609Y1GfMVmYn7oXoPWiZ8yKOQR79qUvIu5oDhifvN/KvE63PWatCw5oYvM3IcqeMg9TTp43iP7oHPGQF4xUUZn8wM+3DY+Xg4q4SdnyAEA/MCev0rKpdsVP3UZMqKxZABuzjIGK4OKzLG4um+ZZpnkOTyRur0TUgkMMsqptYRMePUDmvP1nk/sdomXy2iwBkZLD+I/TBNXh3KN36G84xnGK9Wc1M/n6k8g5XO1cntmum0iELtY8HGe3NcxokfmTSDGADgDHP0ruNNt0xGu1ixwemQfavporlgkfKYyXNWbOn0xGdjsA2oAMAc59K6bT1AzwQQSBk1z+lMYyFKqCRyN3eumtwRwcDjr25riqmMC0EGflxuHU471ZjGdx696bEhK55P0qZF4Ixx3561xSR1xZPBkDkY7e1T9R3zUcecDirCCsGdMBqp93FToB3NIFGBUqLnjBqbG8R6hMYNOCr/DjPrTgq7ccDinKoA9qLFDdoJ5A/KpNmRxigKAeOvvUijFFu5QwR8U4KBUox0/OlZRmlYZHjA4pVX1xTgDRxmgYjAHsKbgfjT+3SkpMaEUA8f0o289aXntS5qChCB1pQcr1FNfpSqQRVJiaGkDpUEqdTVg4qNuRWc0VFlQjNIAOeOasNzgY561A3HTrWDiapkZ6+goGe5zTivXIooRLE7UH86NvXr+dOAxgGtIkMjI2urY6EEivKbC1ls5GtZirRw3twkRA6x+c238skV6zLwCR6VwOpxtHqt+skKIiXbtHj+NCqvn82YVy4rQ9DLZWm0VZIpGDMkuAxyRjpXP6okUMflArO5YFj0HBzgetbk85VnO3AHAbpkYrJvnYwkgKwbqCOnpSpYjlVmds8O27oxbi+jLiHCo5XAA4/CqxzHdbGQvuTd8p6YOMYpbm1gkLGQPkHgngCq104+2QESFUB9c8YPFVOanJWOihTcE0yhrkamGT5WGGOB1NccTgkJtAHYmu41J/Ngkfknr05xiuLcDeRwcetd2AlaLRhj1dxZZ16VWZ8EnnrWLp+Wk3HnBrX1oL5sjYAOT29+KztJT524z1xX1C2PiYnU6UhCAYJGQcV6JpEZNkAoHC7utcJpUZMkagAljyM16NYxGOJQFyMZOD1rzcW+h3UF1GvJiZAcggZ47VbeRRIS4I+TJxzx61XtiI7x8KCMjarduua0I4kuZH8wkFQecZ/AVxR5U1c6qvNJaFe1K3cg+zxvvDDjHQVoqpAY4Owfe3Dke1VFYQxPFZkxxscnjlz9e1P8AOMm1z+6nXhwxPzr/AHh71vUhSexyQlVvqVNbRJdPud6kMI2C88jiuFvCkNvZxqCBM4TjgL6gn34rvr7Y0BMefnXY24cnNcXMFkSOBkDOJSqAfw7eQT+Ga4aNozt0PbjrRv1OS0b5J3P949T/ADrvdLgDpE5BV059vrXE6VGftEq5G5ZGwOvGeP0r0XSijRhc9Og5P4GvqLP2cX5HxeKf76V+5radCAThBg88HqPxrooUJRcZ/LNZWmjdLnbk5OMfTpW3A3yf7vQ1w1SaZbRiGwp7E9KnjxnH9aigUnGQfxGatxxgc9TXFNHXAkjXA/8ArVMi8fjSKo7DgdKnjjJUY4J9qyaOqKGxr16+oqxGpwB2p8ceMDoPaplXHXqKVjZMjCd+3SnhQPWpNuegpQvPQ0WKuNVR607GPrTgvNG31pWKQ2nD3oA59qXFIoWgjmhRTuTSAYUoKDFSHGcHFMxz1FKw7iFfSmkcU/FIQMc1LQ0QsM9CfypEGDn86lwCMZppGBxUWsVcjZvr+VNBz1/lUmPWm4x0PFQ9ShjKaiZCSMVYPPU0xhjoalodyIocE0wg1KxO2o/qeamwxpHFL9M0Hg0nToeapEMaxx61wXie6jk1uS2QEPAYkdu2WXd/LFd5IcjnpXmOoF18W67FJt3fa0nRt3Ow26YGO2CprmxSvH0O/LEva69iK7kJGSNy7iNpFU2O6MlRwegqSAC5TcXG/qyjOB+Jp0tp5SMxdxGT1YgEfhXL7KUdz2HOD0Rz13bbiSBn2OelYeqSG2j37AcbWBxnBz3rqG+aYIJPkAyPc1QurRZGPRlbhs8jPvQqnLJX2NaaujGnlDWsjDAVgDgehrlcMWYrnGa6+WzSO4cDnCZx2GDWILRMtuwDk9K9bBxTuc2P0asZWsoQ8igDAPpVfSU+fJxgnoK0NXDCVzweTxiq2nRkMoBOa+pjsfCXsdn4cizcRgYIPqOhr0K2G3BBHPU7cCvN9MZo3Vs4cAYPvXcafdPNGAScAZYkd68vExu7nZRloTqcTNjj592cYFW2BWLIP3ieaqSQyC5H7v5Rhjg9+36VoNuPGdy9SDXG1a1jubumVYJWjlUZ+YD5cCrE53DLKcE8EnOPWmja8hOxVI6Cn+a4XJIAA5AFZSY4mbcSvnbxtXsO1czdQCNtQCjbJEGePjHVcA10epMP3gUnpnp1PpXL+ILhrG/tp9geGaLaCf73ofyNGHg5TsjvlOMaLk9jlNOmddQmcfI+4EjHT616LpDloEzy2eCB0Nee3H7nV5igzGxDgHpggGu+8OPGsYbHzDHA5r6yOtJM+IxatWkmdjpxACjvtJBPBrbjEeAB3rnbBg9xHgvs6BsZ963oZCVDZPJxjpXn1YkwZfgGBznnrV6MD1qrHgYJFXIfvcdxXHJHXTLES5xxjmrUYx3qJO3tU6qeMdKyaOyI8ce9SAc+1EaMz4ALE+lWhaT7cmNsfShI1RDj1NAHpUhQqcHcDQo+tKxSIwKXp6H8Kdt96ZtORUtDQbQTTgvHtRjnqaWkMMUmDTjSCpaKuIevFGfegjnrTSPepYxSR601hmlxQR3pMaGjimNTjzSEGs2MiIoxzTzTT9agrcB0NRnnr/KnGo2PoaTY0B5HFRsMdB+FO2kDr0NIAWHNK1wvYiPNI2ADjr9KcQVyKjB59qaJbGDBI3ZC9/p3rxXwtLPqd/qut3LDFzdzOOfujlVA9goWvWPFU8tn4a1i4tdwnis53THUMEJGK8t8JqkXhTTFiXCG384nBAYt3rnxLtCXyX33/wAj1cripSbLDK6l0jYhQMkjoajklMkZ5bg8NjOanVXP8YIxxj+tPFuJCUxImV+Vq5oOUlZs9Wooxd7FSNFdmBXGBnGOSaNg8snjGOM9CatRjIxgMVIBbGN3+NRXAjghOQCwB3egPpUVKdnYUKl3ojnmjZpZySAcYz9a5+aJxM4CKfmNdcIz5cvQnJrlr1h9qkz1z2Nd+FlZWJxb5mZOppvdznHzEA+vNQWo2Sc4XHU1o6kBNnORhgD2xVKNMyEscc9+a+upu8T4GpozcsHLI+ABg55rp7GR3CCQ4QkfdPfFclpo5kAI5FdLZSxmHA4KkE4Gd3tXLXjc1pSsdDCzESGRmbPJyxB4/nWhBJuVe+4dKq2XlB43Us2VyFJzgg81Zt2lWYsMcHIyK8yppsetTSlcgmjZXZRJ+96tnoKuLGWUb5VJ6kA9aj+ykylskt1OD2qWN/LVi5zyOnH5is5S6ChG2pnakiZ+VTtI+n61zus2aX+jXEUgy21ghx0bII/kfzrq7wpKrfM2GG0tXNas5trffwq/aRwD1VuD9P8A61OkmpLleqOyDU4NSWhxMsQgFo0ikybDHIpOdhHAH6V1Og3MEfllWfcSMBug9vzrD8Q2ckM7uGDw3MpmV/7rAYcZ9zg1PpRYeWRkEc5619RhmqlLc+TzCk4VLs9B0eZPPUJ5gXczFW+UhcdK6ayQorIxLEH8/eue0iFJrFZ5diyo2Se5NdJpzIsKyJuYP/e746/jXPXRxwNa2GVBP+FXoFwdwxUUEBIODkkZx7VZgAIHzAEDivPkd1NWLC+xwatRqSCSahjA79KuQLnGMDFY2udkS/pSYuVJrZI9KzdOT96pz61q7a2itDUoahFu2nofWs54ttbdzGDH0zis6YfKew61DggvYoMADigD5f8A69PYfUj60xupxWLLQntRg96UZA4z+dHWpYwKkcUCjvQTzx/OpY0I3UU09KWkzj1qGMX8aQ0hIzQcUhjSOaMcHpSjB/8A10uBzj+dKwyA+hFMJ46VLKO4qAk8VjLRlojkbHcUhbB6A+tPbrmoWySOAeahsu4qnuSMelLu+lR/mTmmlu+cVSZDQ+bB5GKi4A/rQW3cdu9MkYDHT0ql3IOZ+JWtf2H4M1G4RVaeVRaQqehaT5f5EmuSgjjgJt9+1FIjiTPREUACtH4lst3qWgWBz5cckl/IvXhcIgI9CWOPoa5ZpBLOQ2VwSIyG6YPrXLNxlK0uv9I9zAUWqDmt2dO9o6xeWGRWYZUE5J/wqsgAZhkh17E1W0/UZIkaMjch4YMBk/Q0S3Y3ZCByx79RROMU9DWkqj3LblOWWNtx+8fU1i38hX5FLFgCcHHsavxXR2EHCqOR3/H61g6vcgFmZtz4wea45u8jtoQbYqSqbRTx86E4J9ea5GeTfPIVyRmty9uBFYlNxAUAcfSuWSUHJDOcnOa9HBwcmzHF6M2tQtysYDBvvcZxwKzZYyjHkY+tdLqK7nIcEqeCcY71lahalACV5A59MdhX1lOy0Pz+ZBZ/61egbGPxrqtJgCEAqQCOMf8A165eyIVlGMEEYrs9HQtsOBtx83uKxraGlPVI0rYNFLCTgA/xA5461tDagG0gs3Of61n3cZWMFdpIPAx0q/H89uHBwVGc4rzKq3R6lJ7SHu5ESMTyewGM/WqnzuXUcjPfvV+PbtJDBjjIGO/tVd4jG5ZmIGcD1PvXMkzqlZPVFeeIouFJBA/WsbV7P7TZTwEfM6kBuwbtXQhiV2Dc2emVzVG/SVYxvxz04qVo7o2pu/us870W9aQvp+oZO8+WNw+4wGM/WodKJhnKPuyDt69K1NW0tB4gR42ZFuBuyBghxyQPrUOt2jaffWsqBvLnjxkjADDt7HFfSYSrBzTX2lseHmFCaptPXlf4HUaE/mIiuWYgZZwfumu30tv3Yy2RjjArzbQy4CbWJOc8da7vSpyQij+IcNnrW+IpngwdmdjazsIhgANjGe9WYRjnAGKy7WbeDuH4YrWhPyj5h6dK8ycGjupyuXIj2x35q7AORnFUYmGeuatwnGM4H1rK2p2wZs2JAdee+K1KwreTAznvnpWml2CBkc1aZsmTzfcNZMp46Zq5NdArtA61SkPGM9eKiQbkD4xjPH8qhxipGbPTB96jJrCRogBxQDg0hpP51ncYveg0hNITnpSbKFJFITnpSduaQ4xWbASmk807rnFNPvUsoQMakB4qIGm7+O9JTsA+UjFVjyc/yokf5h71EZDnAJ/KsZyuzSKHPxzz9KaW46YNJknkn8OtDNkfSpGNY56cfjUT4x9aexGM8GomOQBx+VOwmLmq8v3+BjJx+OamIP1rE8V3smn6NfXUP+uSMiIY6u3C/qQaU5csbijHmkorqeb6ndG817UtRLvumlMCBzgJDCSqqPq25z6k1mBhJFxjJOC3bFSYjitVgDAqvyZz1wck/nUYXHy8rk8DGTXLBXdz7ClBU6aiuhfWR8DoQMZ44IpHnfZ8qYDY68GiMBYwWckgcAiq8/zHIJVuOD1q211M2tdBstxlSPm+XPPUZrElk86fIJwgyR6+ma0NQnCowBA3cNjjNY9u22B5G53fNz6HtXOlduR101yxuyrrt3+7CgqE28gE/nWJC+9c57+tTa3O0swXByDg1VgQGP7xr3cDRfJc8LH1VzWR6NqADwu4Zd4Gcc+tVmUXdiW8sEjOQeo+gq2pLR55YZxjjOKm0e3QqYgpKEk5PXHp716ybjJPofHTimmupy6oYnHHfPFdLo16R5fBxynHf61l6xatE4K55Y9eOKfo04jfDfU5PStqyTjczovoegrIkluqgYUc5xn8Kl0+YeW0PBbJU+9Y2j3SukgJJwBhfQVaZjDcCQDaHH4D3ryay949bDO8eU1LVhkK3BU8464qWSPdLufOc4Cg4NVZWVbhCndcDnIq1bgs6YOT1B9Kw5bM7JJyVxRJ5cRyFRQfzrOmKzFlckE8gsa1LpT5bhU6AgDPX3rnbhXaQl9276U1BSLpaIyvFFg1xp7GE/v0IeNjx8w9PrXL6XeHVbY6fdkhlTMXcmQZwfrz0rvXXzIuc4YYycHJ/pXLRaX9l1l5UcJub91uHylxyUJ9xXoYOrFQcZbrVHPjKLnKM4+j9A8OTySKY32mQNtbPBUiu9sMoq7QCVXkZxXAamJLLVpLrGyJgCwGNy44zxXQ6Rf52MzA5GQc8V7iftoKZ8riKTo1HHod1YzkBegIHODW5bylsHJwexNcjpzIWUo3yZycnv7V0lo+cd8dPpXHWgFORuW5OTgD6HpV2F/lDe2TxWXA/wAuCc4zjtVuGXAJODx0PFefJWPQpyNGKQgAAkj0xVlJgTnOQPwzWcGIxnIz3x1qZZDnHJ79KzudKZeMmMDjJpkjjkHOfpiqwc47fl0prSEEc5I5B9KiUjRIeWPYYz60wHJqMyHtz9aC3pWDZoiTPvQW9qj3E8HtQSc81DY0P3e9Nz6daTP59KQtjipuUOPTpimk1Gz4PWmlxjmockNIk3c9aGbg9Ki3Z6Uu7FRzDsDHnIpvXnPNNaQDJJzUDy4J/u1DkUoj5CwyAKgGeetI0hJweDTC+cdh3rJ7ljywGaaHJNNDDkEde9Mb04+tOwiQuTnpim5LHjqKarKAT/KlVgeMfn2q0iGwY7ee9cD4+1QMzafExLxKs0gHZj/qwfxBb8B61291cJBDLLO22KNS7MewAzmvJNXulvdVuLhEYLK/mtu6/dAUe2AB9KxrvaB6GWUfaVOd7IzoxGVILYwcEjnoP/rVOIv3QMb7iDyTwRVMBWbMZKhTj61KJnQ8xRvk8cdvU1pHlaVz1qnPF+6ywg42b8sepHQVDOQCDntgEnJp6XI2knCE8bVNU5pAVLEoVB+93rOtTW6KoVZN2mZl5mWVEB6nLZPQUtxEYowWXHBIBPUUKVlmLKMhuBx2qnrlwEi2LlWxjGefpWVON2oo68RV5InN3bFzn3/WkgRtnBPX1pnLH056EVoWsYEXzEg57V9XhYcsLHyWMrtyudlHOFk2vhdxxWzphCXCjaXKc7QO3rWW1s25ihw3H3jkEVY024MM6sxZXDcejClSlzqx5VeHK7o0dftkkg3bcpnnHUGuQjZg+4KAo+UccYr0y5s0lgd4mZTLhvpx0rgtYsmtbnYBtU5+lddO8oWZwp8s9Da0eXaSNowcckcgV0TQrPEVJGWHTFcfpkojCAkgnvXTW9x0Lfd7D2rzasXzWPZpO3vE9q2IhG6kvGRnA7VpNEcK0TEE9xWY7BWjmi+Yg4PHar9s4dV3sApOQP5Vzzjqd8HzK6JtzbsBvnPXvmob63QtgFt+Owp6EJcYYqEB4IOc1bVYncHO76cGpXulNW1MCCKIb4zCTuPG/jBA5xWfrNmbmznhjbYxUMAehYHI/Hrz711NzaqF3d88Enkj61j3O3IBJ4x3z2rSM3fmRUOWWjOJt2Gox/Zp5HW8iUwtGx/1i5zwexB/SlsXm0u7+x3Cnen3SRjcKZ4u0uUzNfWuTIv38DJIHQj3qKO5OtWC7wkV5BgqV/j9PpX0NCpaPPf3Xuux87jKF5Om9+h3mlTl4vNLrgjPHQV1GnXhOzJUE8da8u0LUmeINjGPlZff6V2Om3/IDMAD71pWgeMrxdmd9bz578nse9XI5OAAefeudsrj5VJ554rWglQrxtbPevIqRsztpzNRJABwcc9BVhJAfrWUk3qasRyZXrXO9DrhK5eMgzycn60m/niq+/OBnJ60bs9DWMmdCJ92OtLvFVi2AD1pA5B/rms2aJlndzyaN4PQ1XByOTz9aUtzis2WmT7/AFpGkyOOtQ7hjrzTd3oRispFIczHINNL9cdahdiTnoKQMQfvCsmaIk3sCKeZc1XLd8ikLjmkrpBox5dTkHrVdpMj29KhmkGDzg5o3grgjBrN6lodvx14pnmjoKhkPPzdKg3AZB/QUkFyy0/YDBx3pnnnJJPpVNpeSSVAqISnOTx7itFFslyNASZznginpLhuaoBxvweM81FdXSQRNJJgIvOc/lWnwq7MtZOyM/xtqaxWRson+eUAyd9qZx+v9K85vG4C8ktljk1qaldNeS/aJmOZSWYE8qOwrMnRpGXb1HJOe3tXFF88nJ9T6vC0Vh6Sh16hAgDsNvHHOfb0qwbfeGC7cgZBqK3KqEVj97gn+8ea1khR1+Xdn2rWTsxSlqZRhKpuKcY+lZepuACVUrkckdM11d3DGsZPKtjAzziuT1NPMlWMHeM5OeaxdTmlY2oJXuyK0QIqknO0cnPI+lc/rFwrz87mK9/U1uSo1rG7Z5A564/WuYnDSyZZs5OeB0rvwtJSndHBja7IgDkHoe4Fa1pEWhBB4J9KzlRd3t6VuWEWbcEPjnsa+nw8PdPlsVU946dZCJCjMct6kYqd4leORe/G18YJ9xWKbgsc9GFTJfiOH5yclhhSe/1rzqbs00bThc7vw/eCfSzuwWRtpB6giszxPp0kvzYDEDdnHas/w5c/Yrl3ZzJHIPnycjPqK7eW1W7tVBBYMATxjk16UduY8erHllY8vVmjJUdR1q5FeS+VwcMgwOeDVjWNPeK5f93hQSAB2rNhHlzZ68gndWdWCep3YerdcrOj0i/aRisrABeMevPrWxHIYWKsv7o/cIrnrS3UOpTHzd8V0se2S3CEAsvQe1cVWKZ30ZuDsyd1D27YwJe3OMGls5wWw2Q68EZ7+1QQOFJR2Ge3vQBHC6N03/ePvWCjY7G7qxZuHa4JBk2KpOOKyrsMpypZvXPGK0QQgDIOGzniorhfMj2vnaFOMDk/X3o2CGkjDkyQdwGOmQMqa5i9s7vSJ3u9K4ixlo8ZK9847iuyurJlLBRkHrtPb+hqkUICrtyF4wTkHPY/hmumjXdN3WwYilGtHle5ycFy15vvrOLZKo3XUKnPX+Ie/wBK6TTtSjfy2WQeXnC+/HWsOXGgaiLhYQ9pKcGP09vpVUFEeW50rZJAvMkSnlefQ9K9enVUtOnR/ofM4vCcruvi6npun33y9Tgepxnmuhtr0HGOSe2eleWWerI8cTKzFgOx4NdNo+oAhd28+vHU1lWpX1OGLadjvoZsjniriTdga5y0u1YfKTWlHMCBkV5k4tHXTma4kIAA4xR5h6A/rWekv1I/Q1MJBjIFc8tDrjMsO5PBzj3oV/lAycdqqCUZNKZRwayZrGRc3nHfNLv/ADPSqocYzQZSOg5PtWTNlJFvecdfzpgbGTmq/mHj73SmhxyO/vWbKuTSSdj+ppob6/hUDSD8KjaTr2qLXK5i4HLcA1WmmYdBxTUJ2sxH/wBeo5HAXJzge/NDiNSGO7DpuJ9aTzz3OMdc1WnkO45JNQPOCvGSO9QoD5y+8oZeGIqBpAepOapG4JIDH26Uwy5PIOfpVKInImlcDgHpURfnPc+9MZhnNML8nGM47mrUWZuRY8zbzkcdCDXLahq41AzRKrpaI2GZjy+PT6mres6iIojErBZCOWPIUGuXtJYrhmQB/JRujHknuSayknVvCJ6eDoqmvb1PkSSuZZc5ILEEntj0o8ot8oYFjx9KZdR+Q2zB2H+XsKbHG42lWIQ85I5rL2Lgj11iYz1JI4leRXaMgZ5P07GtCNo4yR5jbsk5zgfSqqSKV2Mvzd/SkdU5KqQc9R0HNQ7rclz5nYNQuCEflj9BisS2Z/tLSZPBAAPNSapcxojAMWJGefWqG5lgIiDPtGTUUoXkbSl7OncTXr9SjJj5j3Jz+orm5B8p6rnnrU08pkkLFSe4AFREM8uxkcfVSK+gwVDlSR89iqze4ltA0rAYOc/hXYadZstog8tT9TWXpUAYklSBjjFaMt20TlAD8vB9jXuc6pqyR4clKrLQr7G3kMcN1VjVWVQL23eQgryuOwJ6E0gmaQ7pN4KjoaaEuJ/lIiUMQfvZYAe1eNTT2PclGzubenTJbMY5ixt34XnpntmvSdMu/N0y3cEFduGJPTtnivKJ5AsLqSSjAnp37HFdD4T1R7QLt4gnwJFY5wTxkV20altGeXiKHPHmR2OrWMd3a71A4G7jgH864G/Ma3DxgESYBKpzivTE8i5t9wmEi4IAAzzjiuc1fSN+JFQLGvDEcE4rstdWPNhNwlqY+lsB8kmFOQMda1Y7sx3PynCD8M+1YsSPA/AGWHA6U5y7wgDAlz0riqUrPU9WnW5lc25rrzZt6D7vPFTNPHPEATnrwP61z+nXM0UyxsCVPUY/rWtND5Z86MYYjBA6ZzWEoJOx3UaiaszQtpkYbc4YH5gOfxqWNgclsFARjnrWPDIZHaRCMjknpk1dhuMoDnO1TxwOe9YVYdTpTuW2IO47QVxj5ulZMqhZSw5XPbsT0q4ZSWGw/KOoA5+lJcHy4wq8cdB2rJPlRPxPlMW/t0uonguAzLLwcdRjuK4nUdPm0bUCQ7Rtn91MPuuPQ/4V3rvudjySP1PvWdeRwXSPFOvmRvgOM4OfUehrow+KlSbvsy8RhIV43+0jm1jk+zG9tAAynE0Knj/eFaVnqRABB24JyckY9qwb/Tr3Q5BNZTs9uTtD+n+yw+uOauwI1/A1xLItveueMMCJGxyCO31r1PapR5r3TPnq+EcpclrSX3M7/RdQ3Qg5AwQACefrXRQ33QMcdua8l0TUpEvILe+3Rl2GCBjI747V1WnaiCArSMGBGSBkVFSnzO5wOMoO0jv4bsMDywFWPtO5toboM1z8F3FHbl/MDgdT3pIrvLM+4DHeuKdPU2jKxvfaMjvmnpMcAg8/XpWNHdDOSwx6mrC3SZ5b8j1rCUDaMzWEvPXj61N5ny5yc+tYxuc4xz657U4XOVJGQfSsHE2jI1fNHrwPfrSu4KgZOevArH+0Hd8p5PGKcblg2GbHbms3A1UjSMqqvX64NR+ZycdR61QN0FU5HA6Cqsl+fu9B6+lLkHzM2mmUDbuGR1qOSVSMcHj1rOhnDLy3ucjBpZrgdfXtinyBzCyEbuo69zVaRwpPOfp0qtJcgE4IB6dahlnX5TI3GMjNL2Yc5dMo7GkL7kOOorPa7QHrVZ75Rht53Z+po5GgUzUeUKRlguB0PWsjVdXWDMUUmZCMf7tZOoa6XLrbsNqjBlzwT7Vzs8wkl2q/JGWz3Nc9STfuxPWwOB52qtbZdC7Ne/aGOX3KTn6/WmxsAMlwGOenSqFuq5I7L6+taCQNO2IgTIRnAxnFFK9JnrYinGorbWLNzdNKyuuSuPl2HhT71Tt7mZW8u4ZSM8MpzkVXmD21wFdGQnoHBUVIRHOY0Xf5rHaEjTO4nsAOc+1dTnHltJHlVITg7xZtqihEMkcj5AYbDu69OlUry9ijJCMqnriom02+gyv2TWIpsggCxkCEeu4DII+lVNds9TsgFls55S67leKGRy3A6/LkHnoa86pKnJpQkn8zehVu/fKfm+fLvyuAR1GBmqOqXLQu3lMyM3dSRx6Uyd3t41DwXEJ5UGWFo8/TcBn8KyZZd5ILMTn1yK7MNQu0PE4pNaEhu5g67ZXDHoa6Cw1O+aNVkm85Ac4cZB+tYNtFuILA46VqsqwhEgLMznCxjvX0VKCpx8zwK9R1HZHQjUZLyVbaCG2ikIzLcRx4IXvx0zWpbWkcEZSJVVc5+bBJ96y9GgFvGd7qJXILMf5V0lqkckIdizE85ArXbY5W7aLY8tS6zIeWwCRycVbt7glgfmx0Ge1VHtm3HAzz6U+MNER8hwa8uzPdlBNGv+7faVUgnjGcVd0UPBPLHGVRQQyr745rnkuSGxkqMfxCtO0mCQ7s7T69atPUwnTfKz0fw3MsyvGGYSo5GC+AQRwf51v3Cm5txG6Lv6/K2cDNecaXqZhlRwCpXBLDuK7+GeK4tUeGSNmJD5B6DuDXbTqHj4ii07mJqumNHI7RsvTPOK5uaQwyEYO7qSD0NdreqQsuWKI2WO0da5LxBBICsiKNnGG9RW8oqSMac3B6jDLvXIb64J4/Cr8N7EQEDNhfX9a4u4v/ACZCFVgRxzyTVqDV0kLDfg+45rjnCx6VOfNqjrXcxyh03Mrc896JXO4yR8bsF9xzWFFqgC7SS3OFJ6AU77aUkYlhgDHPNZuCZ2RqS67nR21yIypJB7EnsaRB5m/HzN9481gG93vuVhnv78U0X0gk4kIweCOvNYSpJ7GyqO9zXussqhFycdv8Kz5JcFgASTjB49KiN4ych/n7Ennv0qA6iWA6KRgg4746k9efyqVSRTrO5PMUkgaOZdysu059awG0+4sZV3Rma2Dg7h1GK34HS5nkdpI4VRN4DgtuPQhSOh7812GitaIkTFgZMDzG3ZDHIwBx2q6d6enRiquNaKutUeeS6hZSwFJ4ldd25Fzhsj09KbaM25nhJdd3zAn5h9fWverfTI7m7m8iG2inlymZUT/Vt8xJ459q6mHRbGVWWfTbcln5YRAgjHy5P0/nXTCpCK0PNr0+bSex89w30jQgKrGI4wVHB96nF26bQNxweh4r6MOi27WqW4hjWFV2gKoAxjGOlZd/4P054swwx7gMBAgwc03Ui+hx/V+zPD11CRNuUJyOmc5qZNQlKkbGATnHXNenXfgqGGGSVTHEI0+/InU9T0rib7T5IZWMkfBLYJGMiuadSJpHDXM9NQdQA6k5GTzUseoNtPBAJ7nNMMALHCKB29qcEByAB61zyktzZYVjxesCcK34HpU0V3uCq2QKqlTn/VnpzzTwvHC4xjvWbkmarDNFm6JXDBy+fSs66uJcbEUgd+auRqQD8vTIGDStDnGQ3H/6+aV0P2DRUt7sxbhn7xHXjBpsly7Akk/UnrU7weWhL8Z7etU5ZECEBRle+eKbkhrD32GzXKRR+ZMxx2yeM1j3mvnfsjQhQMgjrUmrXMT27qBulGD8pBFcbqF9saRVkSPIwSAGP4e/vRGcXoU8FU7G7LqzZyGYsONueRWTfapcT70hSV2B5YA7UB9T0rBeWRgF8wx2/Xk5Le59a6zT/iDqml+FptEsLOzWF23eeUJkznJPoelbwoe1V7P5G8aaw7vo2ZMt8WKwRguFGcerfh+NRLe5dctyeprHudSnluzM8pSU85X5T+lRiYc85GOmKzjh1TfvI65YiU17rO5tvD+u3VxPbWmmzSyxRfaHI+6qdR83TJ9OtZMl1cRTNHcxyQXCn/VupUj8KzNN8Rappew2V7dQ7OgVztBP+yeDUep6ze6neSXmoXUlxcucNIwAJHpwMCtKlKlo4owjiKt2pbG/e+JdXu7WOyvL2WW1iYbYpCGQYP05qob68gdLy3YQzxSiWN0OFSQEMvH1/SufN0UY/MDnpxUL3jMMDgEd65asVLS1y1JyWuh9j+FNfi8S+HbHVrUlRcJl48/6uQcOv4EGtfe5I2s2frXzn+z74uFh4jm8PXkubXUz5luT0S5Ucj/gaj81969V+LXjEeD/AAjLcQOo1S8JtrJT2cjmTHoo5+uB3r8ox+T1aOPWEpL4n7vo/wDLW/pcpVIqDb6HkHxu8XP4g8VNp1rKJNO0kmIMp/1s54kb6DG0fQmvPUxuGRx9elVI5pJSQAee/cnuSfXPNXJIZzA+1GyePpX7DlmBjg8PClDZfn1fzPJqVlKVjSskMyARnbH/ABP1H4Vp2KpbzjyQxLKQXc80tnps5iRdyRIoGGJ9q1oNLDbQ92hwAWbBr1Z2j1MFK/Qv6baecyBkQZ+87vgV0NvPZ28Qi8uN9vdWGKwUtLZCNjyFupwAB+tXITbKmDE5PqZFH9K5pVuzLjRucSkOJcbs5Jz7Vcis1kjLK/1Uio3RVZtoORnNPhaWIZPyrjPfOK5Iz5dGfQSpc2pUuLTBIZcAc5/pTY4WVh5Mm0dx1q8S2SvzH1z0pVMabcBmJyfT86mU9SVSuiKF5yAMAjPBIwTW1pLXludqhljz0DY/KqcJfOVUgDkd62LOToNmParU0tmY1MPdbGvJqkssA86FvlHAA5NVLyYXQQy+ayHqnlnpVm3XzDjb8x4ye1XfJjBJBIIHAH0reOJklozhqYOD3Wp5trGmBt4jWUHdwNp9K5uYSQMQVK+2K9hkiG9QAxBp0mg21wP30aP3Hyiq+tuW6IWD9nszxlNQdMh920e3erB1XAOGyp65r1eXwjp0hwLdMdTVWX4eWFyoby9hI6jtVKpGQnBxPNYNTVT9/mpF1XEgwSe+RyTXcSfDOHJAeq83wzj4Ecp47k03yMFUkuhyg1kBh8+cHNK+qq2xlYA4+Y+9dOfhk+MpL+tQz/DO5C5SVueRjtUckX1L9t3MWLUxtAVhtznPWtzTNaijILEAdgO3NZL+AdURsRs579e1PPgzWExtzk8DjFL2KfUqOIij0rQtWk1eVbLTt13cyOoij3AcjvuPQdefTNe3aZpOo28Si71DzX2qCOwx6HH618gL4Y1yJw0fmxSIweORGIZGByGBHQivZ9C+KHi60062h1XT7K+uEUB5sGNnPqcHArRUrLRozq1eboe2PbTFNqNjPUlsn+VU49Ov42kMd7jd03YYr+leZr8XdXVf3nhiNz0BS5Kj9VpJPi9q7ECPwqp/vb7k8f8AjvNL2Ul0RhdGR401m4sNdv4tU1G4EkZKCN3O1lwCGGOMfrXCv4lQyux1Bu5z14rl9fsPE2ta1f6pqETG5u52ncAHag7KB6AYFYsvh/W41/1D49hXKsLJxXM9TsjiIQ6Hdr4nIdt12jr15XmnW/iyEAneq89c1502l6wg4t3z0ziof7N1nBAt5D+BqfqkjaOJpPoeo/8ACXRYYedHkd8dajbxhHjKyLurzFtN1kYBt5Ap9RT00nWSDmCQDp900vqcupf1ml2PS4/GkQ5eVMfSkfxvE5+a4GOwA4Fedp4b1qXH7iQZHcVKngzWH5MbgHoSKPqndkvEwW0TtZfF0Uiti8xjBzt5rPl8S27ghrgNyTzWXY+ANUlPzKQCO9acfwzuzgOx554NDwdN/aHDHcv2TNv/ABDD9ndEcY9uK5CbUC0jMTXpf/Csyq5klzkcjNA+HEbEAnPrWtOnQo9SKuKqVtEjO+CS+HdS8brbeLXzZSQt5QlcxxGQEHDH6V9Mx2Xw3sovktvDx/3UEx/TJryzwB4GtdJ1iK62u7J0xx1HvXpF3rUVhchRbz7R3MgXP5CvUeJhClCMJtWWydkeZUjVlPVXOW8e618NHsZ9LtNBg1bU5EzDaWGmssm49Dvwu365r5mnNxBcyxNaSW0kbFWicEtGQehz3FfUzXFjPrJ1L7P5c5UI5L53AdAeKoa5oei39xNdPZos03LNkjPvXn1ZUW/a3bb3u7+hvQ9tFctj5lLXDf8ALJvfikSO7kxtRs9+K9nudDtPNIEQCZODjkiqMukQREkRj/PSuR4ulH7J3Rw1WfU8pNleOceW3Wl/su8ccIw7dOlejT2uMlEOfpVNoZM8qwAqPrkHtE6o5bUe7ONtNIv45Y5bd2hnjZZIpF4ZHU5Uj3BGa6vxff63401WG/1ySBXghEMUUAIjTuzDPdjyfoB2olWRQVUHr05P60zZMRyHwc8n1rF1abqKq4rmjs+qvuaf2TfRsr22kCPnzBx1q8ulxum2RyV7ikgtZmYfe59a044WRecnNdP1qUtyVlkYbCxwQRxLg4xwPX6U8eWAvB54xnNKlu0hy2QB2FXIbI4AVeB1p+1b1G8HFEISI8jP8hTlWMDAUEeuamltjGOmT2xxio414P3hz/dzWTlfcpYZH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mature cataract with complete opacification of the lens.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tasman W, Jaeger E. The Wills Eye Hospital Atlas of Clinical Ophthalmology, 2nd ed. Lippincott Williams &amp; Wilkins, 2001. Copyright &copy; 2001 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_29_29136=[""].join("\n");
var outline_f28_29_29136=null;
var title_f28_29_29137="Locally advanced BC";
var content_f28_29_29137=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Locally advanced BC",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 295px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Locally advanced breast cancer. The breast is lifted and the upper half is bulging because of the large tumor. Distortion in the inferolateral contour is evident. The medial skin changes are caused by dermal tumor satellites.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mulholland, MW, Lillemoe, KD. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_29_29137=[""].join("\n");
var outline_f28_29_29137=null;
var title_f28_29_29138="Nail psoriasis hyperkeratosis";
var content_f28_29_29138=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53509&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nail psoriasis with subungual hyperkeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Marked subungual hyperkeratosis is present on several nails of this patient with psoriasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_29_29138=[""].join("\n");
var outline_f28_29_29138=null;
var title_f28_29_29139="Diaphragm in correct position";
var content_f28_29_29139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diaphragm properly positioned",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 315px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE7AZMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuP8AFWt6h/wlmgeG9BcR3dxIL+/nZFcQWMTDeME/ekbbGDg4Bc8FQa7CuN8F/aNU8T+KNeuYPKgacaTZBlXeYrZnV3yOcNM8uAeyqaAOyooooAKKKKACiiigDzfQPFWp60t/Zq0pvLfUtQgRrOW2MpjhumRd8Uu35QpQZUk8DJya0Jde1q0ZPt7RWqxkFzeWZgjcFsbTOkkqKeR2rkNV0+HQ/itqtvdHTxp2sxR6raxalZpJbfaAUguR5mN0bkC3IJypLnjPFd5a2ctrbiW3tL2xG7yxHplyk8AQkfOqSAADk/dQHjvQA/7fqtvp0U1yJ0dGVHcW6XKPltpOI2DHG0nIC4DjIJBxajvr65svOt5ICVQOZrcC5gcZOQoDK+4jBxyBkAFqzNPtit411Z2tnf7mO6VYhZ3sQZ33FhgbucnnZn5jzmr8uk6VJcyS6lborzhR+/ijVty5+YSKMkkLk/Meg6dKAKUOq6xdkPp8lteBSu/7MqMFBBOHikdHjbGP4257VWj1zVNQRrIGWO9X5z9hWOC5UAA4aC5yNpzjcrMOeCOTWzdWFk88ou9LW7mFqgwPLdioZjsVmw5wSDzx0xzmqc2iC5jFtHO0nlybokv40uki+Ug8PiTHH97PzccdACnbahq175EI8RWVrdwnzZbebTjFOVCZ2vG0h3LyCSm3kcNjINn+1tUu9MuHgJu4eWh1HRDFJuAwSDFKxwc5GFLE47Hismzt5buT+zHtJx5WFCxPb3Fqh27CwinImRRk5QDoDgnOS/WlFnrl9Myok04aNDMFs5XBReLe4T5WJIGFkOcjqBQBbbVNZ1C2dNNvYrmRP9YLS2W3urduweG4Ygqe+Shx0NVptV8Q3VykVrdBb2AEvaR2kcTthl5aKWT509GjmXG7ucYi1s/vlk1a0yDB5ROt28IVgcEqLmHIiPX72QTyOlN1DdBbWrajBdRxoztF/bUUV5bLuYDaZ03OgIPDueh5zjFACWGr+JpNalWO8S437g1jLaRxywYIGVjaRCU/2xLID2FSWOveJoorj5IdRlglHmRGEK6KZGX5trb1HynBETjAyC/JBFaLLb20xtbu1gEhkhYiHUrOPBI3KTmRUZRnjYBntVZrS6vLb7cFlvkaRf8ASNPeOeMp5hJ2NkXEZUnO1WYKegIyKAJrzXdYi02ItqEtgsvlFZ7+3iOW3/Mn2iPdFGcDHzxDr6n5X3Or+KIotOt7tvIupSowkMMTzNtPyqzSPE57ld0bHGQQMisy18RS2tu97FYS32lTHM8rmFWRyAGDNCCD7+eidPmPYWdK+zXcscC2oWxu41WJ4Vt1juAVcqpUF4JCAq42kN/sheSAVW1nxtb3VrYw3Nvd3SykNDeW8dpczfKTx8xikTufLYNxjjmpD4p8V2dzdW15ZzPNPl7eJ7ZIHAK5Kxyb2VmHJVAsrfKd3BGJb6U2NqtlPlQ0waO0ubaIQEhQFUJMyjJOTiOQjK8Y3YMN3pN1Z3eoWFr/AKVEVEsllaeTJHGQgYbrSf8AhzkAxOM4AIyCaAJ08X6hLbGKG+h+c+TG1ysVvcM/Hyo+54WlGRmNgh5HTrUOt6344E7WOlLay3xUs1tJCtnc4AUhoC7SQyrz83zZGT0OKxW0xbq21Z7TTBHOihLhYIlMShowDhDtuoOBnYQ6jOQr5pA1mYjtEkem3j+Ykd0ljJamZVA2AA+UWJyMBoZOf4v4QDai8ba3f60mieTPYasA0qQzWSQSTCNgH2K8rRypg87JVYAgjIzWhP4j8RLrBtlWNmhRy0cdp87AFckwPIrNjnDRSSA55XOKyhqG61ihu4GgWCQFrHWVims4v3irt37TNDkN8hkG3oBkYzoarBb2FjDFd2k2kW3WJNRhiu9PhfcF2lgS0Qbdwcoo7YOQQBbbxXrMi3F7HLayWsUixTb4cQxEMQd3zCaAkfeEkbhSM5xVpNe1hbS2jZ5Fku40aMTm3Esu/r9nnUmB2XPyqyDdgZ4Oax57QWphuZLSSCVJQttdXDRzxlfM+UQ3afvIxhjtEw2/Ntxiq0FvbWGryWV7YXce8RMYra1tllmjDg5ltxujnCk58yFS64IwONwB0NnrPiNyLFiZr6FEZ/8AQ1gmBwwLPG8uySNiM7opBg8VEuu+IJJJb+ymWezVhHJH9h3pCQASGRXE0T88jEowVIA5rL0m8aTSIjFBFqekWr/Z/KIL26EAj5dyGeBhgfe3IAwwwHI0YtPsTJbSobi3um+a2F60ayMNhCeTdx5zw+MMz5XIIxzQBm3PiTxGugC7h1AQxXjb7W5uktyoJUnYtwhMZG4YXzIoyR8pZSQw231jxLLdGCW3ntLiINMixwwt5qAIMPEZSWALNgxS54GQMgFr2iQ3cgvtMljaeJpJJYYYxLIpU70lCqYZRy3BOfRe9SrpkWo2sd3pDafPpsv7+2t54Y2tncjtxvikJJGRkDn5c8UAQR+Ita23l75iyWsKvGXW1LW4cAMpdAftEDYyGDK4AKke839s608ENvBK3nSqJImkSEyTLuXJjlVvJk6kbSI2KkYwRmn3clvNqEMb6ZJZa66M8QmZEuJFTAzFOpZX25J8tzzuywA6lvp0Q1CS3e1a5iWQmdoreJC/zhgJ4iAJACciSMZ4PQ9QBH8Qa0BcWd/bXEMuNyXNjAvnRgSKpYwOX3pg5JjZztzwpxWffX3jOMfb9KvrfV7JzHIPs9kqxjDbZYyvmGVcD5sASNuUgleldFd/2Z9hs4r+zjuftMuIWVG2bmA3MjHIi6kgbgeDjms/VNC+y6osmllnnJR3+zSpDegeZ9/ecLMmMArLnhTyWOCAcn4c8e+INd+KegaSPKh0x9OuLy6jiEZ81QVRGYfMYiHypQOTn7wFetXsxje1RbiCGSaYIolXcZMAsyqMj5tqsc84wTg15f8ACO4n1/x541124WaW3tfs+i2lxdQRxTgxGR50YJwSJJRkgAHA9K9AuFa78VWsfnQmGwgNw8JTLiSQskbgkcDas44Ofm54oAuatqdtpUEMt67Ik1xFaoQpOZJHCIP++mHNXawPE62E+o+HbXUBK0kmoeZbohAUyRwyuC4PUDbn/e2ntW/QAUUUUAFFFFABRRRQAUUUUAFFFFAHN/EXWrvQfCF7d6XGsuqyNHaWMbEANczSLFFnJAwHdSfYGrvhDQofDXhrT9It3aRbaPDyv96WQks8jf7TMWY+5Nct4nS28RfFDw5oj3LNDpEMmt3NvHjBmVo47beew+eZgO5QGvQKACiiigArzbx78RNH0O1vrq/1+TS7LT7k2jC0jimnvJxGrmOMMGAC71DZUYbgkAc+k18N/GOa4u4vAavqVvDHPpUVwZrhiUaae4keeRgFbgOqMR2xgA9gD3bRfihpPjS7u4/C/iy80vxDGF+y6Zqotfs902FwgKZDbjkHbJvBZsDAAr1Xw74ht9ae7gMM1lqNm4S5sbhk82ElQwJ2MwKkEEMCQfqCB8HX+g6dPPefYb1bBY4jcJ9ruEVSyKrqu4okgcI8qYEfLwnBbJ2+7fDHx1rviTUTpfiK7gs/iJpUU62Er+UiahGWjaS2mi4KsSi/dCsACR918gHo/wAcLGaKx0XxDZ3q2Uum3sdtPJJceTEbW5kjikDkgjaG8pzuBGEOQelZtkxVnttIs7PUroKX8q1uLJSU3KT5UsDRSLyMklDyRXocEum+NPCs8csLtY30Utrc28y7XjOTHJGw7MrBlPuOM9a838P6jcPeXPhTxR/YOoano87QWn9q3Itrua3JBhnRgr7yyFQzKF+ZSD60Aao8UQ2agalHf29xbN5ipqKwzBAWI3KGKTtjnkA4B71pXfiDTjpsUS388Rm2h0tZYrnbzgr5co8wjpkBM4b8l04yaVugvP7e0qAEKquyX1tgtxiQqzqvb5tuB6dauxIU0OWzGnaLqsTxLJHaW0oRLhCSQRE4KqMgH7xH5AUAZFrpVtcQ3M9vq+nNHAiNEmlaZB5iyYJJeJldt5UKMAqcL0GM0/TNSgl8q2/tDTtShklKQ+XcIJYyIyGzBNkhuWyA3Qn5RyDX8wtplnbeIo7+0WMLIjaxbR3FuMg4xLEFaNl/vMVPXINSx273cP2W1vFv9OUDzLazvIb5U+XIYxzRltmQAFVyeRgdTQAl3YWyW32PUdQbSFgAS1luoIXSPZGuMebG6hepwJP4eMc1HLbyRarf6fbSxXEs29JrfRprdScqmWmtLglAR/eU8gjI5rWttGvrvQjaOtm7KqmGTzJoDEwUlW8vlo3y2Dh/5YPOa2b/AFJngK2msfZVw0SNBqKwHaByAIZ0ckH5lLnrx0wAQrcxWN35d3Yf2bP8wdrbytPldNq5DxSk28w9WVzwOB1p7PaafOrpPBp0/wAzHz1j027CB1zh1H2e4X2I24PXvUUOunTrZ4JNWubaEbo5LcXyXDwPgEBoryJJmQg8BWJxx70+2uYrFVfTb6zjDObeS302+S1klJbGBZXSFEfjoGUnnHUCgB93D/Z80F21pcWVuf3iXrxQ27RhmXIM9qWjxnHEihT6mp72+0+bS9U1K3NnefZkE8pmezLeZu2o3mwyKV4yQT8xDYHPy1nW10NIu5Xj1KDR2RGeT7UZNKVV3gfOkkctueWxuQLncMdapap4+hhvo7KG6jv/ABO5jhhS2t0kvpI3kyPs8xhELxMvzbmVVwSSc4oAfPq9nfYuZTO1zG8JP26K3kK7jmMxsrRXWMnAOC3HQ85raq3h5LMSeI5LdFhb97I09rmTKtkZfybjOTuwd2dvRqoW2j+IrXxC0E+u6Zo9u6Ks+iaQE1G8kDfOY3iMS28Z54k8vHzdSCK3tA+EgiitWudPt5JlRVW6129bVp7eMj5kSEosKPnAypZRjoaAOXufGPgzSdP09odW0w3Eky4ntp1d44xGQQpgXeoYqDteIrnqMkGudu/HHhCcF7P+1bS0lQtKbjTE+zK3lBf3RSNkV/lQ58pSe7rxX0lF4dnSKOF/EGrtBHjbGgt4VAC4Cjy4lIHfGfShvD12u8W3ibXLdGOQo+zy44A4MkLHtnr1JoA+frD4leGtUiuTdaja3iweYYv7TVBIBtRlVC7iVCDv2skshBB45Wuoh1/w3ruLqx1i1nu54XR1kvrZZXTgAeci7ufkXbcrhscgHmvW5dD1F87fFOspx2iszj84KyfFHw08MeJrPGu6VBqF+qnbeuFguC3YmSJVI6Dt26UAcDp8Fhaavb/2xFNFp8paS2kMttArIXSQk/MYOCBlrd0Y4yU71qytNayR6ppsOsaTaTSOSkqRLa7A+DkxBgoIPDSIwOMh8fM3GWGleMfCF3/Z3g/Vb0XsXmzTeHdauIpPti4X57O48oLIMAbgQCvOcFsm74R8U6fr+j/Zzbw2Fy04gvtLsrp1nt3SYZYWB5TGMloXLDGRyCAAb2lyxLqUv2W3fypSga8sngi80Fn+SQx7raXg8bxGxDDA5ot4dMubYaTc6Xb3cVysXlwO8VlEzF8LOEztD54EluWBLDgZGGR3N5/aAv7a7i1O1iSJTqNvqKx3FpgvxPiIEqQANsqNg7tzjk1BPqeotpF0fDuo20OpFrd4rHfBaGc+cQxCurRPJkEbo3Cs2AwGMEA37bUNrW+oCW4kjWIFLmWS0WUAIQwSdD5MgGMFJMYPzA8DEVhqtuIp9Pk0yK6Erb2jtobZZ5iIgwaW2YhZcgEh4CwYLxjBAWya4XVpp7G6eLUpQhmtf3djfSHDHa8ToYJ26kSLs6EbiKZFcJcC3sp/Lk2uqvpiqiSwsItwYWjruU7c58mTuWXIzQBstq2m6z4ZsYrqTTS8LKsiWz7Y4H2NtYN9+3PBALAFSCp9aS70S1t1m1Jb6VI5bYzPcwxQieT7ow7BDFKD1y4JU8g4JrK0m8ZhDdvJBftbWe60u1kBcHyzlRcbRjCmT93OnJAJY87eimvLwXN4PDxt7mZonY2BuVtpoiQAGKNG3zbgQGOF+bkN1oAz7mSS5sri2lVdUtFjLRSmK3aA/LlJHjdlRsHcSY3X7h4Xk1zEOsT2Bgs9V+2sYJJENtqIj4XeGDxSq5mhAA4di8eMDfxuHoA1Rbu6ENrdzJNAGFxb/IsyE7W+eFl+YYx8ykcMcdc1V1iztru0it7Zol095vNikSf9wrh1xtkUboXz90qcZJGDnFAGRB4y0uP7FGkOqB5N4kO61cz4KKMlWKzn5wMRlnB4IyRnP8ea7pGjeEtcvxZxR2tmgcrDHHJCG3MI1lgba8bOw2EgA5/iGMh13b/aJEuL/wAm5aQ4LGaJJJ4xKoysmwQ3KFcNsdVZcepyOe1eE6p438M+C9A1KW9tPMXU9XW+hUvDbW1yHSEnYHG6XI2scDjaFU4oA9D+FOkQeEPhXocF4BZNDYrdX73DKuyVl8yZnbpwxbk9AOvFb/hnfcWJ1KWWd21HZciKSWKVYFKLiNGjG0r3zlslidxBFcz8YbmK50bTfDG+T7R4kv4bAxwyBZDbBw9ywz/CIVcE4/jHqK7uNFjRUjUKigBVUYAA7CgDkY86t8UJHUhrbQrEwkZ6XFwVY/iI0Xr2k967CuI+El3PrHh698Q3Kun9uX8t9CjY4gAWKHHA6xRRnnnJJ9q7egAooooAKKKKACiiigAooooAKbI6xozyMFRQSzMcAAdzTq4T4y3KnwhHpAuZre41u+ttNjMIYuUeVTN93kAQrKSegAoAr/Bcx6ppeu+KVuFum17V7qeOYKAfs8Uht4U46gJFkf7xr0OvNv2cbf7N8FvDSiPyldJplTJO1XnkcDJ5PDCvSaACiiigAr5K+OPhvUbOx09rSaGJrLVb7RizyriSG4T7VGDu2qMI8inJABPHt9a15H8cPDlxqOg6zDp+myuZoH1aO8t2d3jvbeMKFKdMSQgxjHXkEcg0AeBW2q29vb6tPJewBrt/PlbSVP2WN1ijnhTyTEMOR56/LKp5ZdwAFYdzoms6OZo7ZYFs9L82eCaK/t9yXO62ZngkCk5RTbFkDMfv/PlmFdDa2ljPrstzaFpZbdJNRhWKWO0mEbrbTKEMXny/MJZQE9GxuG0qNMWGqaZdXV5PperR3FlZS5WWCe4kmtY3WFhcJKojMckDLzHnPkKfk24oA9I+G3xEjmnGp35js7yRkh1+wM6RosjPHDFfxow+6TiOQBhsPDAlee5+LOkXhtrTxJpC+fe6UpSeya1juFvLN5ImmQo2CWURh12sDlcfxceVN4bfRo5ZdGig1G60u5b7Pp2ixy3ZmsHcvcWVzPsVHUxDbGjgsGjQKSWxXqvwt1+2ubSHS7SWS60+SKW80q93ySCe185l8ti43LJDujjKsSeh9QADG8MajFqtpDqHg26hmtnCyT22iaqr7FLHn7NcRbY8jOVBU5GOSM1py6ok2621LVNLvYZAALXW1OnXUZJI4O35sleoQcjg4xXK+KNIXwx49a3njim0DW38+y+2Wct0INQeYvLDFJH+8g358xeo3B8CtZby7nkVrCeVbgxrHPp6ao1y5werWt5GjdugZWPueoBo6trlzYWNlb3aavpN3HIgjSSVpo5QA2dk0cUplOP4JBkgZwCNwwn1l9RdjqLWWqKGBikGJZFBUMCs9qBJHznrCCAMkiraXT2P2aOG3uNLmlkDRLbXc9nuYg5VLa5T7PnOSUDntgniqd8wM2n2aCS7dokAtdU3TTuUjwZFhcCVeQfnhkdeCcHnABYv9QlvobWyj1M3phU3MT22ordPGQjAZ8tY7gYDH5gH/wBoHOKdqzpdWjXU+q219PZpuyjLeSQJtOWZoY4p4gp/iG7qCR1qvqDWt+8NjfWt1HciM7IGu57piAoJP2a7VHf6w5ceoNXrvVp7Zns3mvIfMgYmJru6DTHjaQJvLlTqP9U7nqCCaAGTazcvb/Y4dagvYZQwCW99balgjadjxPHHI4Kn+FmbJxjoahS70yGyZRq2jaZZxMWubV9U8iNYzMAWa1uoWEWGYcDb8xAzyKzfG/iW10xCupx6pDJchY0toriS7ed34AS1vIhvwT0j56Zxzin4T8P6pdXdous2q3uqWkkV1beH4J3hsNIJIZJ7ogtumwMrEN20H5QAdwAEsNQbyVvdEuU0HRJppLSDU4xDJqGuDzgira2oXyUUthRIVJxtO1QSa9Q8EeFYtG0C1SCG40q8lm+132J0uJ7uQsSftExTLsc5O3GDwp2jm/4b8MQaTcPqF1PNqGtzKyzXs8jscM5cxxqzERRgkYReMKuckZroKACiis7V9ZsNI+zi/mZHuZPKhjjjaWSVsEkKiAscAEnA4oA0aK8+8Q/Eu10FhNqsVppWns2yKTVbtreac4PKQLG77enLbfp0zqeGPGcerXVtaX1r9luL2FbqwkhZ5re9gMavvjlKLyN2CrBSODggg0AdbRRRQBmeI9Etdf037HeeYm2RJ4ZoiFkglRgySISDhgR3BB5BBBIPzr8W7G90LWdd8TyTre3mhPai9W4jjjk1PTLh4wiFo0AV0mjcBwAwAHPyjP07XD/ELRdP1E37XvluZ9BvreWAq2ZkDRMG3DgbDnHfMmR3oA4Sx8Q2OqRW8/8AbVpFLHse3u7q+R0CFiyrHfomUI6GKdCWxgg5JrTuLi7jnuY3m05Jr1YJTb3b24N2rSYyBtEVwDk4IMTkkBiMrjzP4Lw3s/w+0DULO2XUJbRHjkRbuZrmJDcSKGUIBLCm0kfujKp28pndXUadONIstQsrdb6K0sGhMzEynylZip82BoxFIvCsTIsDkBjknkgGzZ39zPb2enx+VgeWo0W6YyyRERsCFguo45XUbT8yS8DOAQDm5HqTC2t7Cdi9pGvz2s2L5IMRsGjeMql1GR2f5wM88dINPlMa6fp5iEtlLboywJHPf2zwjeqN9lmUSxjIwDEWC4Xd8u0nXsJrsxwW1naPLaqRBJbmeaeKNwmNrB08+3PTDAMvPOCQaAIkvFis0uI9Wt0fd5EF79tjliCiMsI/tPk9cYysytnqCTg1b1vUbWS4fTJZ7BNLt0e3Wae9RY2dVVjiYbjHKueYmXBXkcAinW2kwajpst/pwknkuD5UmzUJVmAA+ZFmxulxjISUcEFTt5Ax7pGsvts0EN/cWohJjuZbZ7SZIwozH8qCKRQQwEUwjx0GVIoA20W7eeS3SYaitmjyfYNQYJfwuFUh43UHdk4ww4+YjnGA8z3Mt3HceH9TF1eqri4gdoo7hwrKpzGUVZApDYOUweAxBIrIS4EEjxRxrNaW8R822ZbqNIWBR438llaW2AXO149y5BBwQMaNvNpF9FAmrzXcV8Y3NrNAJ2mKhlI8uYAi5xvBUgEgE5H3qALd94i0HSbzU21i6trK0Qsbryp/OhIzg+fEVPlEnvjDE43E4rG+A+myXFprPjCVnjg1+fOn2ZTYtpYxSS+SoXsW3s5xx8wPrWJrUw+J3jC18J6Xez3vhfTZ/tmvS3FpJHmSOQFbHcwAOWwWQjKhPvZGB6j431xvC/hW71G1smvLiLy4bW0Q7TNNI6xxRj0y7qM9qAOf8M3Fv4l+J/iDWIA0trokKaLbTBw0ZnJ8252jHBH7hCc9UIrR+Kuvz+HfBF/c6dIqatcbbLTwcEtcysEjwO5BbdjB4U1N4G02Dwj4W8PeHp2QXwt9snlb3WWcLvmk3HnBcs2Wxy3qcVmeL54tU+Ivg7QktxcSWU8mt3RIOII1hmhiJ4xlpJOOf+WbUAdT4Z0pdC8N6TpCStMthaRWokfq4jQLk+5xWlRRQAUUUUAFFFFABRRRQAUUUUAFeXeOLm3v/iIsaQTTTeHfD19fllztjmm2Rxe24ok+PYmvUa8k0S1E3gn4keJpLr7RcaxLqKrIuQI7e282CJBn0EbN9XNAHSfBBPL+EPhFRnnTYW591z/Wu3rk/hGgT4VeDgP+gPaH84UNdZQAUUUUAFcl8T7bVJvDBudDmEN5p8n24OGkDERozbQqZ37jhShBBVmHXFdbRQB8o+LEfwT8Q5jpkmo2nhjV4hd2EtiqlTDOojlSN2XEZEku/ByAuz7vFdj4e1uLxVfanLdaXquq20lmvlXM19csrxSRKssG2zieL78R3dCcjg4qz8TfCMkmjaxpenS3dteaRp93daONskyT2MkSrcWp9SHClRyy5iK9KwdHur/UNDs7TRpBcxzxGdRaTahcRyBm3OWxK4X5jzuTIJI29qAPRRq8upwWuj6ZpMkM1rFvFla6h/ZwOGCsWVMvFEu4EA7XPGEI3Y4DwzJe2Gt6ppVhYPcGxubjXdClt5pthRLhFvLGKSRAZdwJ6AqWkz2BG0NEvovDyWskNtY6J9oEt/JqSNb2jETKygxsVLg/KNohi3kYL4Yg5Pixp9N8efDzWIL6QquriwjWa3ezjeKcpH5VrbFsiNEJLOQdzFPmIwAAet+LLCPx58P5F0W7Ecl1HFeafdcr5cyMssTHHzLhlXOORyOteR6D4rXXtPs5JI5i7QQySW9yxvo3l3MskapeBJdyyKQRFI/QdTivXPAMotZNd0F1RJdN1CV0VFYL5E7GaIjPHG9kwDxs7cCvLvEehR6b8SdZ8NQ3d/FpuuxR6xbwLZ3N1bxS72WcBI5lHLiNzlGA3jIAAyAdDbXShrGyvbW/sZHiU7Ir64YMTxtFveIEdec7V3MuPxLH0+3WS00r+zbW4/ehbNb1r60gO6M5P2eRfKZx8x2q49sEYOB4bsjcSQ6HqNxdyWpchYVgml2gBsb7c+WI1zxzbED+90NLpV9qZvZ9Ph1LVNLlE4SOGFZrwwJ5Y4S3dopVjHUboGA/vEcAA1tUt49QtrbR3tvJvSuwWw1WctkxnmK2vI1SRQTxggjsQRT9Xul0fSdQn127vNN0+3t5TJNdNcSB1AX5Ps9wJYXJdgAFkBIOBjGByWtTajaaeNN1d7i6jt3MGwGYvMNnysIrrILk9FSHHPysBV7wTaf8J3rVzquoX8dxounXD2eh219LO0d5fqiv5zxmd0YR4ZQEyGG5hjFAF/w3pV/Nriav/ZC2PiO4glOh6NPcEw6FbOnzXEoCELJJJ/DgnGFHCtt9l0HR7TRLAWtkrYZ2mllc5eaVjl5HPdmJJP5DAAFVvDOhjR4rqWe4N5qd7L595dlNhlfAUALk7UVQFVcnAHJJJJ2aACq2o31rpllLeahcRW1rEMvLI21V5wOfqQPcms/xLr8Oh28Q8mW81C5JS0sbcZluHA5A/uqMjc5wqg8npXgHxq+K1rJ4kj0fwekmo+IoCsJJeaWC3ukkICxW4wsswZshyrAbVwCQdoB3Xj34yWnh0SI0cemRsiGGbU0lWeUFyGaO0CbyoCnDSNEpbjPBNfMeu/EDxFq+pW6aW2tadqctpCISl7PNeXDDf/y02Fxv3lwkZSPB6HjHc+FPg7rOva/p2q/EfXr7S7y+eFrayVpbnUJ0TqzsWZodvyEs2du7B2YAr37w14CXwpc3UPgzStA0G0JCrdSRy3lxOMfxEuhUAngF2+goA+VLX4U+J/EOoTap4mhm0q3muRby3msG4knnkOQBbwkedKdpBAIOSnXAIr62+HWhT29vYXt1Fc2trZ6fFpul2Vw372G3ULmSYdBK+1Mr/CFAzksK2dH8LWdjcWt7dzXWp6rAhUXl7M0jKxGGZEJ2RkgkHYq8cVv0AFFFFABXhXxm1y9vtE8Vz6c0oREXwzpscZfN5dXEsf2jaAuSVCBBjOSsg9q9S8Za9JpMMFtp+w6pdMpj8yF3iihEkazTSEEBVRZN3LLnpXzzY3o8X+KdKidrx/D2gefcaTeyWd1dPql15mZbsiGQPtEisVK5C7sHGQKAOm8FiPSPD9npX2GS6t9FUozzpcI1uyySKzxXEEJkTc4LNHKqlQ3BKiukW4jkNi9xFNe7hsglu7mSGaHK/wCrh1CFSkoJJADupJPJzWVps9yySXsl80pg2oLpzcujp5mPLa8t2WRMBh8txGzLnksMmn3lrHZaXJJNFcwx3TQecXg2rOrEYc3EZNpMOcfvkG4cMVyDQA66jstI1Ox0+Ke5jaSYSw28ulzqpfEg3OoACNnaPMgILHcWVhyOgs5XmuE1CeznmjiLiNonmuTGwQFlEyoLiM53Ao6EHoOoFY1pNf20ttpukzXN7byRQj7FNZSTwyxMjkB4p5d0YGFAkRzFnCsFqfSp4pL6zguI7uy1YxrGojW4ZkTyc4MW9bhV4XI3PGGA53c0AdVomrQ3tjDesly3n3Hlxm2YvvG0PggfLIAoZSzANhcEBgcZ/iYXWla7NeaciwWV2A8rFykUsh2ho5I23Izsq9SIm5C7iTisE3qNpl9cSXcyCZvIklgEi7j5eQXLsInbaCpSVEkOVBOdpbp7qGMtc25vmQTWnkmWaGWZlbAd1eKRixjZVbr0BYBlJ5AMWSO2vp93k3ekXFlA4dIZ7pIkjKozAMAj2+AQR8uxsdHKjby/jDxF4kMkHhez024bxRf3O21uHYvFtUpi8kVY2j8tMqwkTa25RlB8ynQ8d+JIPDWjsLq/nLTIf7MSE3FxHqblAqrbTRuXiZvulHLqCQQCMk9B8F/hy/hi3fX/ABDtm8X6jGwuXT5Y7aJmD/Z40X5AoIB4HXOOMUAdf4A8MxeEfC1ppSTyXVwu6a7u5SWkubhzuklYnklmJ65OMDtXI+JdUsdW8bXEl6s1zo3hIQyGKFJT5+qTOPJjAA2u0a7CACcNOucY46r4heIZ/Dfht7nT4oJ9VuZ4rHT4J22pJczOEQMeu0E7jjB2qelc1oOiNo8tjoM9+11HYzDV9WvFi2Pe3c8zmNSqH5Rvy+OcBIweM0AdN4f03Uvt9tqOuSeZeLpkMDAMNqTFmafCjjkiIZ7hRWJ8MrubxJqeveMSAunam0dnpgycta27ShZCCBje8kjAehWtD4hX2oaN4GkXS54l1i6lttPgmkzgSzzJDv4I5XeW/wCA1u+GdIh8P+HNL0e1YvBYWsVqjEYLBFC5PucZoA0qKKKACiiigAooooAKKKKACiiigDnviJqUujeAfEmpW0ix3FpptxNEzdA6xsV/XFZDeHI/DXwYuvD9mqkWmiywZVeHfym3Nj/aYk/jVH40RNrNl4e8JxqHGu6pDHcL/wBOsP7+U9R2jA/4FjuK9DnjWaGSJxlXUqR7EUAcp8IJVm+FPg5kzgaRaLz6iJQf1FddXnn7Pzyt8IfD8U+3zLZZ7QlRgHyp5IwfxCV6HQAUUUUAFFFFAHKfEC3ltrO38SWWTe6F5lyY+T58BT99Fx6qAw/2kSvMtX0658OfEmW006/e38M+IYJNRsrSyguWHnqsSzKFt3VvmBWTdwPmbpgk+7kBgQwBB4IPevI/FfhCO+0bXPCdtpqNcW7NrXh3zURogylGMIzwo80lSpwNkoA4HABl6wkFhFZmXSxYy3MvmIUsooL24k3rhwzSzXAxz92Mv9OKw3sdSvvH/hnSbTQbO21N3i1XUCyoskNql5BK0ryNK0skjNFGo3hTgv8ALzlJtP1efxHNF/wj0VlpEl3MqPDZ20cNxgzIHWVYnMjYIbf88Q4JJ6A5v9p3Hw98XaxY/D6TS9Qgv7l59QuG0szzWcgeOJotyThnAkfIRlyDKuN4ZmUA9vWWS0+KEkTxjydS0hGjfgHfbzNuHqeLlD6DB9a5v47aRaS6RoniCaO2+0aNqlsQ89p9pUwzyrBIhjBBYYkDbRySgxXMfD3x1f8AxHm0++msrOLVNC1SOQyIVjSeyuFlhyqs7FWyMkZO7au0ndx3/wAa9HOu/CjxRYIA0hsnmQEA5ePEijkgdUHPagDh9Es/7St430a0tNQW2t1QRWE0N9aISrfK1tdMksBKnG1XHHB71Ru/D9w32OWysZSltKXa1XSXjRC0eMmCaWduC2C0cRz0DcVgaYI5rHS9XvNH0ywt720haJLq12WzCSPfiNJ2eLbluAk8Tc8rXSajpF/JDbvb27yNbL50Edzpcl1HJCIcFI5g10oQ9RH1JyFIJ5AOR8dS32qeEbPTPDenWsep6zdLp4htMWqLI8bF2eJLlgMKpzviXB+bjgH3TwLY6XbtPp+kWWnppXh9xp1i8abpUfYrT5c9yWUHHJZWJJJwPAvCs19f+PZvEFlatHD4Yso4bSxEbLFNqN1GY44wjSsVT95nA27QOVU5r6qt4IreMpBFHEpZnIjUKCzEljgdySSfc0ASVR1q9n0/TJri0sZr+4XCx20JAaRiQAMnhRk5LHoATUup3tvpmnXV/eyeVa2sTzzPgnaigsxwOeADXiHxq8f6r4a8Kf2mZdSstQ1mB7bTdMEKRvbR+ZH5s0rCRwZNpQIR9wycrndgA87+LXirUdS1E+DNBMOreLdXnew1a9jUqI2WSNxaW2ZMxwqco5YBW2kk5349F+CHw7Hh6GKfSE09po5CLnXprdZXumWZlkhtVD/uYwFZS5GXLZ28DHJfAL4VSwtL/adkiPuC6q9xEkmwpJG6WcRD4+ZQDMxU9fLwCGNfUFtBDa28VvbRRwwRII4441CqigYCgDgADjFAEmOc96KKKACiuev/ABXaQ6k2nada3ur6hG22aGwjVhAcE/vJHZY0PT5SwbkcV5v40+MNzpN7LYx2a2V4nmK1pGq6lfoFjL72hikEcahQW+aUnAztxkgA9h1C9ttOtJLm9mWGBOrN+gA6knoAOSeBXnPi74i3umaWNQSyTRNOKkx3GsoDPdNnAS3tFcSM54OHMZGRkdceZ3sXiua6l1e0stLsRdoRZ+INYe3v7yXgACKVJPs8JJY7E+VTt+8TU+n+F5tNvNYS+0ebVNfMb3Bm1O2Se+nCqih4pfN8xSF4/ctMB2VW+UgGVdadqnjSyj+32y6ZoesTidbt1gNzrbiUMYpbhWdbcggeXAwIzHsJ+Wugbwsul39rYDSoLSaZ2K2U9jBDFeMzKM+V5rW0rhTghHgfrjg7amurdZbW3u5bWCIXMskT6j9njgeUmcbop5kLRSOSF+W4hjDc52vmtC8tdQsb+2tbizjs1uNu6wmsoo7a5bzEZQYzO9u7jH8LxPnBG7pQBmWVhfJcauLjSmkktCsisLEi9sj5jKNrJN56oBggobhSvQ8FK0dPu5ooNKudPVoJbhYkt5HEaC4UswMRmjk8idgxY7JFidt3BDE4ltoroTXUJ8O2N1HA29dNubIP9mDTMHZELmWJWXPESzJ/EvdazZtM0jU9IXUdNP8AZ1ndeXI1zqEcV3DuVwDA91Gz4U4CkXKuBxgAjAANqWysbrVG07UvDBs9QgVTB9itYIRcIqv8v2eV2jkChnPyM7AH+HvYsNKlFmkej6bYanoqMEEFrbRPBEQm11ktJpFaOT5myUkyRjKnJzj2drr1hf6fBc+H44bW6McqWsdjFNZeaFckiMzmON842ukqbsjKHqMG6utN0aa9vNQtn8NX9kwaZlMUYI8tlVoUeaOdCRlQqPJEeR82DgA6c6YF05rmCzgnty22O7jU7oMREBTOX82ACMshSZHRScMwU4rO8V+ILHwtDfP4lsdPhtZonlW0ubBGFxPsHlmOJZSu5tzKXicjO7cqZBObpt94w8bWAn8M6PBqMy3ZWHxLfWg08OnkhRNlZA8g5KlPKZSMAk4xXovgX4RaR4f1m61zWvseta9NLvjuPsKQQ2qjG1YYQWVCMD5h83vycgGL8JPh7ef8JJfeMvF+mrZ3kjuul6VM63JsYyQxlaQkkzNjBb7wAwTztX2UkKCWIAHJJ7Utec+I7tvHXiKfwjp0aSaJYSRvrl3JHvjdleORbNPmG5mAbzOCFU4PLYoAwjrrax4ltPGU+mrqGk2sk1joMcMCuzBp4YpbsyM2AXZdsQGCytk8Ekdz4Vs5Yibe4Fol0GN5qUcUW4NcysZAu/8A2OMHkkbDwMZ5jX9SmtFs5EjtJbTRrlbO1t4rfyYrq63AbYoy5/1UIkABYAydPugV0WoX1x4P8DXWpSWC3erSOJDbWkYXzrueUIideRvdE3E9Bn2oAoCKPxV8UZjMRLpnhWNBHG0WUbUJVLF92cExRbMDHBmPORXfVz3gDw6nhbwnp+mYjN2sYkvJkH+vuWGZZCepLNk89sDtXQ0AFFFcN4T12+1X4pePNPmUjTtJj0+3tiAdrO0ckshz/e+dAfYLQB3NFFFABRRRQAUUUUAFFFFAHDalPZ3fxq0GzK77yw0O+uv+uYlmtkU/UhJR+ddzXC+ELea4+Jnj3U5yHSKSy0u36fIiW6zsPXlrkn8q7qgDivhPdwXGh6xbW4Cmy17VLd1HY/bJXHfj5XU//WxXa15x4BZdK+Jvj/QizD7RcQa1ArYO5ZolSQj6PERj0xXo9ABRRRQAUUUUAFct49WWws4fEdnuNzo4aWRAQPNtSVM6c8Z2puH+0i11NNkRZY3jkUMjgqykZBB6igD518caBY2PivUtH1291A+GtcMmpWrC9gET+ZIjTRYnmSMFZWEikIzYl6/Lk50fgjQ9QjeDStF1O40uGOeNtSuFs1WNGbc4iKeXAW3EhWLPs3ZCjbxs/ELS1uPh/o1zb3179o8L6w+jzGycC5W0e4ECpjjLlBbMOm7g9GzVfTWsY3FxJPFcQecUK6lbWks0bFsHImvSQ2fRR06dqAPO30RdH+I1jZQ6kssPiOOSxne2MLra3LSebbJ5iYR5UkWBjtVQoKqoC4z9beH7n/hIfBmm3V4in+0bCKSVccfvIwWH/jxrwL4jXd1qH2fxNLa65d2vhe9tb37bdxxJERHcLvWFE2rtKsSWBkY+WgO0cn1/4UXAttHuvDksxkn0OXyImYqTJZtlrWT5eMGPC9uUb0oA8V8Ff2DfeCfDclrcajbaqtrDG7WM+mJJIViCsGEUiXDqNp+Unf2IPNb1lHFol/pymawSe2m3udtrYXMaFcENDKkLkcgZEzg55D1xfwl8SN/wiel6Pq+s/atO8tAtqTaFbYnfjmeN4yflBw0sbdfk4rs7LWrjRyyaM965SYJjTZgkZGNv3F+024PPTMf3RwMGgDE+AN1ca1q+keeWuoLzVNQ1r7RdMGuNkEUNtACRgHb5sgxgr0xjHH1BXgv7PttZ6d4M+G161rvur2DULBLj7Tt8vdK85XZj58+S3P8ADjvnj3qgDmL3VX1TxRJ4es4LWeytod+sNdJvXy5FYJCq55ZsFiSCoUYwSwx87+FY0+Lf7TmqXupXMlxpPh52lsxAwaFhBMixDdyCrsWfr82D2r2zxNI2n6R8R9e06Rgq6dIM4UhriCB8uhBOQMqhDAENG3UV55+zjBH4T+Al94qYXE1zeCadnVPOaOOFmjUBMjKrh2IyOC1AHrPwskmm8GxS3kfl3kl5etcKUCkS/apd4wPRsjPfFdbWR4SsU0/w/axR38mpCTfctdyBQZmldpGYBQAAS5wB0GBzV3VL+20rTbrUL+ZYLS1iaaWRjgKqjJJ/AUAc54j8aR2GsxaHothcazrchAeG3I8qzB24e5f/AJZrhsjgsR0BrzDxZ4p0t5xaR3J8d64LYRsHuYE0WymYSj97ysYY4fCvvchAAQeTk+IPGV9Z2Vl4f8N3FxaatrsUOsa/q0lxbiSyFwu7yI2dkQS7FwoYghFUrknIytDvY/C2jWd7aXj6XLZWUPziW3tUuIwGyBvEQkbK9Stz14ZickAkhDa74dt7TWrm11G2MzSyaTZPDYWw3LjCxIEmLIeMlZ1baSPa9FJ4ftozJYz29paSIZZ9Juls40ZhHg/dVoEZTnPmxRud3LgDFZuv+K77WBp9xYmSx07WS6m91K0ikmumwqg29pCY3ugWClWkhwCRnAAxsaN8JdV1S4shNa6mltHtlF94ouorxod0fzCCwTMSNuIx5rMFA+6TigDm9T1jQIbrULXSbq4u7ybe1vb6QiXcjjyo8CRYC4ZCxxt85Uzn92RU8mqm1lEd7oR08Tu5fTtSudKtTG5C4dY5mCMcjtDGx3cu1es+IfDHhKyeNfHnjO6mt/K8uOy1HVIrG324AOIoREDwOhz1NQab4++EfhdWbRpdLsyx8sNY6a+6U5HAZI/n5x0JoA8hg8VapbedE1l4VtI/MZZpJvEliGki35CgozyqRgfKzunbaRgU6y1/VRrE39neKvCMdnKPmsbSCbUVYjbu3xW9ukZBx94rnPQ17Kfjj4RhnH9oDVbCydSYr24sn8qUggbQq5kU/MMb0XPbNcNqH7UelLq0trpHh26vYVcqsktyLdmwcbirKQo44y2emQDxQBzjWOs3t9eyIl5CszB/s2leBpJYGPQ7Vuz5aE8EtgE8ZOBW54U8ETzWAQWPxIjuI5t7XYttKsZXOMAFnYysuMDaWK4wuMDFJa/GzxJrMb3djDBZOMFNPWwF2NuTgvL9ojPIHZOMVVvfjf47N/p9jd6PpWgQXVxFC+qXkMxhiRmALkkhABycF+1AGtceAPEepO9kNO8Xy2e1Y4xrfiaC3tUjUEgeTZhu+BjHHHIxWvpPgO78KRW7P8NfBmr20UgJ/s5t94nyj5wbofNgjp5gPQjnNa3gK88d654i0nVZNSlk8JSwNPK1zZW9sLvch8owIrPKq5KvmRlOO3Neg+LfEuleE9DuNW127jtrSEH7zANI2CQiAn5nODhR1oAk8K6vZa/4a0vVtKBWxvbaOeFCFBRWUEKQpIBHQgE4IIrUrgvgZoV94c+F+i2GpvL5+xpxBLjdbJIxdYiQBkqGwcjrntgVy3jj4s6Zd6pd+H9A8RaTpkNsM6lrc15F+6TaGKWsYJaabGRkLhSMctwADqfGviq8m1NvC3g2e2/t54jJeXzlHi0eHj97KpPMhDfJH3wScKDnnfD9naabBaSaHKJWaaax0U3DJNLdSvIPtWoyEffb5WYEYGwHp5gAzPC+t+D7nw9Jp2n6/Z6T4eMUkktuNTt31HVi6qXlm5Z1LfMvDCQ5H3MAV02r6lPEk1vqd/JYatdJLKUElsv9laaLhFZsjJ3NHtGfny44wBwAWNCaG71a0srVIri0id5Lc3LxTyOqTbprwkEn55dqrjHOWIHQP/c+MfiZcQvcefo3hbyJRCqq0Umot5ud5wcmJPLIAI2u+TyBinpV7b+CvBFxqMOmzyX0rRw2mnF4xMiPL5Vlb4yNo2spOScEyEknNdX4B0S40Dwxb2mozrcanK8l3fTKoAe4mdpJCMAfKGYgf7IFAHRUUUUAISFBLEADkk9q8g/ZhlvNS8E6zr+oBt+ua3dX8bMOSh2J+QKMMe1a37QniK90D4dSwaOJP7W1q5j0izZCo2yS55JPA+VWGexI6dR2fg7Rl8O+E9G0ZWVvsFnDbFwMbiiBS34kE/jQBr0UUUAFFFFABRRRQAUE4GT0orB8f30ul+A/EmoW+fOtdNuZ0wcHcsTMOfqKAOa+CTNfeH9Z18z+dFrutXd/AfSEMIYx/wB8Qqe/WvQ6w/A2jDw74M0PRwAGsrKKB8d2VAGP4nJrcoA4a+torX426PeeYFfUNBu7Yp03GGe3dfrgTSfrXc1538U7aa18ReBPEdqhd9P1dLGYbiP3N5iBjxwcOYjz6V6JQAUUUUAFFFFABRRRQB5r8RvD8N9q81m9wba38S2L2TswXyxfQlZLV84yGwJf97YoxkV534E8TeJ9W0hHmv8AVrmfLmeC2JZkkVyHBCrIy4fOAWX5cfKAcV7F8UWS38HzalJbif8Asq4t9S2kkELDMkjkEd9iv7evFeM+K47fQ/Gi6P4n0uLUbK8u7rVNMvTfTBCk04kZFiVZA7oznKLGeMPkfMQAaesaBrXinSr7TLqz1NvOh8pXvDcBQpJDM0k5MceAc5WJ2wPlwQDXV/CPVFuB4cka5iuBqXhWxCSK3Ly2zOsw+oM4z6EH3xy9zaaYh32N7o90fM2+RPrVumw5HymOW04ORjBGeOap+BrV/D9+mnx39l5Gj6lY6hZldT+1EW18Wtp4C+1c4lHmHjBLL04oA8x+Hsfi3xWll4S0U2wv7OARzXN7FFcw6XFG8sbD94rssj4ACpsGMcHJZfdNB+BtrpOsQapH4s8VjVbZFSO/+3xyO67cFCjxMoTgYUluMelejeHPC2l+Hb3WrrS4PKm1e7N5ck4OZCADg4zjOWxzyzEda8m8XePtLtTqNpZeD5fEugaHctBdanqGoA28Vw2N6bpt5bHmBf8AZycYUZoA6TxdpsXw/wDAvhSTSHePS/DGo2zztcMCz2zB7eVyQMZxOX6Dp0HSvUa+OfH3xRtX8I6lpdvoeo2thPa/2WbY6iuo6duWPMTJOrEJLH8rbVJDY+YZO4fSPwg8dW/xD8D2mtQJ5VwGNvdw5z5UygZGcDIIKsPZhQBzPiS6hb4O/Et7WxWwvA2px3luHZsOVI3/ADdN8Rjk44+fPesH4L2cuq/CnwH4dMrQ6Te2l9d34QkSTolyo8nPZXMx3EckLtGA1J8fI2sZPFg06R4TqHhma5uokdtszxz28fmFM7dwjJXdjOOOlN/ZxF0lt4ZN2hFvJot7HZp5+7yGi1FhOCoG07g9vhh/zzI47gHvaqFUKoAUDAA4AFee/H+RovhPrBW2ku90tpG1tGcNOrXUStGODywJXoTzXodcx8RVLeH7QKrMf7Y0s4HoL+3JoA8ai+H/AInu/GuteIfDxsbzT9auk1Cz1SLUxbbYscRkrA0vTj5WC46g1T8O+GL698Yu9g+leLPFOmRKbm+ZkttH065YOADFEha5nXDZZsEZXJUgY9L+IaaZ4RZLrwxZWFp4z8QTJpVlIFIy0jrvlZF6hB87NjsM9ai8RXUfwX+E2mWmgWdvdSQyRWMbXU3lRmaUndPIxOAC5LEZUc4yoHABejstC+G9peeK/GetfbNauY44bnVLtEV5CsYHkwRooCqSjMI1BJJJJOMjh/Evxc8Q32jT2OmaNo9hdX9oDDd/8JLbb7cSx537G2EuuemcZB54545DJLqdjqni3xvJd3UbGQG21qSQ28jQhJAscFs8SDlhgHgMRlupjhtbFJXkXVE1aI4AEUlyZyQg5P8AoTtnBwCuBzkbc4oAyVivNGt7uzu7G0IuvMhkuBqelQSSoQoIZ5lndmOckmQ9sAVU/s6TzLzUrXUP7PgjjEMk2q6na3ESuRlVCRiNWY7flLADA/Ct6C10a71G/gu0a7voggK6hLcSS2m5chTu05vvcH5gMDJHU5ivbv7NbWNrpljo8O+9lS7uLm++wxRqRGquo2WrOo2yZJQj0Y/MFAMOewuRGmoXPiTR7o/NIkNpdxadNHIXX5jJh4sYDcO6dTg54O/b6A0dnBd3UmhTSPlob6+vNMnI55+d2bdgnJIB+mSar63c2Nhd2l7f/wBkPLauJoZp7fUZkT5t26KcHYy/KBvVsHGQcYrsvC9jqvxZvo1vLxR4YtxHJdSWt1dvHMS+9bdGklIZwu3fJtBQ/KvIDAA4rWrLZ/ZNrd2dtJJJdRTWcC6baWcl7KZAsahlRNwZmUEoWAHzlWUEV7H4c+D2dNEPivUra4SSeKeWx07S7O3t2Ebh1jZxAJJFyoycpkZGME109p4R8C+Bry68QvbWGnXUz5m1PUbou5Zm5/ezMSCSex54rNSbV/iUYWtjeaL4IbbL5ys0N5qycMApBDQQnueHdTgbQc0AaM/xBttR1qPSPBENt4kvgBJcyw3YW0tIyWAMs6q+GJQgIFLHvgc1k3dnD4fNr4w+K/iaA3NlI72ltG/lWNpI0bDbEmA88mzfgtubk7VWuq1vWPD/AMO/CUUt7JFp+k2Ua29vCp+Z8L8kUak5ZyFOB14J9TXF6fa351ay8S+LoRN4rvZwdE0KPUJDDp8bRBXyAApcK0hkkKkdAv8ACCAVtQ1DxB4w0qKfxHqMPgvwrqVtIq2MJSbVL2N1K4JZCsZIZTtRWcZxkHp0Xw/0Dwt4Sia20Pw1Lo0BG/7beKoaY8DG53Mme+CABg9O80sD6AbIRtbX/jXV4/sxuLmfb91Gd2UbSREhBO1VAJK55Oa6q50ixvVg/tK2hv5IYzGslzEjkhsbjjGBnaM4AoA574k+BbLxppS/M1lrlnmXTdThO2W1mHKkMOSucZXuPQ4I5PwcL688OJcXklvPqCatOfEE8FwrPNd2s+yK3jDKuFdkj2qdu1MDkturr9L0tNA8YwWemO8WlXWnzP8AZGuHdIpI5Y8GNGJCAiYghcDhfavI7nWrjRPif8Q/C/haZLfU9cvLBLJD83lXE0Je5uVHoiDe3+1t9QCAdj4ZtZ/Fvjc3NxFjSPDl9ctI32gut1qbbQcAqMpAheMMcEtjj5a9YrL8M6HZ+G9DtdK00SC2g3EGWRpHdmYu7szEkszMzE+prUoAKKKKAPJPEeqS+Iv2gfDPhu0MMlj4et5dY1AFsnzXjaKJcDoy+Yrc9nz2GfW68p+A048Rp4p8by2iwy6/qbC3fqWtIEWKL9VfPvXq1ABRRRQAUUUUAFFFFABXDfHG5a3+E/iUR8vc232NRnGTMwi/9nrua88+NZEmi+HbJj8l94i06Bx6r54c/wDoFAHodFFFAHIfFzTbzVPh1rUOllhqEKJe2wXOWlgkWZFGO5MYH41t+Ftat/EfhvTNZsv+Pe+t0uEGc7dyg7T7jp+FaleefCOYadL4m8ItbLanQ9Rke2jRHCmzuXeaFgW4OCZE4PHl0Aeh0UUUAFFFFABRRRQBHcQx3FvLBMu6KRSjrnGQRgiuH8P+G7DxJ8NLfw94otxqFrayS2Lb5W3P9mneJH3qQwY+WDkEHkj1rvK88lN/Z2Pjvw/pcsqaqYbjUNLb5snz0ZsqfVZy/TpleOeQDy1W8LWPxL1Hw/4d8QNp+h2tjHA6XNxezQrepNIZI0fzVKsI9uQr49sg1o/EMeGrey07UrXXDdanDElnqzwG4mM9hIQsjKpLlfKZhMozwUPOTXhXw+uvsXizSDYahfWbeYsly7OsTlwpL9Z0GSgUHP8AfbJ6A+63upWOpKyDV/Ft8dwjktbHUIZllDHGGjWeX5ccY2njPFAHqfw/1y38YeDIEu3ke+ihjt9RjJaNhLsUllIPKNkOrqSGVgQa8gsvHqfB3xB4gsr3TbjVvCWo61NdprVnMJRbTSKu+3kUcB1KtlSwbHODmqPw18V3/hTxZb6bfQXPkKq2KWItp5roWavclAx2As8KxqwBQM0MpwCVWvXPEPguz8VW/wDa/h7UIo4tVjE11DdJJdWGpRPEqoZIPMQBgFiIkUqw285oAgXQ/hr8WIJdSSwstSlB8uadEktbkfL92QjZJgqejcEHjiq1r8K5PCV3c3/wz1iXSJZYwr6dfl7yymKgBMhm3ocLjcGJAOAMDFeO6TpF3o8EiPZ6hfX1mzWV7/ZsksWv6MfKQDyyr/6VaABSmcja6/3cD1Twj438QSae15ZXtj470m1Biun0+zaw1GF1wSTbyNhzjPyjYSemelAFT4gJ46uGtW1jw5FLYSaZf6bfzeH7o3cipcIgDLDIkb5Vo0PyliRuGMkV5f8AAzxBrui69Bp3iFNQ/tWz1NnMN95qz3UF4yRzlFdd7FJRDOQRypkJwea+m9C8YaJreoy6dZ3bx6pEglksbuCS2uFTCnd5ciqxX5gNwBGeM1b8ReHNH8SWYtdd062vol5TzUy0Z45RuqngcqQeKANWvI/2gPGWneHT4Q0+7nk8261u0uZIYRucwQyiQnHQjeIxjIPJIzg1u3vw7ntXt5vCPirXtEmgQIsM93JqFq65Xhop3bsCPlZTz1rxj4qfBPxbq+sT63quoSeK2YoENvi3ktk3ksiWzHa8YBOAJkbJ69cgHYeONZTUviH4N8TeHdRtrmwu7C703TL0o0lvaajKFEXm7QSpfcqbWAIwcjg103xBsJviF4Z0p/Dpt7240rU/Ou7WWZ7NyyQyxtH80bFH3SKRuQcc9wa8D1bU/E/gvw9Hob6k2u6Rf+VcR2GvWN7pd3A8biQCKQsvzBlXAWV+VGAc87Ph34ganpeseHo9bXXItdubaCNJzp1yLuRUWUBbm3LbL2P95xKhSTIJIBoA01tPEXg9Le0TwZr1nOTw2jQXFzGMgbm81LttoJ7eWOmcDty2reOdO1+B7HVXm14wocWs5v38iQA5LYCsGGGz1x7817Zp3xisLXVhYa9qGlMjM7C4aObTHRBHuXMN0ADuYFQVkI5HAGSOWivfgbp16813ommrLdYlnd4xexJIyeYVXazqSCSv7sEZBAoA4OfWbKy1QabBqaWOnWirLHEk91byiRo435S6jnYgrwBGo3HaQG6V1mm2PjuLSo4tM8Ca1AjIWjkOuvbebIcnLxQzW4j56kpuxjIGAK5Hxhp+h+Cfid4U8WeHre4vfBM93ve2EcxWymh4kUox3K6bTIEbG0qwxgcfTus+PvC2i6hcWGo63ax6hAQJLRSZJwSoYARqCxJVgRgGgDgPhJ8JzYtda18Q9L02+8SS3slzBKbma7ECPtwuJSRuUrw2WbGPmzmur1zxzNPq8ugeBrFNa1qGQxXUrlo7LTzj/ltKAQWyR+7TLcHO3FVtSu/EPji4k03RY9S8N+Hxxc6pc27QXdwRIh2WylleIFQ4MrrxkbV712fh/RbHQNNWw0uJ47cSSSnzJXld3dy7szuSzEsxJJJ60Ac14d+H9rb6jDrfie4bX/EiSPIl5cbvKttxztt4SzLEoAABHzHGSea6zVNQtNK065v9RuI7aztozLNNIcKigZJNS3dzBZ2stzdzRwW8Sl5JZGCqijkkk8AV5XGtz8XdUSW4iu7T4e2ckM8MFxatGddflw53EEQKfKZQVw+SSeMAAPDNzd+Ib7/hY/iTTLyDTobdP7A02CSa4mRW81WneFBt8yVZEAxnavUjGa7DQLW50zTdR17WLOSTWrvdcTQQ4mkjQD93bIQOdqgDjguWbuTVldZl0TQorrxY1rb3Mkvlx29hHJNySdkSAAvK+0c7VGcE7QBWvpdxLeaZaXNxbPazTQpI9vIctExUEofcE4/CgDJ8OaXd2dpNqGolLjX7xA85LbUQgZWFMZ2xrnHGSTljkk1n+Gb67Gt6tDd3QuLazjDX13IzCNblvm8qIH5VSOPGT1O8ZOQ1O1DVJfE8Z07wxdTR20jNHdatDGdkSAEMsLkjdITwGXcF5J5ABuaj4dFxY22jWnlWmgFHW7hiBEkynGIw3ZWy29vvHtgkkAGbpN/AsWv+M9RNzHpwiL2pmicOlnFGGZhGfmG9w7YwCVCcVyfwO8IahFq3iDx14kgu7XVdeuZpLaxuXbfZWzuCEdTgByI4+2QqIOORVy/m/wCFpeJLjR7WRj4I0qQpqM8UhA1S4wMW6spH7pM5c9zhemTXqdABRRRQAV5z8ctZ1O08LW+h+GkaTxB4in/sy02SFGhDKzSTZHO1FU5I6ZB7V6NXjPw6mT4lfEu+8eyW1yuiaTF/Z/h55PMRJs7xPcBWxyc7M46cEbl4APUPCGjr4e8KaNo6lWFhZw2u5RwxRApP4kZ/GtaiigAooooAKKKKACiiigArgPiqqzan4Bt5MhX8Rwvn3SGZx+qiu/rgviwxhuPBF0oJMXiS1Xt0kWSI/wDodAHe0UUUAFed+K5Lzw18TNE8QIWl0bWEh0K/RYyxgk8yRraXI7GSUxkngbh616JWH438Ow+LPCmpaJPM9uLuPCTp96GRSGjkHI5V1Vuo6UAblFcv8NPETeJ/B1he3IKalEDa6hEy7TFdx/JMpGTj5wSOehFdRQAUUUUAFFFFABXJ+MS+k63ofiJTF9ngc6bdhgAfJuZIlDhiRjbIkROf4S/fFdZUF9Z22oWc1pfQRXFrMhSSGVQyOp6gg8EUAfJfxa0Fvh58TLm8trKG40TVZIb8PNbOBC3nSGWKJ1kUMcM5ZTj93IRgbc12GmfbtYjtJLWz8MLYypG8E+n6JcXMkag5OS0Eqkjt8w5/Md5L4ek8QeHtU8CalK1tfaQ0FzpmpusU7CLzGNtKFznenlNG2Qu7aeSGrwPRtP0iwvG8P+MfDOt3D2wt0udPsoUjjtp3JLCWSIZdHYK0bKScNtJYgZAOz17wToVlDax6nbtd3yRSxW08mnTadGJ2Vvm3MSz7c7gkEYO4Z7fKnw08c3fgL7HZ6ghuPBVzLCiX8WnSRJBI9tGzc72VW8wHfEBy7uVOQYx0GkaZY29xnTfh7pFjbxIrNPcaTJO4UqxP725+zqABxwzdcYxTdK1m1kv7+91bT7bW9Lt7J7aWMQwzJHCqBiE2yG2t4fkGUMju525AwMAHoGteHPCvxK8PtqmnCxe/nh/0LWoYcXNpKOUbcNsilGwTGSvQqwHIrh/EnhTw/wCNNZk0XxpbQ6D46WSRrDWdOhe3GoKqpiSN2GJCAyhoizMu1sHHzVydtFrvhK91DxX8LIzP4YiiSW9sr4qsKr5QLRCR5gWMXABCjbkpltuyvXvCnivwp8V9NvLK70pXms5dtzpOs20ZmiYcbzGS2BkkZ4I9qAOA8Z6T4/8AD9hGutaBofxP0m2idVnmshHqEW4AEAZbI90BY9SRTdL+MHhPGlpoPjF/DdvDCbNtF1vSJblY2U4VjKrAqw4zmVhjGQpzXpF0/inwleTTwxXHinw/I8spt4wo1CzyAwVWZ1WdMh8LgOMqAXxWD4i8D+CPi34YvbjSYrSz1Gdyr6jBaiO6hlV/nSZDtYnKkFH9c+hoA09N8a+IbWwhutX8PrrWmyfNHq3hiQXMUqFhtfyGPmDg8hTJ904zWs/xI8LQXCwahqE2lyMQF/tSynsQ2TgYMyID9a+RfHvw68ZfDK/u9YWJo7GKUtFrWk/uQPnYoGRWzECWAIIKghFBODu1fD3xj8fSpJZ3lxb6zp8pQBNQ0+O4yjTmP5jGybxnOTyMqAMZzQB9k3tpYazpzW97b2t/YTqN0cyLLFIvUZByCK898T/BHwTrYD2umR6PcBlYNp8aJGxUMBvgZTE2Nx5KZ9xXzvceJr3XI4rLSvAPhCeRLdLzNnosts0I8vzXYSQ3G5QoMYzxlnxxjmDTPiX8SdAltY9KvLedblVaPTheJfIp3SAKC8ssuCEJ4dcAD1BIB6u37P2qafdpqPhzxTYafqqkh5YdI8pJ0xgLJEJTEeQCcRgZ5xkVc/Z28Tx69ZvLrmheG9Ou0vDpdnPploEaeeKIySZKgqPkAIIIBw2Owrx+x8QfEf42eMLTwxeay2k2Utv9pmW2jMMawmNW3Mm4NJkOmFLEfODwOa9m+BngfTtP1Z7rSmtrjStBaXToLiS1lSa6uyqC5uBufYAG3RAhSdoK7sLkgD/iR4bEmq+JfDV3BYTaf4vt57/Sd0OxoNWhgiQJu5XLqu8N8pOHHOefPPgj4th0OXSri9W3S602b+wtac20kU8dtIsX2aWbnafKmR4Nx+6pUHGRn6I+KWgP4l8BaxYWlus+pC3ebT+QGS6VSYmRiRsbdgBsjGfSvnHxffR6X8T7vxVp+kR3ejazb3Ues6U9uBPGsKwLewSKH27lCrMHGAS5OWGDQB9c1T1nVLLRdKutS1W5jtbG1jMk00hwEUfz+g5PQV594b8UQ+B/A8Nr4vuZ2mtbmSy05tyzz6rD5mLdoERmZyyNGPXIJPHNeceJtW1n4l/FHwZo19GumaCNQmuJdLkHmtIluscpW7wxjLEjb5QyY953dQKAOk1IXfjd7PWvFvnN4dkvWXQ/C0MLRSaoUf8Ady3IlxuUhfM2EBAmCc857dZrjT10+21O207UfEcZWSwtLGzkjhsEZREcyDfsQAyfOdu4Bgq8YrR8KaM6anqOt6xD/wATu5lkiQSFGa2tFkcQxptJChlAc4PLMc9ABX8Qabp2n65Jrd9rb6Zb3H2dZ4VdU+0vEzeWCxy2DvwVXGcc8EggGjpmgGLUW1jWJItR1jZsjkWBY0t0G75IQSSuQxySxLeoGAMrV4ZZ7eyufGtzaw2HnLt0q2iaUTysCEjc8mbGSdqovK5OQK6i11G2udMTUA7RWrJ5m64QwkL6kOAR+NeR+H/F2jz6hdv4O8Oav421yFmMuurFDHBJNswVW5kZVQAHAVBgDoDnJAPRNMvprPSn1O+S00bw7b2oljtJbcxzW0SxgnzCH2ptw3yBTgAc5yK427l1X4sfa7LT5p9I8BMqxy3Zt5IrrVlZAWSMSBfLhwxUvglsEDjNWLHwJq3iy603VvijdWt4LdRLF4etoB9hglKlSZNxYzOAx5JABzjIPPp1AFbTdPs9LsorPTLS3s7OIYjgt4ljjQZzwqgAVZoooAKKK57x74qtPBvhqfV7yCe6KukMNrbgGW4ldgqIgJ5JJ+uATg4oA82/aY8bf2b4cXwbokjyeKPEJjtYYEB3CGRyjNnGPmIKAZz8xPavTPAXh6Lwp4M0XQofLxY2qQu0a7RJIB8747bmLN+NeHfCTwPeeIfizqPjDxXdNe6hpflrOjwAxJfOhZ4IyXbC24KKCB94nB+Xn6PoAKKKKACiiigAooooAKKKKACvP/jmFh8B/wBpFir6VqNlfoc4wUuY8/8AjpavQK5D4wWsF58KvF0V2MxLpdxL0yQUjLqR7gqD+FAHX0UiMrorowZGGQQcgiloAKKKKAPM9RkHgf4qJqH2ILoXisQWU00IH7rUVZxGzrngSK+0sAfmRc9a9MrG8YeH7fxR4eutJu5p4EmKOk9u22SGRHDo6nsVZVP4VifCvxW3iTw+LXVPMi8T6UEtNYtZgiyJcBRl9q8bHILKRwRnHQ0AdpRRRQAUUUUAFFFFAGfrWmDU7QxJdXNlMHjkW4tmCyKUcMByCCpxgqQQQSO9eTfFzwxb+NdQvv7M0y5Hi3SYoWFnNLBGmqWbTdNx3gD5JQrHayseQAwz7TWB4s8LWHiWG1a43W2oWcqzWeoQIhuLV1dW+RnVhhtgDKQQw4NAHyd4eufDN7bWoS01ybUVjQlLSQ70dRyHX7MVLKcjcB1B7811t1q1rot5o15/wjsEv2edlQ3Bt5p5z5EgTMEEMcsmGKgM2VDEHg4ZdnxL4WOtaqsf2TTtD+I5tUa4tJVtja68oaUu8JwWEhKM24gMqsFcFTkcfpnjC70fUH0rUb2bw1eQOyT6e8LMyOSOAtsImIIYMHztYFcHsADv/E2m3evNBb+Nb/U1Q70t9Dt47V7u5kaBstHDGWjhVQzYeV5Cu3O9MgniviLp41PU5PEegWsNlf2sRgtEsWgZZPJWAiKOWJfNMyRq7NKCY4wix7iC2XaXYeHIdTj8nUWEM53NbE2ttaBvLKgyx3ckjFs7RvZXIBwEyQR0dlH4Z06G7vrq4t9ek3lS/wBphi0tXCxKkUt1Js844VG8pMoNoxEpUZAPTfhb4wvvEllCl1aXN1aPbi4tNcSNFgvY/lGGUNmKYMWVkxjKMQcECtTxJ4C0HXbgXxtRp+tK6yR6tYKkV3GwP/PTadwI4KsCCCeK8C8NXyaL4o1naqC00jVrPxDFLFbC3VobiP7LdOsXBWP5tyg/wqGyc5b6noA88/tXxV4YW6tvEukXHijR13NHqempG1zsL4CTW3y7iFPLRA5C/dFc1N8Ovhz8SLOPWvCH2PTr63JRZrK0jURyBicT2sibSQ2chlDEcZxivaK5TxL4A8Pa/MbuSwistYEiSx6tZRJHeROpBDCTaSemMHII4IoA+S9a8D+Mvhct7qGsaVp91p+5Lcah9mW4tVTgB2QEMmSsSnKYPufvSaWLHxBCsMVnIs91bJGix6KoWVlt23yAYZWdI5VYnfGBvRgM8p9QfDjXbvWY/EPhzxLJBfatodz9iupvLVVu4nXdHI0X8O5TgjG0kHHHA+YfiFonhzwn8W9YtF0e70ko8N1pUT3SwwOxzulDhGKpvVNoLKq4fcyjKUAdTpHhQWSRa94AtdcPipGAgv7ewggsMsvziQK8kZQgn7hwuRggACvTvhlqU9/Pp3iDQo2tbHWdQmh8RaW0CCK1vlt8NNE68gGSBVOWYMZgeGzXksFxY30ttbXFxozacimW5Ej6XLLLIIxlw6SQ7ctIdpEztxzg1peCri/nt7X4bta2V34X8Q2919gGp2bRXMBWBpUlk2BVkHmKDvXJyR8+RgAH1VXhPxq8Iw3GqXtrNH51p4lidrIOibbfWoo0EGHYYVZo49jA5B2Y43V6l4K8SS69Be2+pWJ03W9MlS3v7QypIEkaJJAyFWOY2DjaTg8EEAg1J4+8MW3jDwlqWi3YUfaYiIZSMmGUcpIPdWwaAPkq0n0+/wDCNgurW+pwXPhKfzEdrJMX2mNeRJNF+8LKWhkYqAzGMDIOQxx2l54ek02xHiawN7oOsaNezxaXLLaQeTcTyTKhtmSJWmuHcF0yiiNSpEY2jceL8XeXpHim38SzpbHVIryVNd0gLFt+1hlWcMXKn7PdQiRlJVxuO0ff49V+Fkejt4/0iVp2ufDtzp09z4PiuxDizJlU3duAfn85G2hcE4QOM4FAEmoXfxC8TRWlxqXwjgXUGiWL7Z/wkK24CE5KuiMHKcklCT1PB6Ve0LwD8QJbyyurq68FeF/KUKToejpLOqZyUDSghSfbI74Pf26igDzuz+EPhttbk1fxG194p1FhtSTXZEuEiX+6kQVYwOScbeDyMV3tjaW1haQ2ljbw21rCoSKGFAiIo6BVHAHsKnooAKKKKACiiuX8feOtC8C6Q19rt0Fcj9xZxFTcXJyBiKMkFjlhnsM84oAv+MfEuneEPDV9rutSOlhZoGfYu5mJIVVUepYgDtzyQOa8UFjq+oi/+KHizSXvdSSWO28JaHcKsf2YSzhLd5VJwJC8kZJJyuCeyhd/w34U1n4g+KovFvxDtjBpFjM8mg6FPCqPCrFcSzgZJchFOxicHPTodX9z8QvibPGbmZ/D/g+eJhGiqI7jVBvJy3JIhUpwMYduc4oA6z4deGk8JeDdM0j5GuYog13MpJ864bmWQk8nLEnJ7YrpKKKACiiigAooooAKKKKACiiigArN8S6WmueHNV0mU4jv7SW1Y+gdCp/nWlRQBx3wf1WTV/htoM1ySbyC3FndZOWE0JMT59CWQn8a7GuG+HS2Vh4l8faTaOQ8WsretCSfkFxbQyFhns0nnH67q7mgAooooAK89+IEN/4Z1mPxxo4ubqCGFLfWdOi2/wCkWieaVlTKk+ZG0pbAI3LkelehUUAV9PvLbUbC2vbGZJ7S5jWaGVDlXRhkMPYgirFeV2pPwn1f7NKbSD4fajdqltLLdSZ0iVojuVt+QIHdBg7lCtIeMEV6jBLHPDHNBIkkUih0dGBVlIyCCOoNAD6KKKACiiigAooooAx/FHh+28RWMMFzNc201tOl1bXVswWW3lXOHUkEdCykEEEMQQQa87vrODxbLa+GfGlzbaX420wrJYX0PlyG+Bt/nmiWWIK6EmUSQgELs5I+U165WN4s8PweI9KNrNJLb3ETGa0uoZGSS2m2sqyKVI5AY8dCCQeDQB876L4n1SGz1Pw34lFvbapa7rK+RVWNCNv31EOmyKqMpyMt0NUdPu9Y0e61u60hZYZbcKLPUb+0aeKJduWjS8uzAkIDH7vlYAxjd0qh8UrnzPEHhHxMmlDVLnxXoUO61gmmj8+/UKqsPLIyQJFXHHyg9zzZf4VXniPxZeQS6XpdxdW0QiezsrmVLK1fygFN3dEebPLlVJjTnuXXJyAS/D99T8deMvE8634u5fETNpbzGVXMOnQeX504xEikPuSOPCLlmcnlCT9YVy3gbwTpnhG3Zrbdc6jNGkdxeygBpAowqqo+WOMfwxoAoHbvXU0AFFFFAHH+M/C95d3yeIPDF69j4mtYREm5v9HvIlff5E6kH5TlwGXDKXJB7Hzn47XOieJ/gRpvi7U1ms7tIrfUdPNswd47iRRiIuAPky3zEbfug9QBXu1cl4S0KDRbfUvCsOkvH4cgjDWsk9x56TJMZDJDtYZUIRjBLZVl56igD5Q8JwR2uo6W0Wtadpt1GFafUW8QW0UUcpR1ChwhlfasrKSkkowUDFAo2yazNd6XKNXstWMF/o7ySJqNqMeexjYsvmtD5jbyoGJQy5JG7BJHK6FYzW+pKdUvI9MGn6iyLY/2n9kvIpF4WPzXB8sR5GJWAUZYBtx213WnaFbQ2F00Ot6FYBogqyxa9LeXkkSINwQwh8xgAAgxAjkdAKAPXbGfVtD0C1+JWn3VprzTaIjeIoI50iW5aJQwniKIR5qL5ilTgFcDgjn2iCaK4gjmt5ElhkUOkiMGVlIyCCOoIr5T8JeNbfwVeeIVkg03UvB2qSK19bQTLbyWRYLE7JAyRtIGQhmCxrwOTxz7d8LJU0vUvFHgyGeWe08O3ECWZlYs0dtNCsiRFj12HeoOSdoUHpyAZnx48O/bNMtddUzC3sgbfU1tkHnvYvJGzSRttLCSF445lxgfI2c5wfB/C+p2nhrxTZeHPEusy3OgT6gNQtdbjuYXCXInUxXsTvGQFYKYpVLPhvMLEdK+zK+cvGGl+GdS8R+JdCh8S6bFYGzudWtr46kB/Yd88qxTRM2SFinabLRk4zvAXkYAPY/D3jKz1PxHqmg3QjstVs5A0ELzAm8tmUMlxFwNynkHGdpUgnpXVV8v/s7a54+v/D88GhaHZXek2qLDp1/rN06LB8uJI43WMvJHvAIUY2gbSTxj0WGx+NsshFzq/ge3jY/egguJCo9gwGce5oA9brL1DxDoum3UdtqOr6daXEjiNIp7lI3dj0UAnJJ9K4TS/hlrE96Lvxd8QPEmqsE2/Z7KdtOgJOd25YSC3J45HTHI4qn4j+C3wytvD1yLuxh0aMMJf7TN66SwvzhvNkY+vQ5B444GAD1uuJ+JHxN8M/D23X/hIL7bezQvLb2cSM8k20dOAQuTwC2BnPPBx4pa+FfiH4vkvI/B/wASdQu9Gsp0tBrE140KXOFBk8lYlYybSVHmFwGIYDPJr23wJ8OdH8I3cmpJLfanr9xCILnVtRuXnnmUY4yxwo4HAHYZJxQBys+sfFfxfpQbw/oWmeDVL48/V7kz3DIejLEsZVCPR8/1rd8F/C+x0DxFN4l1fUr7xB4onj2SX99tCx56+TGoxGOMAc4HAIBIPoNVtT1Cz0qwmvdTuoLSzhG6SeeQIiD1LHgUAcT8bPHX/CC+CLu7sXhfXZ0ZNPtmOWdhjfIF5JWNSXPGOACRmrnwbtvs3wy8Ps159umubf7bPc7g3mTTMZZDkf7bsPwrI+Hlq/jDUr/xzqrvLZX8cllo1m+8JDY78NIUYAb5iiueM7Qgz2qb4DxwWPgOTRLebzv7E1S/01m3ZI8u5k2g8kj5GTg9sUAeiUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwGtNb6L8ZNA1CV5oo9b02fS3IB8p54nSWAMegYq1zjPXBFd/XK/E/Q31/wRqdvaI51SCJrvTpI22vFdxgtEysOQdwA+hI6GtPwnrtt4l8O2Wr2QkWK5Q5jkQq8bqSrowPIZXVlPuDQBr0UUUAFFFFADJoo5oXimRZIpFKujjIYHggjuK8utbq5+Ezy2uqR3Fx4BaY/Y74TTXUukoIlxDKmwt5O5WCuGbblQ2AQa9UqK6t4bu1mtrqKOa3mQxyRSKGV1IwVIPBBBxigCUHIyOlFeaXWg658Praa78EF9T0CEeZL4euXklkjRUwRZyElgeARE2VJzt25xXZ+G/Eml+JILiTSbh5DbSmGeKWF4ZYXwDteNwrKcEHkc9qANiiiigAooooAKKKr6jeQ6fYz3d0XEEKF38uNpGwPRVBYn2AJoA+edakfTPDvhVoZXF5o134jtopE+/H5VvebMehwkZH0Fe9eGNFtPD2h2um2EeyKJSWJJLO7Hc7sTyWZiSSeSTXg+oaXqWp614P8ADsk32fVdSsNY16/LW7qbWS7gkjVQhJYBGmZcZydvY8V79oeqWmtaPZ6lp06XFpcxiSORAQGB9jyPTBAI6HmgC9RRRQAUUUUABri/F9+sHjzwHaRX88NxdXl0HtUlYLPCtpMWLoDhgriLBI4JGOprsLm4htbeS4upY4YI1LvJIwVUUdSSeAK8t+GZsbu+8V/EPVHC2l3cOmnX98zgxadGBgp5mPLiZ97gADORnPFAHkf7TSCH4saVLb6BcWtzcWzQrqIuGRL92TYuFRSWMe7aV++4YLjG3PF2er2ml2kuptHNq2lW85tRdIphSSUQghI7iaEkFUUjYRHJj+JwVr0LWvB/iD45eObzXdNvrvSfB8YWLTr69jkEjL5Q3m3h3L8kjYyxIJAHP3lr0zwd8CPCeh2tn/bCXPiK+tyGE2oys8QYIEwsGdm0AcBgxHHPAwAeC61r2peL7bSTqw8T6T4Dllf7fewpfzxGAAH5vNaRSCwIUq3AzlTgCvU9S+I3gnT9e17V9G+JMFj/AMJBbxExrpcl20FxGqIswwvH7tdpRh1wexB9+KgrtIG3GMY4xWdb6Bo9tcNPbaVYQzscmWO3RWJ9cgZoA8ZvdbvvEh0/SfDfhfxfrgkV5Z9X1DUb3RrUsxQGQYI3oSCwjAG0ZCLyQLXhf4MXl7dRT/Ea/s7zT7cg2nh7Sw8WmwMDw235TIcddw5ydxavbqoa5rFloenm91KV44PMjhHlxPK7PI4RFVEBZiWYDAB60AXYo0hiSOJFSNAFVFGAoHQAdhVLXtYsdB0qbUtVmMFnDtDuEZzlmCqAqgsxLMAAASSRXFyeNvFGpFx4Z8Bak8PmeWl1q86WCEbsFzG2ZduMn7oPTirOneDdR1PVbTV/Hmo2+pXdqIZbWxsEmt7O1nQsxk2NK3mvlhh2AxtGADQBzcvxE8dRa7pMbfDq8fT9RsftEaW7s8scpLbUnkdUSEhQCytnGQAScgbul+BW1y+fWviJDb3+oG58+005biWaysECBFURsQkkn3mMhT7zcYAFeg0UANjRY0VI1CooAVVGAAOwp1FFABXl8E8nxR1+GSOGRPAmlXLnzDLhdYuonXZhAvMEbq5zuw7BeCFNTeItQvfHXiK78KeHb+ey0azV49c1OCAkmTMeLSGUsAshRnLkBtvyjgmvQNL0+00rTraw063jtrO2jEUMMYwqKBgAUAWq8q+E9rLpHxL+KOklGW2a/t9UiJYkMblGZyB/vIR+HtXqtefWV/Ha/HvVtMUIHvvDtpdtwdzGK4nTr06SDr6CgD0GiiigAooooAKKKKACiiigAooooAKKKKACvPdAa88KfEa58P3FzFNouvfatW04uSJYbgOjTwDJIZSZDKuAMZcc4zXoVcp8SfDs3iDw8G0uO0Ou6dPFf6bJcx7lWeJ1cKSCCA4UoSD0Y9elAHV0VieDNe/4STw/DqDWktlP5ktvcWsrKzQzRSNFIhKkggMjYOeRg8ZrboAKKKKACiiigArj/FvgOy1u6m1PTLu70LxG0exdU0+Qo7YxtEyZ2zICB8rg8DAIrsKKAPP4/FXiLw5fG08a6Q95ZNvMOsaHaTTxkDGBNbqHeI4zyCy8dRXSeFvF2geK7dpvD2rWl8EGZI43xJFyR88ZwyHg8MBW5XNeIfAfhTxEZm1nw9pl1NKMNO1uqzdc8SDDg+4NAHS0V55b+BfEOi3Eg8L+OL6DT2Hy2er2w1FYuTwjl0kAAwACx/HjGpJpnjlrUxL4p0FJCBiYaDJuHTsbrH6d6ANzxAdaFnF/wjq6c915y+YL5nVPK/iwUBO7pjtXC+NfGVh4Y8VzGHVtQ1vX5bYwWXhWwCv8+A+91VSynAzvc4C7sA1D/wAKjfWPm8d+MPEHiINjzLUTfY7R8Z/5YxYxnPrXbeGvCPh3wxGE8P6Jp+n/AChC8ECq7gf3nxub6kmgDz2T4d+ILmKfxjdajD/wsgLHcWpjRltLcLEAbHY0jAxMTIGcEHL7hgjm7o3jG2bV4rLw7p0enavNO11rHh+/ge2un3bUaWB2IicjbuO3cJAc7lPX1KsnxB4b0TxHDHFr+kafqaR7vLF3bpL5e7qVLA7ScDkY6CgCXWta0/RIoptVuBbQSP5YmdG8tD/tuBtQe7ECtGvLB8KLnRLiQeA/E9xoelThhcaRd2w1CzbIAO1HYFM85+Y5z2HFc/qnh7xnYX+yb4feDtesdpRJtElOl3CLuBGS7fLnA4Vj069iAe50V5loUt1ocMU1h8L9ZhvyhjZvt1lKwUkMy+a1wWK7gOuOg4Fakvi7xQFby/hzrTSYJUNqFiFJ7AnzjigCHx2sHjWe38KWLw3MMV7b3Wr+ZA0tv5EMqyNbs4BQSsVT92TnaSSMEZ5z4hWT+NPiFonw8jtmTwnZWy6lrAtnaJSo3pBbEoQApZQ23gkAEEbc1FpN18RLKAaX4T+GWheFrWSbe09zqMU0Slj8zmOEgk4Hr6dhiofB3wETSpNSk8QeMNc1VtRlE12lvI1mt0RniZlYu4+ZuNwHJ4zQB7HaW9npGlwW1skVrYWcKxRrnakUaDAHPQAAUlnqVje5FneW1wen7qVX/ka5qz+GPgW0tlgi8IaC0agAebYxyMcdMswJJ9yam/4Vx4H/AOhN8N/+CuD/AOJoAm13xx4f0TVItMvL5pdUkUstjZW8t3cbQM7jFErMo9yAKzLv4kafAJDFoXi+52oWAi8PXg3nj5RujHP1wOOtdDonhrQtBaRtC0XTNNaQYc2dpHCWHvtAz0Fa1AHnEeh+KfGhju/EeqX3hrSxLI0Gk6VJ5F26bl8s3NwrtztBJSPbjfyxxitnTvh7odrfWt5dNqmq3NpJ51u2q6lcXiwv2ZEkcqGHZsZHrXXUUAFFFFABRRWb4h1zS/DmlTalrl9BY2MX35pm2jPYD1J7AcmgDSrzXW/EOoeOb268PeANQS3sVhli1LxCsLyJbuQAsVsysoeb5ixYMQgA6sQBA8HiD4o2WL2Ofw34JuljY2zYGo6lE0eWV2VysETFgCoy5CkEqGr0nTrG00yyis9OtYLS0hG2OCCMRog9AoGBQBV8P6Hp3h3S4tO0a1W1tIyWCAliWJyWZmJLMTyWJJPrWlRRQAV5d4ombT/2g/BEgk8sanpd9ZMMD94I9soX8+fw969Rryv4ws2n+NvhhrCxJiPWzYGUgEr9piZNvrzg/kPagD1SiiigAooooAKKKKACiiigAooooAKKKKACiiigDzHXbZPh543/AOEnsrfy/DesusGtqkiRx21y8qJFd7WIHzFyshHPRsEg16dVfULK11Kyms9Qtobq0mXZJDOgdHHoVPBFeb+DL0+ANd/4QjXLhY9HlYHw5eTvjzEZubNmY8yIWUIM5ZSMdMUAeoUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUVm61r+j6FGkmt6tp+mxv91ry5SEH6FiPUVyt78VfDS3r2OhyXfiTUUG422iQG6IGQOXGI1xnncwxQB3lFcFe6r461uf7LoegxeHbUqhbUdYmimkGT8wS3hdgSB/fdRSt8NNP1S8trvxlqWo+KJ4I0VIdQMaWqsMksLeJEQkk/xhzgKM8UARz+PrjXZriy+HWmDXZIyqPqskqx6bCx3Z/eA7pSuASsat94fMKn0P4fW/8Aaza74wni8ReIC2Yp54dsFmvGEt4SzCPG0HdyxOSTzXZ2drb2NpDa2UEVvawoI4oYkCJGoGAqqOAAOwqagAooooAKKKKACuB+Mdt5+m+F5Ngb7P4m0uXJx8ublVz/AOPY/Gu+rjfizLHb+EoLmZgqQavpcpY9FAv7fJ/LNAHZUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFZHizQLXxPoFzpN9LcwwzFGE1tJ5csTo4dHRuzKyqR1HHIIrXooA898LeK7/R9Vt/CvxBuNPh1gwRtZaikpSLVcuyEBWVQkwxHmMFslwV44HoVZniTRLLxHol1pWqI72lwBu2OUZSrBlZWHIZWUMD6gV5fB8QZfh748t/BnjzVUurC7txcadrlwFiZVyw8u5PC7hsxvGM5UkckgA9joqO2nhureK4tpY5oJUEkckbBldSMhgRwQRzmpKACiiigAooooAKKKKACiiigAooooAKKKKACq97btcxIiXM9uVljkLQ7csFYMUOQflbG098E4IPNWKKAObj8M3cUyyReKtfXBkLKzW7q29iwyGhONucLjHAwc1SvvDHiUsrab491SJhnK3dhZzKevZIkPp37V2NFAHnw0v4m2wEcPibwzeqB/rbnSJY3J9wk2KWPw78QZ2aS88eWdsXH+pstETbGf9lpHYn15FegUUAcRb+FPFIuA1z8Q9WeHnKR6dZIfzMR/lRqHgCbVHX+0/Gni2eJVKmKK6htVbJHXyIoyenr3NdvRQByWg/DjwjoV39r0/QrX7bkn7VcbribJ6/vJCzfrXW0UUAFFFFABRRRQAUUUUAFFFFABXnH7Q8/2X4SatcdPKuLF/wAryE16PXmX7Sm7/hS+v7GVW32mGY4Cn7VDyT2A9aAPTaKRTlQTjOO3SloAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvNvH3lN8XfhgpRTMZdS5zzs+yNkY9CSv5V6TXm/i9GuPjf8PUHC2tpqdyT65SOP/2agCSPwbq3hC9iuPh7PE2lsSLjQNRupFtlGGO+3k2u0TbsfLgoQTwMCtHw98Q9M1C7stM1e3vtB1+5U40/Ubd49zr94RylfLlHBwVY5HOB0rs6y/Evh7SfE+lyadr9hBfWb8+XKudrYI3KeqsAThlIIzwaANSiuAuvDHijQr83XgrXftVpKf32leIbia5jBwo3RXB3SocKeG3rlicCrMfjPVNOvmtfFPhTU7QFiIbvSkfVLeRQF5JjQSockjDRgcdTQB21Fc94b8aeHfEk0kGj6rBNdxZ8y1kDQ3EeCQd0TgOvI7gfrXQ0AFFFFABRRRQAUUUUAFFFFABRQc4460DOOetABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFee/tBwi4+DHitCm/Fpvxz/C6tnj0xn8K9Crh/jkM/CDxcNu7/iXSnH4daAOw06QTafayjdh4lYbhg8gdasVj+DXEnhDQ3VQqtYwMACeAY19ea2KACiiigAooooAKKKKACiiigAooooAKKKKACiiigArzXxRJFF8d/AwmYh5dN1FIhzyw8piPT7obr6fSvSq4Dx1YCT4l/DTUMndBe31vj1EllKx/9FCgDv6KKKACiiigDH8ReGND8SRomu6VaXpjBEbyxgvFnBOx/vL0HQisaP4daLBaG3sbrxDZpxjyNevRtx0wDKRj2xXY0UAcEngrxHp8Ji0T4gawqcEDVLaC+wc5PzFUYjHGN341tWlh4qjjgF1r2kzMswaVl0l03xcZQDzztY8/NyOfu10dFAFHSYdRht0XVby2u5gigyQWxgBbnJwXbg8cZ4weTni9RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACAHLZORnjjpS0UUAFFFFABRRRQAVwfx3l8n4PeLWyRmwkXjPfjt9a7yvNv2jIHu/g9rlrGxV7iS0gBH+3dQr/WgDuPDlubTw9pdsVCmG1ijwO2EA/pWjSIoRFVeijApaACiiigAooooAKKKKACiiigAooooAKKKKACiiigArjPiX/aFu3hbU9Msp70afrUUtzHboXkEEkUsDsFAJO3zgxx2BPGM12dFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVxHxXF3c6ZoWm2em3F+t7rlgtx5UJkWGCO4SZ5HPRVAixk/3sV29FABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The diaphragm fits in the space just above the posterior surface of the symphysis pubis and extends to the posterior vaginal fornix, deep into the cul-de-sac, thereby covering the entire cervix.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_29_29139=[""].join("\n");
var outline_f28_29_29139=null;
var title_f28_29_29140="Chronic thromboemboli PA";
var content_f28_29_29140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69313&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic thromboembolic disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph in a patient with chronic thromboembolic disease shows enlarged, irregular central pulmonary arteries with left lower lobe oligemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter F Fedullo, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_29_29140=[""].join("\n");
var outline_f28_29_29140=null;
var title_f28_29_29141="Sucralfate: Drug information";
var content_f28_29_29141=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sucralfate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?16/47/17140?source=see_link\">",
"    see \"Sucralfate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/4/8261?source=see_link\">",
"    see \"Sucralfate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F223520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carafate&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F223521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Sucralfate;",
"     </li>",
"     <li>",
"      Dom-Sucralfate;",
"     </li>",
"     <li>",
"      Novo-Sucralate;",
"     </li>",
"     <li>",
"      Nu-Sucralate;",
"     </li>",
"     <li>",
"      PMS-Sucralate;",
"     </li>",
"     <li>",
"      Sucralfate-1;",
"     </li>",
"     <li>",
"      Sulcrate&reg;;",
"     </li>",
"     <li>",
"      Sulcrate&reg; Suspension Plus;",
"     </li>",
"     <li>",
"      Teva-Sucralfate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F223566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Gastrointestinal Agent, Miscellaneous",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F223523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stress ulcer prophylaxis (unlabeled use):",
"     </b>",
"     Oral: 1 g 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stress ulcer treatment (unlabeled use):",
"     </b>",
"     Oral: 1 g every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of duodenal ulcer:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial treatment:",
"     </i>",
"     1 g 4 times/day, 1 hour before meals or food and at bedtime for 4-8 weeks, or alternatively 2 g twice daily; treatment is recommended for 4-8 weeks in adults",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance/prophylaxis of duodenal ulcer:",
"     </i>",
"     1 g twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Stomatitis (unlabeled use):",
"     </b>",
"     Oral: 10 mL (1 g/10 mL suspension); swish and spit or swish and swallow 4 times/day.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F223543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/4/8261?source=see_link\">",
"      see \"Sucralfate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses of 40-80 mg/kg/day divided every 6 hours have been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Stomatitis (unlabeled use):",
"     </b>",
"     Oral: Children: 5-10 mL (1 g/10 mL suspension), swish and spit or swish and swallow 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F223524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F223525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aluminum salt is minimally absorbed (&lt;5%), however, may accumulate in renal failure.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F223498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral: 1 g/10 mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carafate&reg;: 1 g/10 mL (420 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carafate&reg;: 1 g [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F223484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F223501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tablet may be broken or dissolved in water before ingestion. Administer with water on an empty stomach.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F223500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term (&le;8 weeks) management of duodenal ulcers; maintenance therapy for duodenal ulcers",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F223562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gastric ulcers; suspension may be used topically for treatment of stomatitis due to cancer chemotherapy and other causes of esophageal and gastric erosions; GERD, esophagitis; treatment of NSAID mucosal damage; prevention of stress ulcers; postsclerotherapy for esophageal variceal bleeding",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F223573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sucralfate may be confused with salsalate",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Carafate&reg; may be confused with Cafergot&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F223564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Gastrointestinal: Constipation (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Back pain, bezoar formation, diarrhea, dizziness, flatulence, headache, gastric discomfort; hypersensitivity (urticaria, angioedema, facial swelling, laryngospasm, respiratory difficulty, rhinitis); indigestion, insomnia, nausea, pruritus, rash, sleepiness, vertigo, vomiting, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F223504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to sucralfate or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F223488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duodenal ulceration: Because sucralfate acts locally at the ulcer, successful therapy with sucralfate should not be expected to alter the posthealing frequency of recurrence or the severity of duodenal ulceration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with chronic renal failure; sucralfate is an aluminum complex, small amounts of aluminum are absorbed following oral administration. Excretion of aluminum may be decreased in patients with chronic renal failure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered absorption: Because of the potential for sucralfate to alter the absorption of some drugs, separate administration (take other medication 2 hours before sucralfate) should be considered when alterations in bioavailability are believed to be critical.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F223493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): Sucralfate may decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Sucralfate may decrease the serum concentration of Digoxin. Specifically, sucralfate may decrease the absorption of digoxin.  Management: Administer digoxin at least 2 hours before or at least 6 hours after sucralfate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Sucralfate may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., aluminum-containing products such as sucralfate) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Furosemide: Sucralfate may decrease the serum concentration of Furosemide. Sucralfate may impair the absorption of furosemide.  Management: Avoid concomitant oral administration of furosemide and sucralfate. Separate administration by at least 2 hours. Does not apply to parenterally administered furosemide.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Sucralfate may decrease the serum concentration of Levothyroxine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Sucralfate may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Sucralfate may decrease the serum concentration of QuiNIDine. Specifically, sucralfate may decrease the absorption of quinidine.  Management: Administer quinidine at least 2 hours before or at least 6 hours after sucralfate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Sucralfate may decrease the serum concentration of Quinolone Antibiotics.  Management: Administer oral quinolones at least 2 hours before or 6 hours after the sucralfate dose.  Greater separation of doses may further lessen the risk for a significant interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Sucralfate may decrease the absorption of Tetracycline Derivatives.  Management: Administer the tetracycline derivative at least 2 hours prior to sucralfate in order to minimize the impact of this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: May increase the serum concentration of Sucralfate. Specifically, the absorption of aluminum from sucralfate may be increased, leading to an increase in the serum aluminum concentration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Sucralfate may diminish the anticoagulant effect of Vitamin K Antagonists. Sucralfate may decrease the serum concentration of Vitamin K Antagonists. Specifically, sucralfate may decrease the absorption of Vitamin K Antagonists.  Management: Administer vitamin K antagonists at least 2 hours before or at least 6 hours after sucralfate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F223517\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Sucralfate may interfere with absorption of vitamin A, vitamin D, vitamin E, and vitamin K.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F223495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F223507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Sucralfate is only minimally absorbed following oral administration.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F223528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F223508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take with water on an empty stomach.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F223506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Carafate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g/10 mL (420 mL): $113.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Carafate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (100): $227.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Sucralfate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (100): $72.95",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F223509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alsucral (FI, MY);",
"     </li>",
"     <li>",
"      Alusac (UY);",
"     </li>",
"     <li>",
"      Alusulin (HU);",
"     </li>",
"     <li>",
"      Andapsin (SE);",
"     </li>",
"     <li>",
"      Antepsin (AR, BR, DK, FI, GB, IE, IT, NO, TR);",
"     </li>",
"     <li>",
"      Calfate (PT);",
"     </li>",
"     <li>",
"      Carafate (AU, NZ);",
"     </li>",
"     <li>",
"      Ciprid (EC);",
"     </li>",
"     <li>",
"      Dip (CO, EC);",
"     </li>",
"     <li>",
"      Dolisec (GR);",
"     </li>",
"     <li>",
"      Exinol (VE);",
"     </li>",
"     <li>",
"      Inpepsa (ID);",
"     </li>",
"     <li>",
"      Iselpin (PH);",
"     </li>",
"     <li>",
"      Keal (FR, LU, TW);",
"     </li>",
"     <li>",
"      Neciblok (ID);",
"     </li>",
"     <li>",
"      Peptonorm (GR);",
"     </li>",
"     <li>",
"      Profat (ID);",
"     </li>",
"     <li>",
"      Sucrabest (LU);",
"     </li>",
"     <li>",
"      Sucral (PY);",
"     </li>",
"     <li>",
"      Sucralfin (IT);",
"     </li>",
"     <li>",
"      Sucramal (CR, DO, GT, HN, IT, NI, PA, SV);",
"     </li>",
"     <li>",
"      Sucrate (CL, HK);",
"     </li>",
"     <li>",
"      Sucrate Gel (SG);",
"     </li>",
"     <li>",
"      Sude (CL);",
"     </li>",
"     <li>",
"      Sulcran (CN);",
"     </li>",
"     <li>",
"      Sulcrate (JP);",
"     </li>",
"     <li>",
"      Taxilan (ID);",
"     </li>",
"     <li>",
"      Ulcafate (PK);",
"     </li>",
"     <li>",
"      Ulcar (AE, BH, CY, EG, FR, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ulcerfate (IN);",
"     </li>",
"     <li>",
"      Ulcerlmin (JP, KP);",
"     </li>",
"     <li>",
"      Ulcermin (PT);",
"     </li>",
"     <li>",
"      Ulcertec (MY);",
"     </li>",
"     <li>",
"      Ulcetab (ZA);",
"     </li>",
"     <li>",
"      Ulcogant (AT, BE, CH, CZ, DE, HU, LU, NL, PE);",
"     </li>",
"     <li>",
"      Ulcumaag (ID);",
"     </li>",
"     <li>",
"      Ulcyte (AU);",
"     </li>",
"     <li>",
"      Ulsaheal (AE, BH, IQ, JO, SA);",
"     </li>",
"     <li>",
"      Ulsanic (ID, IL, JP, TH, ZA);",
"     </li>",
"     <li>",
"      Ulsicral (ID);",
"     </li>",
"     <li>",
"      Unival (MX);",
"     </li>",
"     <li>",
"      Urbal (ES);",
"     </li>",
"     <li>",
"      Venter (EE, HR, HU, PL, RU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F223487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Forms a complex by binding with positively charged proteins in exudates, forming a viscous paste-like, adhesive substance. This selectively forms a protective coating that acts locally to protect the gastric lining against peptic acid, pepsin, and bile salts.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F223503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Paste formation and ulcer adhesion: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Up to 6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: &lt;5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Acts locally at ulcer sites; unbound in GI tract to aluminum and sucrose octasulfate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (small amounts as unchanged compounds)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Algozzine GJ, Hill G, Scoggins WG, et al, &ldquo;Sucralfate Bezoar,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1983, 309(22):1387.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Allison RR, Vongtama V, Vaughan J, et al, &ldquo;Symptomatic Acute Mucositis Can Be Minimized or Prophylaxed by the Combination of Sucralfate and Fluconazole,&rdquo;",
"      <i>",
"       Cancer Invest",
"      </i>",
"      , 1995, 13(1):16-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/29/29141/abstract-text/7834470/pubmed\" id=\"7834470\" target=\"_blank\">",
"        7834470",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barker G, Loftus L, Cuddy P, et al, &ldquo;The Effects of Sucralfate Suspension and Diphenhydramine Syrup Plus Kaolin-Pectin on Radiotherapy-Induced Mucositis,&rdquo;",
"      <i>",
"       Oral Surg Oral Med Oral Pathol",
"      </i>",
"      , 1991, 71(3):288-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/29/29141/abstract-text/1707149/pubmed\" id=\"1707149\" target=\"_blank\">",
"        1707149",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Collard HR, Saint S, and Matthay MA, &ldquo;Prevention of Ventilator-Associated Pneumonia: An Evidence-Based Systematic Review,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2003, 138(6):494-501.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/29/29141/abstract-text/12639084/pubmed\" id=\"12639084\" target=\"_blank\">",
"        12639084",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cook D, Guyatt G, Marshall J, et al, &ldquo;A Comparison of Sucralfate and Ranitidine for the Prevention of Upper Gastrointestinal Bleeding in Patients Requiring Mechanical Ventilation. Canadian Critical Care Trials Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1998, 338(12):791-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/29/29141/abstract-text/9504939/pubmed\" id=\"9504939\" target=\"_blank\">",
"        9504939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Domingo JL, Gomez M, Llobet JM, et al, &ldquo;Comparative Effects of Several Chelating Agents on the Toxicity, Distribution, and Excretion of Aluminum,&rdquo;",
"      <i>",
"       Hum Toxicol",
"      </i>",
"      , 1988, 7(3):259-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/29/29141/abstract-text/3391623/pubmed\" id=\"3391623\" target=\"_blank\">",
"        3391623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Epstein JB and Wong FL, &ldquo;The Efficacy of Sucralfate Suspension in the Prevention of Oral Mucositis Due to Radiation Therapy,&rdquo;",
"      <i>",
"       Int J Radiat Oncol Biol Phys",
"      </i>",
"      , 1994, 28(3):693-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/29/29141/abstract-text/8113113/pubmed\" id=\"8113113\" target=\"_blank\">",
"        8113113",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gonzalez Sanchez JM, Serna Juan SA, Galindo Sacristan E, et al, &ldquo;Aluminum Intoxication After Parenteral Sucralfate Administration,&rdquo;",
"      <i>",
"       Farmacia Clinica",
"      </i>",
"      , 1994, 11:760-4.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Loprinzi CL, Ghosh C, Camoriano J, et al, &ldquo;Phase III Controlled Evaluation of Sucralfate to Alleviate Stomatitis in Patients Receiving Fluorouracil-Based Chemotherapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1997, 15(3):1235-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/29/29141/abstract-text/9060567/pubmed\" id=\"9060567\" target=\"_blank\">",
"        9060567",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Makkonen TA, Bostrom P, Vilja P, et al, &ldquo;Sucralfate Mouth Washing in the Prevention of Radiation-Induced Mucositis: A Placebo-Controlled Double-Blind Randomized Study,&rdquo;",
"      <i>",
"       Int J Radiat Oncol Biol Phys",
"      </i>",
"      , 1994, 30(1):177-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/29/29141/abstract-text/8083112/pubmed\" id=\"8083112\" target=\"_blank\">",
"        8083112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Overdahl MC and Wewers MD, &ldquo;Acute Occlusion of a Mainstem Bronchus by a Rapidly Expanding Foreign Body,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 1994, 105(5):1600-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/29/29141/abstract-text/8181371/pubmed\" id=\"8181371\" target=\"_blank\">",
"        8181371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robertson JA, Salusky IB, Goodman WG, et al, &ldquo;Sucralfate, Intestinal Aluminum Absorption, and Aluminum Toxicity in a Patient on Dialysis,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1989, 111(2):179-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?28/29/29141/abstract-text/2742249/pubmed\" id=\"2742249\" target=\"_blank\">",
"        2742249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9953 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.211.0.116-751ADD8550-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_29_29141=[""].join("\n");
var outline_f28_29_29141=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223520\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223521\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223566\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223523\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223543\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223524\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223525\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223498\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223484\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223501\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223500\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223562\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223573\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223564\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223504\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223488\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300087\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223493\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223517\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223495\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223507\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223528\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223508\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223506\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223509\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223487\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F223503\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9953\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9953|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/47/17140?source=related_link\">",
"      Sucralfate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/4/8261?source=related_link\">",
"      Sucralfate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_29_29142="MRI vestibular Schwannoma";
var content_f28_29_29142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F86508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F86508&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI vestibular Schwannoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 508px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 30-year-old female presented with hearing loss on the right and has findings consistent with an acoustic neuroma on the following MRI images. The T1 weighted image without contrast (A) shows a mass centered in the right internal auditory canal (white arrow). It is isointense to the brain parenchyma. Following gadolinium the Schwannoma enhances homogeneously and has the classic \"ice cream cone\" shape (yellow arrow). The high resolution T2 weighted image, shows loss of the normal fluid signal in the internal auditory canal which can be appreciated on the left side. The mass (green overlay) projects into the cerebellopontine angle cistern (blue arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_29_29142=[""].join("\n");
var outline_f28_29_29142=null;
var title_f28_29_29143="Cervical vertebrae transverse view";
var content_f28_29_29143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81612&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical vertebrae transverse view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 672px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 3rd-6th cervical vertebrae have a \"typical\" structure; the 1st, 2nd, and 7th are \"atypical.\" Typical vertebrae demonstrate rectangular bodies with articular uncinate processes on their lateral aspects, triangular vertebral foramina, bifid spinous processes, and transverse foramina.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley AF. Clinically Oriented Anatomy, 5th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_29_29143=[""].join("\n");
var outline_f28_29_29143=null;
var title_f28_29_29144="Bronchopulmonary sequestration";
var content_f28_29_29144=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bronchopulmonary sequestration",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/29/29144/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/29/29144/contributors\">",
"     Christopher M Oermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/29/29144/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/29/29144/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/29/29144/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/29/29144/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/29/29144/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/29/29144/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchopulmonary sequestration (BPS), sometimes referred to simply as pulmonary sequestration, is a rare congenital malformation of the lower respiratory tract. It consists of a nonfunctioning mass of lung tissue that lacks normal communication with the tracheobronchial tree, and that receives its arterial blood supply from the systemic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/1\">",
"     1",
"    </a>",
"    ]. Sequestrations are classified anatomically, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intralobar pulmonary sequestration (ILS, also known as intrapulmonary sequestration), in which the lesion is located within a normal lobe and lacks its own visceral pleura. In some cases, ILS appears to be an acquired rather than congenital lesion (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Extralobar pulmonary sequestration (ELS, also known as extrapulmonary sequestration), in which the mass is located outside the normal lung and has its own visceral pleura.",
"     </li>",
"     <li>",
"      Bronchopulmonary-foregut malformation (BPFM) is sometimes used as a general term to include all foregut malformations. However, the most widely used nomenclature reserves this term for a rare variant of sequestration, in which the sequestered lung tissue is connected to the gastrointestinal tract [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/2\">",
"       2",
"      </a>",
"      ]. This may occur in either ILS or ELS.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The anomalies are composed of normal lung tissue, including airway and alveolar elements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital anomalies of the lower respiratory tract are rare. BPS is estimated to comprise 0.15 to 6.4 percent of all congenital pulmonary malformations, making it an extremely rare disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/3\">",
"     3",
"    </a>",
"    ]. In several reports, even tertiary care referral centers diagnose less than one case per year [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/2,4-7\">",
"     2,4-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ILS is overall the most common form, consisting of approximately 75 to 90 percent of sequestrations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. However, ELS more commonly presents in the fetal and neonatal period. The difference in prevalence of the disorders may be related to the pathogenic mechanisms, as discussed below.",
"   </p>",
"   <p>",
"    Males and females are equally affected with ILS, while ELS has a male predominance in most [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/1,2,4\">",
"     1,2,4",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/9\">",
"     9",
"    </a>",
"    ] reports. In a series of ELS cases diagnosed antenatally, the ratio of males to females was three to one [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In contrast, BPFM has a female predominance [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The embryologic basis for the development of BPS and other congenital malformations of the lower respiratory tract is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. The lesion may occur very early in embryonic development, prior to separation of the aortic and pulmonary circulations [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/5\">",
"     5",
"    </a>",
"    ]. One possibility is that all malformations of the primitive foregut and lung buds represent a spectrum of the same embryologic abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/5,9,12\">",
"     5,9,12",
"    </a>",
"    ]. For example, abnormalities of development during lung bud formation could potentially result in BPS, BPFM, congenital lobar emphysema, congenital pulmonary airway malformation (CPAM; previously known as congenital cystic adenomatoid malformation, CCAM), or bronchogenic cyst anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another proposed explanation is that a portion of the developing lung is mechanically separated from the rest of the organ by compression from cardiovascular structures, traction by aberrant systemic vessels, or inadequate pulmonary blood flow. Unfortunately, this mechanical hypothesis does not completely explain all types of lesions, specifically BPFM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative view is that some ILS may be an acquired rather than a developmental lesion. In a series of 15 pathology specimens of ILS, most were thought to represent either cystic adenomatoid malformations that were not recognized until they became infected, or developmentally normal lung supplied by an aberrant systemic artery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/17\">",
"     17",
"    </a>",
"    ]. Potential postnatal origin of ILS also is supported by the age at presentation. ILS usually presents in adolescence with signs and symptoms of recurrent infection, while ELS usually presents in infancy with respiratory compromise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sequestrations are characterized by their location, connection to pulmonary or other structures, vascular supply, and association with other abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Location",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most sequestrations occur in the lower lobes; however, they can occur anywhere within the thorax [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, ELS may present as a subdiaphragmatic or retroperitoneal mass [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/19\">",
"     19",
"    </a>",
"    ]. Although the frequencies of laterality vary among small series, ELS almost always involves the left hemithorax. In ILS there is a lesser degree of left sided predominance; approximately 60 percent of cases are located in the posterior basal segment of the left lower lobe [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/1,2,6,8,20\">",
"     1,2,6,8,20",
"    </a>",
"    ]. In contrast, BPFM is more common on the right side. Rare instances of bilateral pulmonary sequestration also have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Connections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most ILS have no bronchial connection to the proximal airway. If a connection exists, it is abnormal. However, anomalous connections can link the sequestration to other bronchi, lung parenchyma, or the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/8\">",
"     8",
"    </a>",
"    ]. These connections",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the pores of Kohn may allow bacteria to enter the sequestration and cause recurrent infection, a common finding in ILS (",
"    <a class=\"graphic graphic_picture graphicRef57362 \" href=\"UTD.htm?38/14/39139\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    ELS similarly lack a bronchial connection to the normal proximal airway. They may connect to the gastrointestinal tract or, rarely, to intrapulmonary structures [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/8\">",
"     8",
"    </a>",
"    ]. Infectious complications are uncommon in ELS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Vascular supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;In ILS, the arterial supply usually is derived from the lower thoracic or upper abdominal aorta. In a series of 25 cases, 16 had a single arterial trunk and the remainder had multiple arterial vessels (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81513 \" href=\"UTD.htm?17/63/18431\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/22\">",
"     22",
"    </a>",
"    ]. Venous drainage is usually normal to the left atrium, although abnormal connections to the vena cava, azygous vein, or right atrium may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, the arterial supply of ELS comes from an aberrant vessel arising from the thoracic aorta [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/8\">",
"     8",
"    </a>",
"    ]. The vessel is usually small, with low flow. Lesions typically have anomalous venous drainage to the right atrium, vena cava, or azygous systems [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Associated anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital anomalies may be associated with BPS, occurring more frequently in patients with ELS than ILS. In a series of 28 cases in children and adults, associated malformations occurred in 43 percent of ELS and 17 percent of ILS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/3\">",
"     3",
"    </a>",
"    ]. Associated anomalies include congenital diaphragmatic hernia, vertebral anomalies, congenital heart disease, pulmonary hypoplasia, and colonic duplication [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Congenital pulmonary airway malformation (CPAM) sometimes is noted in association with ELS, occurring in 23 of 46 cases (50 percent) in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/50/810?source=see_link\">",
"     \"Congenital pulmonary airway (cystic adenomatoid) malformation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of BPS is variable, and depends upon the type, size, and location of the lesion. Many cases are identified by routine prenatal ultrasound examination. The affected newborn can be asymptomatic, but may present with signs and symptoms of respiratory distress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prenatal presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of BPS on prenatal ultrasound is typically an incidental finding of an echogenic thoracic mass that may be small or occupy most of the hemithorax [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. Mediastinal shift often is noted. In the majority of cases, the lesion regresses during the course of gestation, while hydrops occasionally develops, likely because of vascular compression [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/24,25,27-29\">",
"     24,25,27-29",
"    </a>",
"    ]. There are no reliable criteria for determining which lesions will grow and develop hydrops versus those that will stabilize or regress.",
"   </p>",
"   <p>",
"    The variable prenatal presentation was illustrated in a series of 41 pregnancies with ELS identified during a 14-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/24\">",
"     24",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The lesion was detected between 18 and 36 weeks' gestation, usually on routine second-trimester screening.",
"     </li>",
"     <li>",
"      In 28 of the 39 pregnancies that continued to term or near term (two were electively terminated), the lesion partially or completely resolved before delivery. All these infants were asymptomatic at birth.",
"     </li>",
"     <li>",
"      Hydrops was present in four cases and was thought to be due to fluid or lymph secretion from the mass resulting in a tension hydrothorax and increased central venous pressure.",
"     </li>",
"     <li>",
"      Seven fetuses without hydrops developed respiratory distress after birth and required resection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In cases demonstrating in utero regression, postpartum imaging is still required, as few lesions resolve completely. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Postnatal diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Postnatal presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;ELS typically presents earlier than ILS, although the age at presentation is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/1,2,4-6,9,20,30\">",
"     1,2,4-6,9,20,30",
"    </a>",
"    ]. The diagnosis may be made in newborns or infants who develop symptoms; however, some cases of ELS are detected in adults. In one series, the age of diagnosis ranged from newborn to 65 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/9\">",
"     9",
"    </a>",
"    ]. Among the 50 cases of ELS, 12 had prenatal diagnosis and 23 were detected by three months of age.",
"   </p>",
"   <p>",
"    Infants with ELS who become symptomatic typically have respiratory distress; recurrent pneumonia is a less common presentation. However, many patients are asymptomatic, and the lesion is detected as part of the evaluation for an associated anomaly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19161?source=see_link\">",
"     \"Approach to congenital malformations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with ILS usually present in late childhood or adolescence with recurrent pulmonary infections; rare cases presenting in the neonatal period have been reported. Signs include fever and cough. Older patients may have hemoptysis or chest pain [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In some cases, the lesion is detected as an incidental finding on a chest radiograph. In rare cases, heart failure occurs due to high flow through the anomalous artery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/8,32\">",
"     8,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common complication of bronchopulmonary sequestration is pulmonary infection, which is often the presenting sign of ILS. Rare complications of either ELS or ILS include heart failure due to excessive flow through the aberrant artery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/8,32\">",
"     8,32",
"    </a>",
"    ] and massive bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Cases have been reported of fibrous mesothelioma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/35\">",
"     35",
"    </a>",
"    ] and carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/36\">",
"     36",
"    </a>",
"    ] arising within ILS. These disorders may be related to an association of ILS with CPAM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/50/810?source=see_link\">",
"     \"Congenital pulmonary airway (cystic adenomatoid) malformation\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis typically is made by ultrasonography. ELS appears as a well-defined echodense homogeneous mass [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/24\">",
"     24",
"    </a>",
"    ]. A pathognomonic feature is a systemic artery from the aorta to the fetal lung lesion detected by color flow Doppler ultrasound. If the artery is not visualized, ELS can appear identical to an echodense microcystic congenital pulmonary airway malformation (CPAM). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/50/810?source=see_link\">",
"     \"Congenital pulmonary airway (cystic adenomatoid) malformation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prenatal magnetic resonance imaging (MRI) may help distinguish pulmonary sequestration from CPAM, congenital diaphragmatic hernia (CDH), or other less common lesions. This was illustrated by one series in which 16 of 18 patients with fetal chest masses had an ultrasound diagnosis of CPAM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/37\">",
"     37",
"    </a>",
"    ]. MRI diagnoses included two BPS, nine CPAM, three CDH, and one each of foregut cyst, lung atresia, tracheal atresia, and bronchial stenosis. MRI results were confirmed at surgery or autopsy in 17 cases. In one case, BPS was found at autopsy of a lesion that was diagnosed as CPAM by ultrasound and MRI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Postnatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;After birth, the diagnosis of BPS is suggested by chest imaging studies and confirmed by pathologic examination. A plain chest radiograph should be obtained. Patients should be further evaluated with ultrasonography with Doppler imaging and either computed tomography (CT) or magnetic resonance imaging (MRI) to define the lesion and the aberrant artery. These techniques have replaced the need for angiography to identify the vascular supply prior to surgical resection (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81513 \" href=\"UTD.htm?17/63/18431\">",
"     image 1",
"    </a>",
"    ). The radiographic appearance of other developmental anomalies of the lung is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30487?source=see_link\">",
"     \"Radiographic appearance of developmental anomalies of the lung\"",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;On a chest radiograph, sequestrations typically appear as a uniformly dense mass within the thoracic cavity or pulmonary parenchyma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64563 \" href=\"UTD.htm?29/48/30479\">",
"     image 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/38\">",
"     38",
"    </a>",
"    ]. Recurrent infection can lead to the development of cystic areas within the mass [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Air-fluid levels due to bronchial communication are seen in 26 percent of ILS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, most sequestrations occur in the lower lobes. However, they can occur anywhere within the thorax, and ELS sometimes occurs in a subdiaphragmatic location or as a retroperitoneal mass. The left hemithorax is almost always involved in ELS, and it is usually involved in ILS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical sonographic appearance of BPS is an echogenic homogeneous mass that may be well defined or irregular [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/40\">",
"     40",
"    </a>",
"    ]. However, some lesions have a cystic or more complex appearance. Doppler studies are helpful to identify the characteristic aberrant systemic artery that arises from the aorta and to delineate venous drainage. In addition, ultrasonography can be used to guide biopsy of a subdiaphragmatic mass [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/40-43\">",
"     40-43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The parenchymal abnormalities associated with BPS are best visualized using CT, although their appearance is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The most common appearance is a solid mass that may be homogeneous or heterogeneous, sometimes with cystic changes. Less frequent findings include a large cavitary lesion with an air-fluid level, a collection of many small cystic lesions containing air or fluid, or a well-defined cystic mass. Emphysematous changes at the margin of the lesion are characteristic and may not be visible on the chest radiograph.",
"   </p>",
"   <p>",
"    Conventional CT does not consistently demonstrate the aberrant systemic artery, with visualization in 16 of 24 cases in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/41\">",
"     41",
"    </a>",
"    ]. Lack of visualization was thought to be due to the small size (sometimes as small as 1 mm) or unfavorable orientation of the vessel. These small vessels may be detected by contrast-enhanced or helical CT, which also enables evaluation of abnormalities in the lung parenchyma or airways (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78368 \" href=\"UTD.htm?7/61/8145\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/40,44,45\">",
"     40,44,45",
"    </a>",
"    ]. Advances in the use of multidetector CT angiography have improved our ability to simultaneously visualize the arterial supply, venous drainage, and parenchymal involvement of pulmonary sequestrations and may make this the diagnostic procedure of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI can demonstrate the location of the lesion and define the aberrant artery and venous drainage, especially if enhanced three-dimensional MR angiography is used [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/40,47,48\">",
"     40,47,48",
"    </a>",
"    ]. However, CT allows sharper delineation of thin-walled cysts and emphysematous changes than MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of BPS includes other cystic lung lesions, such as CPAM. In contrast to BPS, CPAMs are connected to the tracheobronchial tree, and are supplied from the pulmonary circulation. However, hybrid lesions with histologic characteristics of CPAM and a systemic arterial supply have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/12\">",
"     12",
"    </a>",
"    ]. In another series, 25 of 50 cases of BPS were associated with a CPAM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/50/810?source=see_link\">",
"     \"Congenital pulmonary airway (cystic adenomatoid) malformation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to CPAM, the differential diagnosis of BPS consists of other space-occupying chest lesions. These include congenital diaphragmatic hernia, bronchogenic cyst, and congenital lobar emphysema. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/11/44214?source=see_link\">",
"     \"Congenital lobar emphysema\"",
"    </a>",
"    .) BPS also may be confused with a mediastinal tumor such as a teratoma or neuroblastoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14585?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of neuroblastoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristic abnormalities are seen on pathologic examination of sequestrations that are surgically resected or detected at autopsy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ELS vary in size, but usually are relatively small compared to the normal lobes. They are completely covered by pleura with a pedicle that contains the vascular connections. On histologic examination, ELS may resemble normal lung or show parenchymal maldevelopment similar to the small-cyst type of CPAM.",
"     </li>",
"     <li>",
"      ILS are contained within a lobe. There are often changes at the pleural surface overlying the abnormal region. On cut section, the parenchyma of the sequestration is usually sharply demarcated from the adjacent normal tissue. The abnormal parenchyma has enlarged airspaces and thickening of the airspace wall (",
"      <a class=\"graphic graphic_picture graphicRef57362 \" href=\"UTD.htm?38/14/39139\">",
"       picture 1",
"      </a>",
"      ). The airways of the lesion typically are dilated and filled with mucus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The histologic appearance of ILS typically shows more distortion of the lung parenchyma than ELS, with regions of inflammation, mucus accumulation, and microcystic changes. Sometimes dilated lymphatic channels are associated with the lesion (",
"    <a class=\"graphic graphic_picture graphicRef63011 \" href=\"UTD.htm?14/4/14406\">",
"     picture 2",
"    </a>",
"    ). ILS can resemble small cyst-type CPAM or bronchial atresia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=see_link\">",
"     \"Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some cases, lesions may have pathologic features of sequestration and CPAM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/9,12,49\">",
"     9,12,49",
"    </a>",
"    ]. In one report, five cases of ILS and one of ELS that were diagnosed prenatally had a systemic artery detected at surgical resection, but histology was consistent with CPAM. In another series, 23 of 46 cases of ELS had histologic features of CPAM type 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/9\">",
"     9",
"    </a>",
"    ]. Of these, 11 had rhabdomyomatous degeneration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/50/810?source=see_link\">",
"     \"Congenital pulmonary airway (cystic adenomatoid) malformation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to treatment depends upon whether the patient has respiratory distress, recurrent infections, or is asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In symptomatic patients, BPS is treated by surgical excision, which is curative and is associated with minimal morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The procedure is performed urgently in newborns with significant respiratory distress. It may be done electively in older children who present with recurrent infection, which are usually due to ILS.",
"   </p>",
"   <p>",
"    Complete excision of ILS usually requires lobectomy or segmental resection. Resection of ELS is simpler because the lesion has its own pleural investment. With both types, all vascular connections to the lesion must be identified and ligated. The arterial supply of these lesions may arise from the subdiaphragmatic aorta, and careful identification of the feeding vessel is crucial. Thoracoscopic lobectomy is an alternative to thoracotomy in infants and older children with ILS or ELS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Case series of treatment by arterial embolization have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/54-58\">",
"     54-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether surgery should be performed in asymptomatic patients with a diagnosis of BPS made on prenatal ultrasound or as an incidental radiographic finding is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/59\">",
"     59",
"    </a>",
"    ]. Elective resection is usually recommended for ILS to prevent infections that often develop, but the optimal timing of surgery has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/3,30,60\">",
"     3,30,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For ELS, serial monitoring is appropriate unless symptoms develop [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/11,24,25,61-64\">",
"     11,24,25,61-64",
"    </a>",
"    ]. Lesions should be monitored by CT, since they may not be apparent on plain radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/62\">",
"     62",
"    </a>",
"    ]. Malignant transformation or degeneration has not been reported with ELS and infection is rare. Thus, we recommend studies every 5 to 10 years in asymptomatic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Fetal intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, most pulmonary sequestrations in the fetus regress or completely disappear on serial ultrasonography. Few affected fetuses develop hydrops. Thus, fetal intervention is rarely required and is warranted only in cases where the fetus is severely compromised. It should only be undertaken at centers experienced in fetal surgery. Prenatal intervention requires extensive counseling to the parents on the potential risks versus benefits of surgery.",
"   </p>",
"   <p>",
"    Nevertheless, advancing techniques in fetal surgery have made antenatal intervention a valuable option in selected cases of BPS. In the largest series, four of 39 fetuses with ELS became hydropic [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/24\">",
"     24",
"    </a>",
"    ]. Intrauterine treatment consisted of serial thoracenteses in one and thoracoamniotic shunt placement in two; the hydrops resolved and the lesion was resected after delivery at 33 to 35 weeks' gestation. The fourth hydropic fetus was not treated prenatally and died of pulmonary hypoplasia after postnatal resection and prolonged support with mechanical ventilation and extracorporeal membrane oxygenation. A review of 294 cases of fetal lung masses included 23 with pulmonary sequestration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/65\">",
"     65",
"    </a>",
"    ]. Among these, three developed hydrops and all were successfully treated in utero.",
"   </p>",
"   <p>",
"    Infants without hydrops may do well if surgery is delayed until after birth. In the series noted above, seven nonhydropic infants had respiratory symptoms after delivery and recovered after postnatal resection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/24\">",
"     24",
"    </a>",
"    ]. All 28 fetuses whose lesion regressed were asymptomatic after birth. In these infants, lesions were not visible on chest radiograph but were present on CT or MRI scans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of other significant congenital anomalies, the prognosis for children with pulmonary sequestrations is generally very good [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/3,15,64,66,67\">",
"     3,15,64,66,67",
"    </a>",
"    ]. This is illustrated by three reports of patients who underwent surgical excision.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 20 children and adults responded to a survey at a median of approximately nine years after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/3\">",
"       3",
"      </a>",
"      ]. Of these, five patients had respiratory symptoms such as dyspnea, cough, or sputum production, and one had been hospitalized for recurrent pulmonary infections. Congenital abnormalities became apparent in three patients after surgery and one patient developed epilepsy and mental retardation.",
"     </li>",
"     <li>",
"      In a series of 10 patients (seven children and three adults) who had lobectomy for ILS or ELS, nine were asymptomatic at six months to 10 years after surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/66\">",
"       66",
"      </a>",
"      ]. One preterm infant (29 weeks gestation) died one month after the procedure from necrotizing enterocolitis.",
"     </li>",
"     <li>",
"      A third report described 22 patients with prenatally diagnosed cystic lung disease, seven of whom had pulmonary sequestration which was surgically treated [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29144/abstract/68\">",
"       68",
"      </a>",
"      ]. The mean length of follow up was 6.9 years. Although the patients generally did well, some had frequent respiratory infections or delays in growth. The authors stressed the need for long-term respiratory care and assessment of growth parameters. The study suggests that ventilation-perfusion scanning may be helpful in the long-term management of patients with unusual postoperative courses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28430079\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bronchopulmonary sequestration (BPS), sometimes referred to simply as pulmonary sequestration, is a rare congenital malformation of the lower respiratory tract. It consists of a nonfunctioning mass of lung tissue that lacks normal communication with the tracheobronchial tree, and that receives its arterial blood supply from the systemic circulation. By contrast, cystic pulmonary airway malformations (CPAM) are connected to the tracheobronchial tree and are supplied from the pulmonary circulation. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      An intralobar pulmonary sequestration (ILS) is located within a normal lobe and lacks its own visceral pleura. This type often has aberrant connections to bronchi, lung parenchyma, or the gastrointestinal tract, and often presents with recurrent infections. &nbsp;",
"     </li>",
"     <li>",
"      An extralobar pulmonary sequestration (ELS) is located outside the normal lung and has its own visceral pleura. This type may connect to the gastrointestinal tract or, rarely, to intrapulmonary structures, but infectious complications are rare. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital anomalies that are sometimes associated with BPS include congenital diaphragmatic hernia, vertebral anomalies, congenital heart disease, pulmonary hypoplasia, colonic duplication, and congenital pulmonary airway malformation. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Associated anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical presentation of BPS is variable and depends on the type, size, and location of the lesion. Many cases are identified by prenatal ultrasound, and most of these regress during gestation, while others progress and hydrops may develop. The affected newborn may be asymptomatic or present with respiratory distress. In cases demonstrating in utero regression, postpartum imaging is still required, because few lesions resolve completely. Some cases (usually ILS) present with recurrent pneumonia during infancy or childhood. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      On a chest radiograph, sequestrations typically appear as a uniformly dense mass within the thoracic cavity or pulmonary parenchyma (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef64563 \" href=\"UTD.htm?29/48/30479\">",
"       image 2",
"      </a>",
"      ). Recurrent infection can lead to cystic areas within the mass, and there may be air-fluid levels if the lesion communicates with a bronchus. Ultrasonography or computerized tomography is used to define the lesion and aberrant artery. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Postnatal diagnosis'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      In symptomatic patients, BPS is treated by surgical excision, which is curative and is associated with minimal morbidity. The procedure is performed urgently in newborns with significant respiratory distress. We also suggest elective surgical resection in older children who present with recurrent infection (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Symptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For asymptomatic patients with a diagnosis of BPS made on prenatal ultrasound or as an incidental radiographic finding, optimal management is controversial. We suggest elective resection for intralobar sequestrations (ILS) because this type is often associated with recurrent infections (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The optimal timing of surgery for this category of patient has not been established. For ELS presenting as an incidental finding, surgery is not indicated unless symptoms develop; serial monitoring is appropriate. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Asymptomatic patients'",
"      </a>",
"      above.) &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/1\">",
"      Landing BH, Dixon LG. Congenital malformations and genetic disorders of the respiratory tract (larynx, trachea, bronchi, and lungs). Am Rev Respir Dis 1979; 120:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/2\">",
"      Stocker JT, Drake RM, Madewell JE. Cystic and congenital lung disease in the newborn. Perspect Pediatr Pathol 1978; 4:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/3\">",
"      Van Raemdonck D, De Boeck K, Devlieger H, et al. Pulmonary sequestration: a comparison between pediatric and adult patients. Eur J Cardiothorac Surg 2001; 19:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/4\">",
"      Kravitz RM. Congenital malformations of the lung. Pediatr Clin North Am 1994; 41:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/5\">",
"      Takeda S, Miyoshi S, Inoue M, et al. Clinical spectrum of congenital cystic disease of the lung in children. Eur J Cardiothorac Surg 1999; 15:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/6\">",
"      Schwartz MZ, Ramachandran P. Congenital malformations of the lung and mediastinum--a quarter century of experience from a single institution. J Pediatr Surg 1997; 32:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/7\">",
"      Nuchtern JG, Harberg FJ. Congenital lung cysts. Semin Pediatr Surg 1994; 3:233.",
"     </a>",
"    </li>",
"    <li>",
"     Clements BS. Congenital malformations of the lungs and airways. In: Pediatric Respiratory Medicine, Taussig LM, Landau LI (Eds), Mosby, St Louis 1999. p.1106.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/9\">",
"      Conran RM, Stocker JT. Extralobar sequestration with frequently associated congenital cystic adenomatoid malformation, type 2: report of 50 cases. Pediatr Dev Pathol 1999; 2:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/10\">",
"      Sakala EP, Perrott WS, Grube GL. Sonographic characteristics of antenatally diagnosed extralobar pulmonary sequestration and congenital cystic adenomatoid malformation. Obstet Gynecol Surv 1994; 49:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/11\">",
"      Devine PC, Malone FD. Noncardiac thoracic anomalies. Clin Perinatol 2000; 27:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/12\">",
"      Cass DL, Crombleholme TM, Howell LJ, et al. Cystic lung lesions with systemic arterial blood supply: a hybrid of congenital cystic adenomatoid malformation and bronchopulmonary sequestration. J Pediatr Surg 1997; 32:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/13\">",
"      Gerle RD, Jaretzki A 3rd, Ashley CA, Berne AS. Congenital bronchopulmonary-foregut malformation. Pulmonary sequestration communicating with the gastrointestinal tract. N Engl J Med 1968; 278:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/14\">",
"      Evrard V, Ceulemans J, Coosemans W, et al. Congenital parenchymatous malformations of the lung. World J Surg 1999; 23:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/15\">",
"      Zylak CJ, Eyler WR, Spizarny DL, Stone CH. Developmental lung anomalies in the adult: radiologic-pathologic correlation. Radiographics 2002; 22 Spec No:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/16\">",
"      MacKenzie TC, Guttenberg ME, Nisenbaum HL, et al. A fetal lung lesion consisting of bronchogenic cyst, bronchopulmonary sequestration, and congenital cystic adenomatoid malformation: the missing link? Fetal Diagn Ther 2001; 16:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/17\">",
"      Holder PD, Langston C. Intralobar pulmonary sequestration (a nonentity?). Pediatr Pulmonol 1986; 2:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/18\">",
"      Shanti CM, Klein MD. Cystic lung disease. Semin Pediatr Surg 2008; 17:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/19\">",
"      Laje P, Martinez-Ferro M, Grisoni E, Dudgeon D. Intraabdominal pulmonary sequestration. A case series and review of the literature. J Pediatr Surg 2006; 41:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/20\">",
"      DeParedes CG, Pierce WS, Johnson DG, Waldhausen JA. Pulmonary sequestration in infants and children: a 20-year experience and review of the literature. J Pediatr Surg 1970; 5:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/21\">",
"      Stern R, Berger S, Casaulta C, et al. Bilateral intralobar pulmonary sequestration in a newborn, case report and review of the literature on bilateral pulmonary sequestrations. J Pediatr Surg 2007; 42:E19.00.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/22\">",
"      Clements BS, Warner JO, Shinebourne EA. Congenital bronchopulmonary vascular malformations: clinical application of a simple anatomical approach in 25 cases. Thorax 1987; 42:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/23\">",
"      Thilenius OG, Ruschhaupt DG, Replogle RL, et al. Spectrum of pulmonary sequestration: association with anomalous pulmonary venous drainage in infants. Pediatr Cardiol 1983; 4:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/24\">",
"      Adzick NS, Harrison MR, Crombleholme TM, et al. Fetal lung lesions: management and outcome. Am J Obstet Gynecol 1998; 179:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/25\">",
"      Lopoo JB, Goldstein RB, Lipshutz GS, et al. Fetal pulmonary sequestration: a favorable congenital lung lesion. Obstet Gynecol 1999; 94:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/26\">",
"      Bush A, Hogg J, Chitty LS. Cystic lung lesions - prenatal diagnosis and management. Prenat Diagn 2008; 28:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/27\">",
"      Plattner V, Haustein B, Llanas B, et al. Extra-lobar pulmonary sequestration with prenatal diagnosis. A report of 5 cases and review of the literature. Eur J Pediatr Surg 1995; 5:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/28\">",
"      Becmeur F, Horta-Geraud P, Donato L, Sauvage P. Pulmonary sequestrations: prenatal ultrasound diagnosis, treatment, and outcome. J Pediatr Surg 1998; 33:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/29\">",
"      Garc&iacute;a-Pe&ntilde;a P, Lucaya J, Hendry GM, et al. Spontaneous involution of pulmonary sequestration in children: a report of two cases and review of the literature. Pediatr Radiol 1998; 28:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/30\">",
"      Gezer S, Ta��tepe I, Sirmali M, et al. Pulmonary sequestration: a single-institutional series composed of 27 cases. J Thorac Cardiovasc Surg 2007; 133:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/31\">",
"      Sato Y, Endo S, Saito N, et al. A rare case of extralobar sequestration with hemoptysis. J Thorac Cardiovasc Surg 2004; 128:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/32\">",
"      Levine MM, Nudel DB, Gootman N, et al. Pulmonary sequestration causing congestive heart failure in infancy: a report of two cases and review of the literature. Ann Thorac Surg 1982; 34:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/33\">",
"      Avishai V, Dolev E, Weissberg D, et al. Extralobar sequestration presenting as massive hemothorax. Chest 1996; 109:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/34\">",
"      Rubin EM, Garcia H, Horowitz MD, Guerra JJ Jr. Fatal massive hemoptysis secondary to intralobar sequestration. Chest 1994; 106:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/35\">",
"      Paksoy N, Demircan A, Altiner M, Artvinli M. Localised fibrous mesothelioma arising in an intralobar pulmonary sequestration. Thorax 1992; 47:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/36\">",
"      Gatzinsky P, Olling S. A case of carcinoma in intralobar pulmonary sequestration. Thorac Cardiovasc Surg 1988; 36:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/37\">",
"      Hubbard AM, Adzick NS, Crombleholme TM, et al. Congenital chest lesions: diagnosis and characterization with prenatal MR imaging. Radiology 1999; 212:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/38\">",
"      Hernanz-Schulman M. Cysts and cystlike lesions of the lung. Radiol Clin North Am 1993; 31:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/39\">",
"      Hang JD, Guo QY, Chen CX, Chen LY. Imaging approach to the diagnosis of pulmonary sequestration. Acta Radiol 1996; 37:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/40\">",
"      Ko SF, Ng SH, Lee TY, et al. Noninvasive imaging of bronchopulmonary sequestration. AJR Am J Roentgenol 2000; 175:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/41\">",
"      Ikezoe J, Murayama S, Godwin JD, et al. Bronchopulmonary sequestration: CT assessment. Radiology 1990; 176:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/42\">",
"      Newman B. Real-time ultrasound and color-Doppler imaging in pulmonary sequestration. Pediatrics 1990; 86:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/43\">",
"      Smart LM, Hendry GM. Imaging of neonatal pulmonary sequestration including Doppler ultrasound. Br J Radiol 1991; 64:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/44\">",
"      Kouchi K, Yoshida H, Matsunaga T, et al. Intralobar bronchopulmonary sequestration evaluated by contrast-enhanced three-dimensional MR angiography. Pediatr Radiol 2000; 30:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/45\">",
"      Frush DP, Donnelly LF. Pulmonary sequestration spectrum: a new spin with helical CT. AJR Am J Roentgenol 1997; 169:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/46\">",
"      Kang M, Khandelwal N, Ojili V, et al. Multidetector CT angiography in pulmonary sequestration. J Comput Assist Tomogr 2006; 30:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/47\">",
"      Au VW, Chan JK, Chan FL. Pulmonary sequestration diagnosed by contrast enhanced three-dimensional MR angiography. Br J Radiol 1999; 72:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/48\">",
"      Choudry R, Salvatore M, Hurie J, Grewal H. Preoperative magnetic resonance imaging for intralobar pulmonary sequestration. J Pediatr Surg 2006; 41:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/49\">",
"      Samuel M, Burge DM. Management of antenatally diagnosed pulmonary sequestration associated with congenital cystic adenomatoid malformation. Thorax 1999; 54:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/50\">",
"      Haller JA Jr, Golladay ES, Pickard LR, et al. Surgical management of lung bud anomalies: lobar emphysema, bronchogenic cyst, cystic adenomatoid malformation, and intralobar pulmonary sequestration. Ann Thorac Surg 1979; 28:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/51\">",
"      Albanese CT, Sydorak RM, Tsao K, Lee H. Thoracoscopic lobectomy for prenatally diagnosed lung lesions. J Pediatr Surg 2003; 38:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/52\">",
"      Jesch NK, Leonhardt J, Sumpelmann R, et al. Thoracoscopic resection of intra- and extralobar pulmonary sequestration in the first 3 months of life. J Pediatr Surg 2005; 40:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/53\">",
"      Suda T, Hasegawa S, Negi K, Hattori Y. Video-assisted thoracoscopic surgery for extralobar pulmonary sequestration. J Thorac Cardiovasc Surg 2006; 132:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/54\">",
"      Tokel K, Boyvat F, Varan B. Coil embolization of pulmonary sequestration in two infants: a safe alternative to surgery. AJR Am J Roentgenol 2000; 175:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/55\">",
"      Park ST, Yoon CH, Sung KB, et al. Pulmonary sequestration in a newborn infant: treatment with arterial embolization. J Vasc Interv Radiol 1998; 9:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/56\">",
"      Curros F, Chigot V, Emond S, et al. Role of embolisation in the treatment of bronchopulmonary sequestration. Pediatr Radiol 2000; 30:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/57\">",
"      Lee BS, Kim JT, Kim EA, et al. Neonatal pulmonary sequestration: clinical experience with transumbilical arterial embolization. Pediatr Pulmonol 2008; 43:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/58\">",
"      Cho MJ, Kim DY, Kim SC, et al. Embolization versus surgical resection of pulmonary sequestration: clinical experiences with a thoracoscopic approach. J Pediatr Surg 2012; 47:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/59\">",
"      Laberge JM, Puligandla P, Flageole H. Asymptomatic congenital lung malformations. Semin Pediatr Surg 2005; 14:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/60\">",
"      Laje P, Liechty KW. Postnatal management and outcome of prenatally diagnosed lung lesions. Prenat Diagn 2008; 28:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/61\">",
"      Adzick NS. Management of fetal lung lesions. Clin Perinatol 2003; 30:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/62\">",
"      Winters WD, Effmann EL, Nghiem HV, Nyberg DA. Disappearing fetal lung masses: importance of postnatal imaging studies. Pediatr Radiol 1997; 27:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/63\">",
"      Blau H, Barak A, Karmazyn B, et al. Postnatal management of resolving fetal lung lesions. Pediatrics 2002; 109:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/64\">",
"      Zach MS, Eber E. Adult outcome of congenital lower respiratory tract malformations. Thorax 2001; 56:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/65\">",
"      Grethel EJ, Wagner AJ, Clifton MS, et al. Fetal intervention for mass lesions and hydrops improves outcome: a 15-year experience. J Pediatr Surg 2007; 42:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/66\">",
"      Louie HW, Martin SM, Mulder DG. Pulmonary sequestration: 17-year experience at UCLA. Am Surg 1993; 59:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/67\">",
"      Halkic N, Cu&eacute;noud PF, Corth&eacute;sy ME, et al. Pulmonary sequestration: a review of 26 cases. Eur J Cardiothorac Surg 1998; 14:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29144/abstract/68\">",
"      Kamata S, Usui N, Kamiyama M, et al. Long-term outcome in patients with prenatally diagnosed cystic lung disease: special reference to ventilation and perfusion scan in the affected lung. J Pediatr Surg 2006; 41:2023.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6341 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-484BBBCA60-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_29_29144=[""].join("\n");
var outline_f28_29_29144=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28430079\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Location",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Connections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Vascular supply",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Associated anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prenatal presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Postnatal presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Postnatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Fetal intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28430079\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6341\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6341|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/63/18431\" title=\"diagnostic image 1\">",
"      Aortogram of a bronchopulmonary sequestration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/48/30479\" title=\"diagnostic image 2\">",
"      ILS chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/61/8145\" title=\"diagnostic image 3\">",
"      ILS contrast CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6341|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/14/39139\" title=\"picture 1\">",
"      ILS gross pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/4/14406\" title=\"picture 2\">",
"      ILS histology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/45/19161?source=related_link\">",
"      Approach to congenital malformations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/27/29114?source=related_link\">",
"      Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/11/44214?source=related_link\">",
"      Congenital lobar emphysema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/50/810?source=related_link\">",
"      Congenital pulmonary airway (cystic adenomatoid) malformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/15/14585?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of neuroblastoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30487?source=related_link\">",
"      Radiographic appearance of developmental anomalies of the lung",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_29_29145="Travelers' diarrhea";
var content_f28_29_29145=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Travelers' diarrhea",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/29/29145/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/29/29145/contributors\">",
"     Christine A Wanke, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/29/29145/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/29/29145/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/29/29145/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/29/29145/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/29/29145/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Travelers' diarrhea is the most common illness in persons traveling from resource-rich to resource-poor regions of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The fear of developing diarrhea while traveling is common among travelers to any part of the developing world. This concern is realistic; 40 to 60 percent of travelers to these countries may develop diarrhea. Episodes of travelers' diarrhea (TD) are nearly always benign and self-limited, but the dehydration that can complicate an episode may be severe and pose a greater health hazard than the illness itself. Nevertheless, it is possible to educate a traveler to manage a diarrheal episode without compromising either their trip or their health.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;TD is frequently categorized into three forms: classic, moderate, and mild [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/3\">",
"     3",
"    </a>",
"    ]. For epidemiologic studies, the three types can be grouped together to estimate a total number of cases of TD. These forms of TD are defined as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classic &mdash; passage of three or more unformed stools in a 24 hour period plus at least one of these other symptoms: nausea, vomiting, abdominal pain or cramps, fever, blood in stools",
"     </li>",
"     <li>",
"      Moderate &mdash; passage of one or two unformed stools in 24 hours plus at least one of the above symptoms or more than two unformed stools in 24 hours without other symptoms",
"     </li>",
"     <li>",
"      Mild &mdash; passage of one or two unformed stools in 24 hours without other symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These definitions allow some uniformity in studies of the epidemiology and etiologies of TD. TD should also be in the differential diagnosis when diarrhea develops within 10 days after the individual returns home. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39304?source=see_link\">",
"     \"Evaluation of fever in the returning traveler\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrheal disease in travelers may be caused by a variety of bacterial, viral, and parasitic organisms, which are most often transmitted by food and water [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. More than 90 percent of illnesses in most geographic areas are caused by bacteria; the most common organism is enterotoxigenic Escherichia coli (ETEC) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/4,7,8\">",
"     4,7,8",
"    </a>",
"    ]. In one series of 30,369 travelers to Jamaica, the attack rate for TD was 24 percent; 12 percent of these cases were the classic form [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/9\">",
"     9",
"    </a>",
"    ]. Departing travelers surveyed at the airport reported incapacity for a mean of 11.6 hours from the illness; less than 3 percent stated that they had attempted to avoid potentially high-risk foods or drinks.",
"   </p>",
"   <p>",
"    The epidemiology of TD does vary from location to location and with the season of the year [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Spices in food and changes in climate do",
"    <strong>",
"     not",
"    </strong>",
"    cause TD, although variations in diet, temperature, or even time zones can alter the way a traveler feels and the stresses of travel may exacerbate diarrheal symptoms.",
"   </p>",
"   <p>",
"    The world can be divided into three regions by risk for the development of TD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low risk (&lt;10 percent) &mdash; Northern Europe, Australia and New Zealand, the United States, Canada, Singapore, Japan",
"     </li>",
"     <li>",
"      Moderate risk (10 to 20 percent) &mdash; Caribbean Islands, South Africa, and countries bordering the Mediterranean Sea including Israel",
"     </li>",
"     <li>",
"      High risk (&gt;30 percent) &mdash; Asia (with the exception of Singapore), Africa (outside of South Africa), South and Central America, and Mexico",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Travelers should be aware that food items on aircraft will often be obtained at the city of departure [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8967?source=see_link\">",
"     \"Travel advice\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of diarrhea is related to the number of ingested organisms that reach the intestine alive. Thus, any factor which enhances the ability of bacteria to survive ingestion and transit to the intestine will increase the risk for the development of diarrheal disease. As an example, an individual who is taking histamine blockers for ulcer disease will be at increased risk for developing diarrhea since the reduction of gastric acid will allow ingested pathogens prior to their entry into the small bowel. Similarly, an individual who has altered upper gastrointestinal (GI) anatomy (eg, after ulcer surgery, or with a blind loop syndrome) or motility may be at increased risk for the development of diarrheal disease while traveling in more contaminated environments. However, it is not clear what factors beyond exposure may influence the acquisition of parasites or viruses.",
"   </p>",
"   <p>",
"    Ingestion of parasites that cause diarrhea requires a more contaminated environment than is usually frequented by the average traveler. Thus, parasitic pathogens rarely cause TD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/5,13,14\">",
"     5,13,14",
"    </a>",
"    ]. However, there are a few locations where travelers are more likely to acquire parasites, including Nepal (where both Giardia lamblia and Cyclospora cayetanensis are common) and St. Petersburg (where G. lamblia remain hyperendemic). The mountainous regions of the West and Northeast United States are also highly endemic for G. lamblia, but travelers to these locations rarely request advice prior to travel. In these situations, it may be that environmental factors such as the juxtaposition of the water supply with the habitat of a certain animal species predispose the area to a hyperinfestation with the parasite.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, a variety of bacterial, viral, and parasitic organisms can cause TD (",
"    <a class=\"graphic graphic_table graphicRef62537 \" href=\"UTD.htm?33/20/34123\">",
"     table 1",
"    </a>",
"    ), although bacterial pathogens, especially ETEC, predominate. In the series of travelers to Jamaica, 322 individuals had stool specimens processed and an etiologic agent was identified in 32 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial pathogens predominate as the cause of TD. In the series of 322 patients cited above, ETEC accounted for 12 percent of cases due to bacteria followed by Salmonella spp, Campylobacter jejuni, and Shigella spp at 8, 6, and 0.3 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/9\">",
"     9",
"    </a>",
"    ]. In another study of 636 travelers to Guadalajara Mexico, Ocho Rios Jamaica, and Goa India, the more newly described enteroaggregative E. coli (EAEC) were responsible for 26 percent of cases, second only to ETEC with 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/15\">",
"     15",
"    </a>",
"    ]. The identification of EAEC in these stool specimens reduced the number of cases with an undiagnosed etiology from 51 to 37 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37960?source=see_link\">",
"     \"Pathogenic Escherichia coli\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other organisms (Salmonella spp, Shigella spp, C. jejuni, Vibrio spp, Aeromonas hydrophila, Plesiomonas shigelloides as well as rotavirus and the parasites Entamoeba histolytica, Cryptosporidium parvum, and G. lamblia) accounted for 7 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/15\">",
"     15",
"    </a>",
"    ]. Twenty percent also had infection with more than one enteric organism.",
"   </p>",
"   <p>",
"    Patients taking malaria prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/16\">",
"     16",
"    </a>",
"    ] or other antibiotics may also occasionally develop antibiotic-associated diarrhea due to Clostridium difficile. However, this is not a common cause of TD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viruses can also cause TD. Rotaviruses are the most common among the viral pathogens, accounting for 9 percent of cases in the series from Jamaica [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/9\">",
"     9",
"    </a>",
"    ]. Norovirus has also been identified as a cause of travelers&rsquo; diarrhea among international travelers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/48/26376?source=see_link\">",
"     \"Clinical presentation and diagnosis of rotavirus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43241?source=see_link\">",
"     \"Epidemiology, clinical manifestations and diagnosis of norovirus and related viruses\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Parasites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although parasitic travelers' diarrhea is rare, C. parvum, microsporidia, and Isospora belli, in addition to G. lamblia and C. cayetanensis, may contribute to diarrhea in travelers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/19\">",
"     19",
"    </a>",
"    ]. E. histolytica can produce intestinal infection but is not a common pathogens in TD, perhaps because the time spent in the endemic area is short. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=see_link\">",
"     \"Intestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    .) Other parasites, such as Ascaris lumbricoides or Strongyloides stercoralis, are not usually associated with diarrheal symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most episodes of TD occur between 4 and 14 days after arrival [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/9\">",
"     9",
"    </a>",
"    ], but can occur within a much shorter time frame if the concentration of bacteria ingested is sufficiently high. The illness is generally self-limited with symptoms lasting for approximately one to five days. However, 8 to 15 percent of patients experience symptoms for more than one week and as many as two percent for more than one month [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/20\">",
"     20",
"    </a>",
"    ]. While it is common to be unable to proceed with planned activities [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/9\">",
"     9",
"    </a>",
"    ], only approximately 20 percent of patients report requiring bedrest for one to two days [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The symptoms of TD depend upon the microbial etiology. The classic \"turista\" due to ETEC generally produces malaise, anorexia, and abdominal cramps followed by the sudden onset of watery diarrhea. Nausea and vomiting also may occur. Typically there are no symptoms of colitis such as blood or pus in the stool. Patients may develop a low grade fever.",
"   </p>",
"   <p>",
"    Even when other bacterial agents such as C. jejuni and Shigella spp. are implicated, the symptoms initially experienced by the traveler may be similar to those seen with ETEC. However, infections with these organisms may progress to include symptoms of colitis, such as tenesmus, urgency, cramping and bloody diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of Campylobacter infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shigella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Belching and other upper intestinal symptoms are typical of giardiasis, while profuse watery diarrhea is characteristic of cryptosporidiosis and C. cayetanensis infection. The symptoms of microsporidiosis may be more subtle with bloating and intermittent diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of giardiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16089?source=see_link\">",
"     \"Microsporidiosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31493?source=see_link\">",
"     \"Cyclospora infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of irritable bowel syndrome following infectious enteritis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=see_link&amp;anchor=H19618498#H19618498\">",
"     \"Pathophysiology of irritable bowel syndrome\", section on 'Postinfectious'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since TD is generally self-limited, treatment is often symptomatic and initiated without documenting an etiologic agent. However, if symptoms are severe and associated with toxicity or if they persist beyond 48 to 72 hours, intervention may be necessary. Routine stool cultures are rarely warranted routine since ETEC and EAEC cannot be distinguished from nonpathogenic E. coli on stool culture and viral agents would not be identified with stool cultures. A stool culture should be sent in a patient with fever and colitic symptoms. In patients with predominantly upper GI symptoms (eg, bloating, gas, nausea), stool examination for G. lamblia and Cyclospora should be undertaken. The itinerary of the traveler should be considered when deciding which patients to culture or obtain special stains for parasites. Examination for C. parvum, microsporidium, or other less common organisms should only be initiated when diarrhea has persisted for more than 10 to 14 days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=see_link\">",
"     \"Approach to the adult with acute diarrhea in developed countries\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=see_link\">",
"     \"Evaluation of diarrhea in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of TD may include three different modalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fluid replacement",
"     </li>",
"     <li>",
"      Antibiotics",
"     </li>",
"     <li>",
"      Antimotility agents",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fluid replacement is essential; antibiotics and antimotility agents may be required depending upon the circumstances. Most cases are self-limited and resolve on their own within three to five days of treatment with fluid replacement only. Antimicrobial therapy shortens the disease duration to about one day and antimotility agents may limit symptoms to a period of hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Fluid replacement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary and most important treatment of travelers' (or any other) diarrhea is fluid replacement since the most significant risk is volume depletion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Patients with mild diarrhea may combine alternating sips of fluids with both salt and sugar to replete and maintain hydration. Broth, fruit juice, or similar fluids may be used. Pedialyte is frequently useful in children.",
"   </p>",
"   <p>",
"    Severe diarrhea should be treated with oral rehydration solution; this replaces needed electrolytes in the appropriate concentrations. These solutions were developed following the realization that intestinal glucose linked sodium absorption remains intact in most small bowel diarrheal illnesses. Thus, in diarrheal disease caused by any organism that activates small bowel secretory processes (eg, cholera toxin turning on cAMP), the intestine remains able to absorb water if glucose and salt are also present to assist in the transport of water from the intestinal lumen.",
"   </p>",
"   <p>",
"    Packets of oral rehydration solution are available in the pharmacies of most countries and can be mixed with clean drinking water [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/23\">",
"     23",
"    </a>",
"    ]. Alternatively, a similar solution can be made by adding",
"    <span class=\"nowrap\">",
"     1/2",
"    </span>",
"    teaspoon of salt,",
"    <span class=\"nowrap\">",
"     1/2",
"    </span>",
"    teaspoon of baking soda, and 4 tablespoons of sugar to one liter of water. The electrolyte concentrations of fluids used for sweat replacement (eg, Gatorade) are not equivalent. If available, racecadotril, an enkephalinase inhibitor, may be an effective adjunct to oral rehydration solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=see_link&amp;anchor=H14#H14\">",
"     \"Approach to the adult with acute diarrhea in developed countries\", section on 'Oral rehydration solutions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link&amp;anchor=H5#H5\">",
"     \"Oral rehydration therapy\", section on 'Clinical management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For mild diarrhea, the use of fluids is the critical factor; the fluid need not be oral rehydration solution. One study showed no difference in outcome between treatment with oral rehydration solution plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    versus generic fluids and loperamide [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dietary intake has not been resolved. Controversy exists about such issues as partial fasting, the composition of the diet, and the time at which solid food intake should be resumed. A restricted diet (eg, beginning with only clear liquids to match diarrheal losses during the acute phase of diarrhea) is often recommended.",
"   </p>",
"   <p>",
"    A pilot randomized trial compared the effects of this restricted diet to an unrestricted diet in which the only specific recommendation was to match fluid intake to diarrheal losses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/26\">",
"     26",
"    </a>",
"    ]. The study subjects were healthy American college students being treated with an antimicrobial agent in Mexico. The mean duration of diarrhea (37 versus 33 hours) and the course of clinical symptoms were similar in the two groups.",
"   </p>",
"   <p>",
"    The general applicability of these observations is uncertain. Furthermore, diet other than hydration is not likely to be important since disease duration is only about one to two days with antibiotic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics are warranted to treat diarrhea in those who develop moderate to severe diarrhea as characterized by more than four unformed stools daily, fever, blood, pus, or mucus in the stool. In addition, some travelers desire antibiotic treatment for milder disease if the illness is a large burden on a business trip or vacation. Travelers may be given a prescription for antibiotics that can be taken if diarrhea develops rather than as prophylaxis.",
"   </p>",
"   <p>",
"    Travelers generally should medicate themselves rather than seek medical advice while traveling (",
"    <a class=\"graphic graphic_table graphicRef75355 \" href=\"UTD.htm?5/58/6060\">",
"     table 2",
"    </a>",
"    ). However, medical help may be needed in patients who develop high fever, abdominal pain, bloody diarrhea, or vomiting and empiric antibiotics have not been of benefit. For most patients while traveling or after returning home, medical consultation is not needed unless symptoms persist for 10 to 14 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Quinolones",
"    </span>",
"    &nbsp;&mdash;&nbsp;When antibiotics are indicated, therapy with a quinolone antibiotic can be initiated after the diarrhea begins. Most commonly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 mg twice daily) is given for one or two days, although any of the newer, once a day quinolones should be effective. Quinolones are not approved for use in pregnant women or children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=see_link\">",
"     \"Fluoroquinolones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The quinolones will lead to resolution of diarrheal symptoms in the majority of travelers within one day [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/8,11,27-29\">",
"     8,11,27-29",
"    </a>",
"    ]. In two randomized trials, for example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (500 mg twice daily) resulted in a mean duration of diarrhea of 1.5 days compared to 2.9 days with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/28\">",
"     28",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    (400 mg twice daily for three days) resulted in a mean duration of diarrhea of 1.2 days compared to 3.3 days with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/11\">",
"     11",
"    </a>",
"    ]. Although two to three days should be sufficient for the majority of episodes of TD, a single dose of ciprofloxacin or norfloxacin may also be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All of the quinolones can be expected to have similar activity against the organisms that cause TD; the most readily available, easiest to tolerate, and most inexpensive quinolone should be prescribed. When",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    is used by an individual who drinks caffeine containing beverages, the drug may increase caffeine levels and cause jitteriness. The newer once daily quinolones (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ) would be expected to be active but have not been approved for use in infectious diarrhea.",
"   </p>",
"   <p>",
"    The quinolones are active against the majority of ETEC strains and also have activity against less common but potential pathogens such as Campylobacter spp, Salmonella spp, V. parahaemolyticus, and, although rarely a cause of TD, Vibrio cholerae [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/4,30\">",
"     4,30",
"    </a>",
"    ]. One concern is the increasingly frequent resistance to quinolones among diarrheal pathogens worldwide, particularly Campylobacter jejuni isolates in Southeast Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/31-35\">",
"     31-35",
"    </a>",
"    ]. For this reason,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    is an increasingly common alternative to a quinolone, particularly in travelers to Asia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Azithromycin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    is an effective drug for the treatment of TD and is the preferred agent for children. Evidence of efficacy has been provided by studies from Mexico [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/36\">",
"     36",
"    </a>",
"    ], Turkey [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/37\">",
"     37",
"    </a>",
"    ], and Thailand [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In randomized controlled trials of American adults with TD in Mexico and Turkey, a single 1000 mg oral dose of azithromycin was as effective as a single 500 mg dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. In the trial from Turkey, azithromycin was associated with a greater likelihood of nausea than levofloxacin in the first 30 minutes after dosing (8 versus 1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    may have a particular role in the treatment of travelers' diarrhea in Southeast Asia where, as noted in the previous section, quinolone-resistant Campylobacter jejuni is a common cause. A randomized trial performed in Thailand compared azithromycin, given as a single 1 g dose or 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for three days, with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for 3 days) in 156 United States military personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/39\">",
"     39",
"    </a>",
"    ]. C. jejuni was responsible for 64 percent of cases and was quinolone-resistant in 50 percent.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     Azithromycin",
"    </a>",
"    administered as a single 1 g dose had a higher cure rate than a three day regimen of either azithromycin (500 mg daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (500 mg daily); cure rates were 96, 85, and 71 percent, respectively. Microbiologic eradication was much higher with azithromycin (96 to 100 percent versus 38 percent with levofloxacin), but this difference correlated poorly with outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Rifaximin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     Rifaximin",
"    </a>",
"    (200 mg three times daily for three days for children &ge;12 years and adults) is a nonabsorbed rifamycin that has been demonstrated to be effective in the treatment of TD caused by noninvasive strains of E. coli. It is attracting increasing interest because of concerns about quinolone resistance.",
"   </p>",
"   <p>",
"    In controlled trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    was associated with more rapid cessation of diarrhea than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/40\">",
"     40",
"    </a>",
"    ] and had equal efficacy to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Rifaximin combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    may provide more rapid symptomatic improvement than either agent alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widespread antibiotic resistance to drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX) have made these agents less useful for the treatment of TD in much of the world [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/38,44,45\">",
"     38,44,45",
"    </a>",
"    ]. Resistance has developed among many routine enteric pathogens. In addition, organisms such as Campylobacter spp or any of the vibrios would not be expected to be sensitive to these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Treatment approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral agents for treatment of travelers' diarrhea are outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef75355 \" href=\"UTD.htm?5/58/6060\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/1\">",
"     1",
"    </a>",
"    ]. The patient should be given enough medication for three days of therapy (except for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    which is 1000 mg as a single dose) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/1\">",
"     1",
"    </a>",
"    ]. Treatment may be discontinued after 24 hours if symptoms have improved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"     Bismuth",
"    </a>",
"    subsalicylate can also be used to treat diarrhea although large doses are required. Sixty mL (or four tablets) should be taken every one-half hour until the diarrhea resolves or eight doses have been taken. The two major disadvantages of this type of treatment are the potential for salicylate toxicity (especially in those who take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for any reason, pregnant women, and children) and the need to carry large quantities of bismuth subsalicylate.",
"   </p>",
"   <p>",
"    An antisecretory agent derived from plants (SP-303 [Provir]) was tested in a double-blind placebo-controlled study of TD in 184 travelers from the United States to Jamaica or Mexico [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/46\">",
"     46",
"    </a>",
"    ]. The duration of TD was reduced by 21 percent among those taking SP-303, and the incidence of treatment failure was significantly decreased compared to placebo. This may be another promising approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Antimotility agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimotility agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    (Imodium) or diphenoxylate (Lomotil) are frequently used by travelers in combination with antibiotics to reduce the rate of stooling; they do not treat the cause of diarrhea. The symptomatic improvement associated with their use in this setting has been somewhat limited but considered to be of benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/27,47,48\">",
"     27,47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2008 meta-analysis of 12 studies suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    combined with antibiotic therapy is beneficial to the traveler with diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, for example, 104 patients with TD were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    500 mg twice daily for three days [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/27\">",
"     27",
"    </a>",
"    ]. They were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    (4 mg first dose and 2 mg for every loose stool up to 16",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo, in addition to the ciprofloxacin. After 24 hours, symptoms had improved or fully recovered in 82 percent of the loperamide group compared with 67 percent of those receiving placebo. After 48 hours, the symptoms of 90 percent of both groups had improved or fully recovered.",
"   </p>",
"   <p>",
"    There continues to be some concern that antimotility agents can prolong some types of dysenteric illnesses (eg, Shigella) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/49\">",
"     49",
"    </a>",
"    ]. While some studies suggest that antimotility drugs can be safely used in dysenteric illnesses as long as they are combined with antibiotic therapy, the studies included in the 2008 meta-analysis all excluded patients with bloody diarrhea or symptoms suggestive of dysentery [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/27,47,48\">",
"     27,47,48",
"    </a>",
"    ]. Thus, caution should be exercised in using these agents in travelers with bloody diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/27,47\">",
"     27,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Travelers often elect to take antimotility agents in certain circumstances (eg, a prolonged bus or car trip). Particular vigilance about hydration is important in these patients since the antimotility drugs do not kill the pathogen causing the diarrhea or stop the secretory process in the intestine. Patients may be unaware of how much fluid they are losing into their intestine since they are no longer having frequent bowel movements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;We favor cautious use of antimotility agents in the setting of TD. They should be administered only in conjunction with empiric antibiotic treatment of the offending diarrheal pathogen, and travelers should be educated about the need to avoid usage in dysentery. Antimotility agents should be stopped if abdominal pain or other symptoms worsen or if the diarrhea continues to be intractable after two days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several means by which travelers can reduce their risk of developing a diarrheal illness, including the following [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/1,8,50\">",
"     1,8,50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Improving food and drink selection",
"     </li>",
"     <li>",
"      Water purification",
"     </li>",
"     <li>",
"      Prophylactic medications",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following discussion is consistent with the 2006 guidelines on travel medicine from the Infectious Diseases Society of America [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Food and drink selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Educated choices in selecting food and drinks can result in a lower incidence of diarrheal disease. Travelers should be aware of the following observations regarding transmission of diarrhea-causing organisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Freezing does not kill the organisms that cause diarrheal disease. Thus, ice in drinks is not safe unless made from adequately boiled or filtered water.",
"     </li>",
"     <li>",
"      Alcohol does not sterilize water or ice; mixed drinks may still be contaminated.",
"     </li>",
"     <li>",
"      Outbreaks of diarrheal disease have been associated with bottled water (including carbonated water with insufficient carbonation) on rare occasions [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/51\">",
"       51",
"      </a>",
"      ]. However, the presence of carbonation when a bottle is opened (eg, carbonated water or soft drinks) can reassure the traveler that the drink was processed in a proper fashion and is usually safe.",
"     </li>",
"     <li>",
"      Fruit salads, lettuce, or chicken salads are examples of unwise food choices; the ingredients may have been improperly washed",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      may have been sitting for some time without proper refrigeration.",
"     </li>",
"     <li>",
"      Condiments on the table can frequently become contaminated. One study of Mexican sauces in restaurants in Guadalajara and Houston found E. coli in more sauces in Mexico than in Houston (66 versus 40 percent); it is important to note that significant levels of contamination was not limited to Mexico [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/52\">",
"       52",
"      </a>",
"      ]. Guacamole was the most frequently contaminated and was second only to pico de gallo for the highest colony count of bacteria.",
"     </li>",
"     <li>",
"      Steam table buffets that offer the traveler a variety of foods from the local region are risky since the temperature of the food can promote the growth of bacteria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations are also pertinent in expensive resorts or hotels; price does not guarantee appropriate hygiene.",
"   </p>",
"   <p>",
"    Hot tea and coffee are usually safe alternatives to boiled water. Bottled drinks should be requested without ice and should be drunk from the bottle with a straw rather than from a glass. Fruits that can be peeled are safe as long as they are peeled just prior to eating.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Water purification",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is usually safe to assume that the traveler will be able to find bottled water or soft drinks unless travel is to a rather remote area. Travelers who are going to be living in rustic circumstances overseas will need to make arrangements for a safe water supply depending upon their circumstances. Water can be purified in one of several ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Boiling for 3 minutes followed by cooling to room temperature (do not add ice) to kill bacteria, parasites, and viruses",
"     </li>",
"     <li>",
"      Adding two drops of 5 percent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/23/29042?source=see_link\">",
"       sodium hypochlorite",
"      </a>",
"      (bleach) to a quart of water will kill most bacteria in 30 minutes",
"     </li>",
"     <li>",
"      Adding five drops of tincture of iodine to a quart of water will kill bacteria within 30 minutes",
"     </li>",
"     <li>",
"      Compact water filters in which the filters are impregnated with iodine remove parasitic pathogens and kill viral and bacterial pathogens; they provide a reasonable alternative for those who expect to be traveling under rustic circumstances. These are available commercially at camping or wilderness supply stores.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Boiling water is usually the most palatable solution to water purification if sanitary storage is feasible. The addition of iodine or chlorine to water can impart an unpleasant taste.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both antibiotics and certain other drugs have been evaluated for the prevention of TD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antibiotics prevent the majority of diarrheal disease in travelers, but cannot be recommended unless the complications of diarrhea or an underlying medical condition make the consequence of dehydration so severe that the benefits of using antibiotic prophylaxis outweigh the risks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/20\">",
"     20",
"    </a>",
"    ]. Daily antibiotics are expensive and have potential side effects that may exact a medical cost that is unacceptable. The side effects include sun sensitivity, allergic reactions, altered GI flora with colonization by resistant bacteria, yeast infections such as candidal vaginitis, and the risk of C. difficile colitis.",
"   </p>",
"   <p>",
"    Some situations in which it might be reasonable to consider prophylactic antibiotics include: known severe inflammatory bowel disease which could be exacerbated by an episode of infectious diarrhea; severe vascular, cardiac, or renal disease that would be seriously compromised by dehydration; or severe immunocompromise such as advanced HIV disease or after a complicated organ transplant such as a liver or cardiac transplant. Studies with prophylactic antibiotics were predominantly performed with older agents such as TMP-SMX or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    . However, these drugs are generally not used since susceptibility among the bacteria causing TD has changed.",
"   </p>",
"   <p>",
"    Most travelers requiring prophylaxis are given a quinolone antibiotic at the same doses used for treatment (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Quinolones'",
"    </a>",
"    above). A number of studies, particularly with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"     norfloxacin",
"    </a>",
"    , showed that quinolones had a protective efficacy of 80 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/20\">",
"     20",
"    </a>",
"    ]. However, emerging resistance among pathogens, particularly Campylobacter spp to the quinolones, especially in Southeast Asia, raise questions about how long prophylaxis with these drugs will continue to be effective.",
"   </p>",
"   <p>",
"    Concerns regarding the development of fluoroquinolone resistance have led to increased interest in the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"     rifaximin",
"    </a>",
"    , which is not absorbed. In a randomized, double-blind placebo-controlled trial in Mexico, 210 American adults received either rifaximin (doses included 200 mg daily, 200 mg twice daily, or 200 mg three times daily) or placebo for two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/53\">",
"     53",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a significant reduction in TD with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"       rifaximin",
"      </a>",
"      therapy (15 versus 54 percent with placebo).",
"     </li>",
"     <li>",
"      Protection from illness was similar at all",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"       rifaximin",
"      </a>",
"      doses.",
"     </li>",
"     <li>",
"      The rates of adverse events were comparable in all treatment and placebo arms.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"       Rifaximin",
"      </a>",
"      therapy was associated with minimal changes in intestinal flora.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonantibiotic preventive methods have also been studied.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"     Bismuth",
"    </a>",
"    subsalicylate (30 mL or two tablets four times daily with meals) can prevent a significant number of cases of TD [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the doses required are inconvenient for the traveler, and the same cautions about salicylate toxicity apply when used for prevention as well as therapy. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Other agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Probiotics such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    GG have been shown to decrease the incidence of diarrhea in travelers in randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/54\">",
"     54",
"    </a>",
"    ]. However, another lactobacillus preparation, nonviable Lactobacillus acidophilus (LA) showed no beneficial effect compared to placebo in a randomized, double-blind, controlled trial in 174 travelers [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/55\">",
"     55",
"    </a>",
"    ]. The authors speculate that the lack of benefit compared to that seen with Lactobacillus GG may be due to either the strain selected for the trial or the fact that the bacteria were nonviable.",
"   </p>",
"   <p>",
"    These studies indicate that there are probably important differences in efficacy between probiotics. It is necessary to think of individual probiotics (like individual antibiotics) rather than to generalize results to the whole class of agents.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/39/25203?source=see_link\">",
"     Saccharomyces boulardii",
"    </a>",
"    also had some protective effect in travelers to North Africa and Turkey [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/20\">",
"     20",
"    </a>",
"    ]. Prevention of TD without using systemic antibiotics is highly appealing; further work on probiotics is needed. It must be recognized that all probiotics are not identical and results of studies done with a particular agent should not be generalized to indicate that any probiotic agent would be successful in the same clinical situation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006 guidelines on travel medicine from the Infectious Diseases Society of America recommended the following oral agents for prophylaxis against travelers' diarrhea, even though no antibiotic has been approved for such use by the Food and Drug Administration in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/9/16536?source=see_link\">",
"       Norfloxacin",
"      </a>",
"      &mdash; 400 mg once daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"       Ciprofloxacin",
"      </a>",
"      &mdash; 500 mg once daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37140?source=see_link\">",
"       Rifaximin",
"      </a>",
"      &mdash; 200 mg once or twice daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"       Bismuth",
"      </a>",
"      subsalicylate &mdash; two tablets chewed four times daily",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines noted that other fluoroquinolones are likely to be effective but have not been studied for prophylaxis and that there is no antibiotic with proven efficacy for prophylaxis against Campylobacter species, which are a more common cause of travelers' diarrhea in south and southeast Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Quinolones'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    With respect to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35285?source=see_link\">",
"     bismuth",
"    </a>",
"    subsalicylate, the doses required are inconvenient for the traveler, and salicylate toxicity is a potential complication. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Other agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of a cholera vaccine is not routinely recommended for travelers. However, a number of trials suggest that the oral, killed whole-cell vaccine given with the nontoxic B subunit of cholera toxin (Dukoral) provides protection for travelers against enterotoxigenic E. coli (ETEC) infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. The rationale for such protection is that the B subunit of cholera is antigenically similar to the heat-labile enterotoxin of ETEC. In two randomized trials, the killed whole-cell vaccine combined with the B subunit of cholera toxin reduced the incidence of diarrhea caused by ETEC by 67 percent in a trial in Bangladesh and 52 percent among travelers to Morocco [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Dukoral vaccine was approved in the United States in late 2006 for use as a travelers' diarrhea vaccine. A conservative estimate that took into account the incidence of ETEC infection throughout the world and the efficacy of the vaccine suggested that it may prevent &le;7 percent of travelers' diarrhea cases [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/59\">",
"     59",
"    </a>",
"    ]. The 2006 guidelines on travel medicine from the Infectious Diseases Society of America concluded that the decision to use the vaccine to prevent travelers' diarrhea must balance its cost, adverse effects, and limited utility against the known effectiveness and costs of self-treatment as described above [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A new strategy for vaccination with heat-labile enterotoxin (LT) from enterotoxigenic Escherichia coli (ETEC) via a skin patch may be an effective measure for protection against moderate to severe travelers' diarrhea. This was illustrated in a phase II trial including 201 participants; protection against moderate to severe diarrhea was observed among those randomized to receive LT patches (protective efficacy 75 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29145/abstract/60\">",
"     60",
"    </a>",
"    ]. The findings from this small study are promising and should encourage further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=see_link\">",
"       \"Patient information: General travel advice (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"       \"Patient information: Food poisoning (food-borne illness) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/0/28673?source=see_link\">",
"       \"Patient information: Giardia (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/3/20530?source=see_link\">",
"       \"Patient information: Travelers&rsquo; diarrhea (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Travelers' diarrhea is a common entity and can be induced by a variety of bacteria, viruses, and parasites.",
"     </li>",
"     <li>",
"      It is uncommon to have to make an etiologic diagnosis. Stool cultures or examination for ova and parasites should generally be reserved for cases that last beyond 10 to 14 days, except for patients with fever and colitis, those with upper intestinal symptoms in whom giardiasis is more likely, or immunocompromised patients.",
"     </li>",
"     <li>",
"      The mainstay of therapy for travelers' diarrhea is fluid replacement. Attention to fluids including those with sugar and salt is sufficient for mild diarrhea but severe diarrhea should be treated with oral rehydration solution. Packets, which can be reconstituted in clean drinking water, are available for sale in most countries.",
"     </li>",
"     <li>",
"      Travelers should be given a prescription for antibiotics to fill and take with them in case diarrhea develops (",
"      <a class=\"graphic graphic_table graphicRef75355 \" href=\"UTD.htm?5/58/6060\">",
"       table 2",
"      </a>",
"      ). Antibiotics should be taken by the traveler if unformed stools occur more than four times a day or for fever, or blood, pus or mucous in stools.",
"     </li>",
"     <li>",
"      Medical care should be sought if fevers persist beyond 10 to 14 days or if fevers become higher, or abdominal pain, bloody diarrhea, or vomiting ensue.",
"     </li>",
"     <li>",
"      Antimotility agents are usually not necessary for mild to moderate diarrhea and should not be used in severe diarrhea except in association with antibiotic therapy. These agents should be discontinued promptly if abdominal pain develops, other symptoms worsen, or diarrhea persists.",
"     </li>",
"     <li>",
"      Attention to choices of food and drink, water purification, and antibiotic prophylaxis are all means of attempting to prevent travelers' diarrhea. Antibiotic prophylaxis is usually reserved for patients in whom dehydration would put them at severe risk.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/1\">",
"      Hill DR, Ericsson CD, Pearson RD, et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/2\">",
"      Greenwood Z, Black J, Weld L, et al. Gastrointestinal infection among international travelers globally. J Travel Med 2008; 15:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/3\">",
"      von Sonnenburg F, Tornieporth N, Waiyaki P, et al. Risk and aetiology of diarrhoea at various tourist destinations. Lancet 2000; 356:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/4\">",
"      Steffen R. Epidemiologic studies of travelers' diarrhea, severe gastrointestinal infections, and cholera. Rev Infect Dis 1986; 8 Suppl 2:S122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/5\">",
"      Black RE. Pathogens that cause travelers' diarrhea in Latin America and Africa. Rev Infect Dis 1986; 8 Suppl 2:S131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/6\">",
"      Taylor DN, Echeverria P. Etiology and epidemiology of travelers' diarrhea in Asia. Rev Infect Dis 1986; 8 Suppl 2:S136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/7\">",
"      DuPont HL, Capsuto EG. Persistent diarrhea in travelers. Clin Infect Dis 1996; 22:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/8\">",
"      DuPont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. N Engl J Med 1993; 328:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/9\">",
"      Steffen R, Collard F, Tornieporth N, et al. Epidemiology, etiology, and impact of traveler's diarrhea in Jamaica. JAMA 1999; 281:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/10\">",
"      Mattila L, Siitonen A, Kyr&ouml;nsepp&auml; H, et al. Seasonal variation in etiology of travelers' diarrhea. Finnish-Moroccan Study Group. J Infect Dis 1992; 165:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/11\">",
"      Mattila L, Peltola H, Siitonen A, et al. Short-term treatment of traveler's diarrhea with norfloxacin: a double-blind, placebo-controlled study during two seasons. Clin Infect Dis 1993; 17:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/12\">",
"      Centers for Disease Control. Shigellosis related to an airplane meal - Northeastern U.S. MMWR 1971; 20:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/13\">",
"      Soave R, Ma P. Cryptosporidiosis. Traveler's diarrhea in two families. Arch Intern Med 1985; 145:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/14\">",
"      Jokipii L, Pohjola S, Jokipii AM. Cryptosporidiosis associated with traveling and giardiasis. Gastroenterology 1985; 89:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/15\">",
"      Adachi JA, Jiang ZD, Mathewson JJ, et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. Clin Infect Dis 2001; 32:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/16\">",
"      Golledge CL, Riley TV. Clostridium difficile-associated diarrhoea after doxycycline malaria prophylaxis. Lancet 1995; 345:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/17\">",
"      Koo HL, Ajami NJ, Jiang ZD, et al. Noroviruses as a cause of diarrhea in travelers to Guatemala, India, and Mexico. J Clin Microbiol 2010; 48:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/18\">",
"      Apelt N, Hartberger C, Campe H, L&ouml;scher T. The Prevalence of Norovirus in returning international travelers with diarrhea. BMC Infect Dis 2010; 10:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/19\">",
"      Goodgame R. Emerging Causes of Traveler's Diarrhea: Cryptosporidium, Cyclospora, Isospora, and Microsporidia. Curr Infect Dis Rep 2003; 5:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/20\">",
"      Rendi-Wagner P, Kollaritsch H. Drug prophylaxis for travelers' diarrhea. Clin Infect Dis 2002; 34:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/21\">",
"      Avery ME, Snyder JD. Oral therapy for acute diarrhea. The underused simple solution. N Engl J Med 1990; 323:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/22\">",
"      Carpenter CC, Greenough WB, Pierce NF. Oral-rehydration therapy--the role of polymeric substrates. N Engl J Med 1988; 319:1346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/23\">",
"      de Zoysa I, Kirkwood B, Feachem R, Lindsay-Smith E. Preparation of sugar-salt solutions. Trans R Soc Trop Med Hyg 1984; 78:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/24\">",
"      Salazar-Lindo E, Santisteban-Ponce J, Chea-Woo E, Gutierrez M. Racecadotril in the treatment of acute watery diarrhea in children. N Engl J Med 2000; 343:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/25\">",
"      Caeiro JP, DuPont HL, Albrecht H, Ericsson CD. Oral rehydration therapy plus loperamide versus loperamide alone in the treatment of traveler's diarrhea. Clin Infect Dis 1999; 28:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/26\">",
"      Huang DB, Awasthi M, Le BM, et al. The role of diet in the treatment of travelers' diarrhea: a pilot study. Clin Infect Dis 2004; 39:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/27\">",
"      Taylor DN, Sanchez JL, Candler W, et al. Treatment of travelers' diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial. Ann Intern Med 1991; 114:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/28\">",
"      Pichler HE, Diridl G, Stickler K, Wolf D. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea. Am J Med 1987; 82:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/29\">",
"      Salam I, Katelaris P, Leigh-Smith S, Farthing MJ. Randomised trial of single-dose ciprofloxacin for travellers' diarrhoea. Lancet 1994; 344:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/30\">",
"      From the Centers for Disease Control. Cholera--international travel, 1992. JAMA 1992; 268:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/31\">",
"      Smith KE, Besser JM, Hedberg CW, et al. Quinolone-resistant Campylobacter jejuni infections in Minnesota, 1992-1998. Investigation Team. N Engl J Med 1999; 340:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/32\">",
"      Hakanen A, Jousimies-Somer H, Siitonen A, et al. Fluoroquinolone resistance in Campylobacter jejuni isolates in travelers returning to Finland: association of ciprofloxacin resistance to travel destination. Emerg Infect Dis 2003; 9:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/33\">",
"      Nachamkin I, Ung H, Li M. Increasing fluoroquinolone resistance in Campylobacter jejuni, Pennsylvania, USA,1982-2001. Emerg Infect Dis 2002; 8:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/34\">",
"      Sanders JW, Isenbarger DW, Walz SE, et al. An observational clinic-based study of diarrheal illness in deployed United States military personnel in Thailand: presentation and outcome of Campylobacter infection. Am J Trop Med Hyg 2002; 67:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/35\">",
"      Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006; 355:2452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/36\">",
"      Adachi JA, Ericsson CD, Jiang ZD, et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis 2003; 37:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/37\">",
"      Sanders JW, Frenck RW, Putnam SD, et al. Azithromycin and loperamide are comparable to levofloxacin and loperamide for the treatment of traveler's diarrhea in United States military personnel in Turkey. Clin Infect Dis 2007; 45:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/38\">",
"      Kuschner RA, Trofa AF, Thomas RJ, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995; 21:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/39\">",
"      Tribble DR, Sanders JW, Pang LW, et al. Traveler's diarrhea in Thailand: randomized, double-blind trial comparing single-dose and 3-day azithromycin-based regimens with a 3-day levofloxacin regimen. Clin Infect Dis 2007; 44:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/40\">",
"      Steffen R, Sack DA, Riopel L, et al. Therapy of travelers' diarrhea with rifaximin on various continents. Am J Gastroenterol 2003; 98:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/41\">",
"      DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001; 33:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/42\">",
"      Adachi JA, DuPont HL. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis 2006; 42:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/43\">",
"      Dupont HL, Jiang ZD, Belkind-Gerson J, et al. Treatment of travelers' diarrhea: randomized trial comparing rifaximin, rifaximin plus loperamide, and loperamide alone. Clin Gastroenterol Hepatol 2007; 5:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/44\">",
"      Murray BE. Resistance of Shigella, Salmonella, and other selected enteric pathogens to antimicrobial agents. Rev Infect Dis 1986; 8 Suppl 2:S172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/45\">",
"      Murray BE, Mathewson JJ, DuPont HL, et al. Emergence of resistant fecal Escherichia coli in travelers not taking prophylactic antimicrobial agents. Antimicrob Agents Chemother 1990; 34:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/46\">",
"      DiCesare D, DuPont HL, Mathewson JJ, et al. A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico. Am J Gastroenterol 2002; 97:2585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/47\">",
"      Petruccelli BP, Murphy GS, Sanchez JL, et al. Treatment of traveler's diarrhea with ciprofloxacin and loperamide. J Infect Dis 1992; 165:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/48\">",
"      Riddle MS, Arnold S, Tribble DR. Effect of adjunctive loperamide in combination with antibiotics on treatment outcomes in traveler's diarrhea: a systematic review and meta-analysis. Clin Infect Dis 2008; 47:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/49\">",
"      DuPont HL, Hornick RB. Adverse effect of lomotil therapy in shigellosis. JAMA 1973; 226:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/50\">",
"      Ericsson CD, Pickering LK, Sullivan P, DuPont HL. The role of location of food consumption in the prevention of travelers' diarrhea in Mexico. Gastroenterology 1980; 79:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/51\">",
"      Blake PA, Rosenberg ML, Florencia J, et al. Cholera in Portugal, 1974. II. Transmission by bottled mineral water. Am J Epidemiol 1977; 105:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/52\">",
"      Adachi JA, Mathewson JJ, Jiang ZD, et al. Enteric pathogens in Mexican sauces of popular restaurants in Guadalajara, Mexico, and Houston, Texas. Ann Intern Med 2002; 136:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/53\">",
"      DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005; 142:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/54\">",
"      Hilton E, Kolakowski P, Singer C, Smith M. Efficacy of Lactobacillus GG as a Diarrheal Preventive in Travelers. J Travel Med 1997; 4:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/55\">",
"      Briand V, Buffet P, Genty S, et al. Absence of efficacy of nonviable Lactobacillus acidophilus for the prevention of traveler's diarrhea: a randomized, double-blind, controlled study. Clin Infect Dis 2006; 43:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/56\">",
"      Clemens JD, Sack DA, Harris JR, et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 1988; 158:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/57\">",
"      Peltola H, Siitonen A, Kyr&ouml;nsepp&auml; H, et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991; 338:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/58\">",
"      Wiedermann G, Kollaritsch H, Kundi M, et al. Double-blind, randomized, placebo controlled pilot study evaluating efficacy and reactogenicity of an oral ETEC B-subunit-inactivated whole cell vaccine against travelers' diarrhea (preliminary report). J Travel Med 2000; 7:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/59\">",
"      Hill DR, Ford L, Lalloo DG. Oral cholera vaccines: use in clinical practice. Lancet Infect Dis 2006; 6:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29145/abstract/60\">",
"      Frech SA, Dupont HL, Bourgeois AL, et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008; 371:2019.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2709 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-FF084CEA57-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_29_29145=[""].join("\n");
var outline_f28_29_29145=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bacteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Parasites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Fluid replacement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Quinolones",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Azithromycin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Rifaximin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Treatment approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Antimotility agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Food and drink selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Water purification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2709\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2709|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/20/34123\" title=\"table 1\">",
"      Travelers diarrhea pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/58/6060\" title=\"table 2\">",
"      Travelers diarrhea rx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32025?source=related_link\">",
"      Approach to the adult with acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=related_link\">",
"      Clinical manifestations and diagnosis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/19/19769?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of Campylobacter infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/48/26376?source=related_link\">",
"      Clinical presentation and diagnosis of rotavirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31493?source=related_link\">",
"      Cyclospora infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43241?source=related_link\">",
"      Epidemiology, clinical manifestations and diagnosis of norovirus and related viruses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33224?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of giardiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13529?source=related_link\">",
"      Evaluation of diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39304?source=related_link\">",
"      Evaluation of fever in the returning traveler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28618?source=related_link\">",
"      Fluoroquinolones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=related_link\">",
"      Intestinal Entamoeba histolytica amebiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16089?source=related_link\">",
"      Microsporidiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=related_link\">",
"      Oral rehydration therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37960?source=related_link\">",
"      Pathogenic Escherichia coli",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12697?source=related_link\">",
"      Pathophysiology of irritable bowel syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=related_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/2/16421?source=related_link\">",
"      Patient information: General travel advice (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/0/28673?source=related_link\">",
"      Patient information: Giardia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/3/20530?source=related_link\">",
"      Patient information: Travelers&rsquo; diarrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8967?source=related_link\">",
"      Travel advice",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_29_29146="Treatment of acute myeloid leukemia in older adults";
var content_f28_29_29146=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acute myeloid leukemia in older adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/29/29146/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/29/29146/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/29/29146/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/29/29146/contributors\">",
"     Bob Lowenberg, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/29/29146/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/29/29146/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/29/29146/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/29/29146/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with acute myeloid leukemia (AML), treatment regimens and outcomes may differ among younger and older adults. Although there is no clear dividing line when considering age in AML, in most studies, \"older adults\" has been defined as over age 60.",
"   </p>",
"   <p>",
"    The management of older patients with AML is a difficult challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/1\">",
"     1",
"    </a>",
"    ]. Older adults are more likely to have comorbidities that can limit treatment options; the disease also tends to be more resistant to chemotherapy with more frequent unfavorable AML subtypes; thus, outcomes are worse than in younger patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43768?source=see_link\">",
"     \"Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the treatment of older adults with AML. The following topics are presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The treatment of adults of any age with acute promyelocytic leukemia (FAB M3 AML). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=see_link\">",
"       \"Initial treatment of acute promyelocytic leukemia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment of adults of any age with therapy-related AML. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link\">",
"       \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The treatment of younger adults with AML. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"       \"Induction therapy for acute myeloid leukemia in younger adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Special considerations for the use of chemotherapy in older patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=see_link\">",
"       \"Systemic chemotherapy for cancer in elderly persons\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SELECTION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the diagnosis of AML has been established, the physician and staff must present the goals of therapy, as well as the side effects of treatment, to the patient and family. For almost all patients, this discussion can emphasize the potential benefits of treatment with regard to both the short and long term outcome. Remission induction, even if short-lived, is an appropriate goal for most patients with AML.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who achieve a complete remission (CR) have an improved quality of life compared with those patients who receive palliative therapy, likely because they require fewer hospitalizations, transfusions, and antibiotics [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Attainment of CR, generally following myelosuppressive chemotherapy, is required in order to assure meaningful prolongation of life [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/4\">",
"       4",
"      </a>",
"      ]. Long term survivors can be seen among patients of all ages [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/2,3\">",
"       2,3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A randomized clinical trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    therapy with a \"watch and wait\" strategy, using supportive care and only resorting to cytoreductive chemotherapy for relief of AML-related symptoms in patients over the age of 65 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/3\">",
"     3",
"    </a>",
"    ]. The outcome was better with initial chemotherapy. The 31 patients receiving remission induction chemotherapy had a significantly longer survival (median, 21 weeks versus 11 weeks) than the supportive care group. Interestingly, the two groups spent a similar percentage of their remaining days in the hospital (54 versus 50 percent).",
"   </p>",
"   <p>",
"    Occasionally, intensive treatment with the intent to achieve CR may be less advisable because of advanced patient age, debility, presence of significant co-existing medical problems,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prior chemotherapy. A pretreatment evaluation that may help to identify such patients is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43768?source=see_link&amp;anchor=H15843336#H15843336\">",
"     \"Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults\", section on 'Pretreatment evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, there are a few patients with \"acute leukemia\" by the usual quantitative criteria of &ge;20 percent bone marrow blast cells whose disease has a much more smoldering course. These patients suffer from bone marrow failure and pancytopenia more than hyperleukocytosis. Their survival may be equally long and their quality of life better, using transfusion support and antibiotics rather than intensive chemotherapy. This may be particularly true for the",
"    <span class=\"nowrap\">",
"     \"hypoplastic/hypocellular\"",
"    </span>",
"    variant of AML. Supportive care may also be beneficial in acutely infected patients with advanced myelodysplastic syndromes. Occasionally, the clinical picture mimics AML, but improves following treatment of the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For otherwise healthy (ECOG performance status of two or less and few comorbidities) older adults with newly diagnosed AML, we suggest remission induction treatment, ideally on a clinical trial. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Induction chemotherapy'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H27\">",
"       'Clinical trials'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Clinical trials have shown the ability of the hypomethylating agents",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"       azacitidine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"       decitabine",
"      </a>",
"      , used as single agents, to induce remissions and potentially prolong survival in a fraction of older patients with newly diagnosed AML or advanced MDS. (See",
"      <a class=\"local\" href=\"#H1358586\">",
"       'DNA hypomethylating agents'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For older patients with indolent AML, severe comorbidity, or unfavorable risk disease, we suggest the use of less intensive therapy or supportive care rather than standard induction chemotherapy. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Less intensive therapy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43768?source=see_link&amp;anchor=H6273191#H6273191\">",
"       \"Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults\", section on 'Prognostic factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is frequently appropriate and necessary to repeat this discussion and counseling later during the patient's course, as a diagnosis of AML often leaves the patient and family unable to cope with the longer term consequences of this diagnosis until the patient has successfully passed through the initial weeks of chemotherapy and recovery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     INTENSIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best chemotherapy for older patients with AML remains to be identified, and patients should be encouraged to participate in clinical trials. Intensive chemotherapy may be appropriate for selected patients with low or intermediate risk disease. For patients with favorable risk karyotypes the complete remission (CR) rate can be as high as 70 to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]. With this approach, median survival is approximately eight months, but 9 to 12 percent of patients will be alive at five years. As an example, in a study of 147 patients &gt;60 years of age with either t(8;21) or inv(16), the CR rate following induction therapy with an anthracycline and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    was 88 percent, with estimated five-year probabilities of overall and leukemia-free survival of 31 and 27 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/10\">",
"     10",
"    </a>",
"    ]. In contrast, outcomes for patients with unfavorable cytogenetics, which constitute the majority of older adults with AML, are worse with a less than 45 percent CR rate and a 36 percent mortality rate in the first two months of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/11\">",
"     11",
"    </a>",
"    ]. Risk stratification of AML is described in more detail separately (",
"    <a class=\"graphic graphic_table graphicRef71278 \" href=\"UTD.htm?21/40/22156\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=see_link&amp;anchor=H2#H2\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Induction chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most older adults (up to age 70 and carefully selected older patients) with favorable or intermediate risk AML and an ECOG performance status of two or less and few comorbidities, we suggest remission induction treatment with a combination of an anthracycline and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    rather than other chemotherapy regimens or supportive care alone. When induction treatment is chosen, it should be applied at sufficient dose intensity to provide the best chance of success within one or two courses. Although pilot studies have used more intensive initial chemotherapy, a reasonable standard regimen for many older patients who are medically fit is seven days of continuous infusion cytarabine (ara-C, 100 or 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day) plus three days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    (60 or 90",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day). Equivalent doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    could be substituted for daunorubicin. Further details on the administration of this regimen are presented separately, as are recommendations for evaluation after completion of induction therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=see_link\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Support for the use of intensive chemotherapy in older adults comes from trials specifically designed for older adults and from the extrapolation of data from trials in younger adults. Randomized trials have investigated various modifications of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    plus an anthracycline for the treatment of older adults with AML. In general, the choice of anthracycline (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"     mitoxantrone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"     idarubicin",
"    </a>",
"    ) does not appear to affect overall outcome. However, higher doses of anthracyclines may result in superior rates of complete remission (CR) without an apparent increase in toxicity.",
"   </p>",
"   <p>",
"    The following studies have evaluated anthracycline dose in older adults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase III trial of 813 older adults (age 60 to 83 years) with untreated AML randomly assigned induction therapy with seven days of continuous infusion",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      (200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day) plus three once-daily doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      at either 45 or 90",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/6\">",
"       6",
"      </a>",
"      ]. All patients then received a second cycle of cytarabine at a dose of 1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for six days without concurrent daunorubicin. When compared with patients assigned to the 45",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daunorubicin dose, patients assigned to the 90",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      dose had the following outcomes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Significantly higher CR rates (64 versus 54 percent) overall and a faster response rate as demonstrated by higher CR rates after the first cycle of chemotherapy (52 versus 35 percent).",
"     </li>",
"     <li>",
"      Similar rates of event-free, disease-free, and overall survival.",
"     </li>",
"     <li>",
"      Toxicity appeared to be comparable between the two treatment groups with similar times to hematopoietic recovery; 30-day mortality (11 versus 12 percent); and no significant increase of serious adverse events. The advantage of high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      was limited to the younger subset of the elderly and to patients with core-binding factor leukemias, those with t(8;21), t(16;16), or inv(16). A post-hoc exploratory subgroup analysis of patients age 60 to 65 years found significantly higher rates of CR (73 versus 57 percent), two-year event-free survival (29 versus 14 percent), and two-year overall survival (38 versus 23 percent) among those receiving the daunorubicin 90",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      dose, while no differences were seen between the arms among patients over age 65.",
"      <br/>",
"      <br/>",
"      The increased response rate and similar toxicity profile suggest that the previously customary dosage of 45",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      of daunorubicin may have been too low for many patients of older age. A similar randomized trial in younger adults (less than 60 years old) performed by another cooperative group reported higher CR rates and overall survival rates with 90",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daunorubicin compared with 45",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/12\">",
"       12",
"      </a>",
"      ]. As yet, there has been no prospective trial comparing 60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      of daunorubicin with 90",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       .",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"       \"Induction therapy for acute myeloid leukemia in younger adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another prospective, randomized trial in 1273 older adults with previously untreated AML or advanced myelodysplastic syndrome (MDS) examined several modifications to standard",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      induction including [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/13\">",
"       13",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       Daunorubicin",
"      </a>",
"      35",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      versus 50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      dosing, administered on three consecutive days",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       Cytarabine",
"      </a>",
"      200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      versus 400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      dosing, administered on 10 consecutive days during the first induction course",
"     </li>",
"     <li>",
"      Three versus four courses of total treatment.",
"      <br/>",
"      <br/>",
"      The response rate was 62 percent (54 percent CR plus 8 percent CR without",
"      <span class=\"nowrap\">",
"       platelet/neutrophil",
"      </span>",
"      recovery, ie, CRi). The survival rate at five years was 12 percent. There was no difference in outcomes seen when patients received increased doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      or with the addition of a fourth cycle of treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following studies have investigated the choice of anthracycline in older adults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial that included 489 older adults with AML compared remission-induction therapy with three days of either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      (8",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day), both given with seven days of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/14\">",
"       14",
"      </a>",
"      ]. Mitoxantrone was associated with a marginally higher CR rate (47 versus 38 percent) but had no beneficial effect on remission duration or overall survival (6 versus 9 percent at five years).",
"     </li>",
"     <li>",
"      A randomized phase III study in 362 patients &gt;55 years of age with previously untreated AML randomly assigned treatment with three days of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      (45",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      (12",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day), or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"       idarubicin",
"      </a>",
"      (12",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day), each in combination with 100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      by continuous infusion for seven days [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/15\">",
"       15",
"      </a>",
"      ]. There was no significant difference in the rate of CR (40, 43, and 46 percent, respectively) or median overall survival (8, 8, and 7 months, respectively) among the three treatment arms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Use of growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several groups have evaluated the effects of myeloid colony-stimulating factors (eg, GM-CSF, G-CSF) as an adjunct to intensive chemotherapy with largely disappointing results. The rationale for this approach is that older patients are particularly susceptible to infection and experience a higher infectious mortality rate during episodes of neutropenia. Shortening the duration of neutropenia might have a beneficial effect and improve the rate of complete remission. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H17#H17\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Growth factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link&amp;anchor=H523774275#H523774275\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, these trials, which have utilized growth factors both during and after chemotherapy, have largely been negative, as illustrated by the following [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/15-21\">",
"     15-21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CALGB conducted a randomized trial involving 388 patients 60 years of age or older with de novo AML [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. GM-CSF or a placebo was given, starting one day after completing induction therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      . The median neutrophil recovery time was two days shorter in the GM-CSF group (15 versus 17 days), but there were no significant differences in complete remission rate, treatment-related mortality, leukemic regrowth, or overall survival.",
"     </li>",
"     <li>",
"      The efficacy and cost of GM-CSF as an adjunct to intensive chemotherapy were evaluated in another prospective randomized clinical trial involving 318 older patients with AML [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/18\">",
"       18",
"      </a>",
"      ]. There were no differences in CR rate (56 percent with GM-CSF versus 55 percent in the control group), duration of survival (22 percent at two years in both groups), disease-free survival, or long-term quality of life. Costs were increased with GM-CSF and there were no identifiable benefits; in the short-term, the administration of GM-CSF was associated with a higher frequency of side effects such as depressed mood, diarrhea, and",
"      <span class=\"nowrap\">",
"       rash/eczema.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Accordingly, the routine use of myeloid growth factors during remission induction chemotherapy for older patients with AML cannot be recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Other chemotherapy programs",
"    </span>",
"    &nbsp;&mdash;&nbsp;An increasingly large number of regimens have been evaluated for the treatment of older patients with AML [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/7,16,20,22-47\">",
"     7,16,20,22-47",
"    </a>",
"    ]. All appear to be associated with similar rates of complete remission (20 to 60 percent), brief remission durations, and low actuarial median survivals. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/5/33879?source=see_link\">",
"       Clofarabine",
"      </a>",
"      , a second generation purine nucleoside analogue, has significant single agent activity in older patients with AML, including those considered unsuitable for anthracycline-based induction therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/48\">",
"       48",
"      </a>",
"      ] and those with unfavorable risk factors [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/42\">",
"       42",
"      </a>",
"      ]. In uncontrolled, prospective studies, reported incidences of complete remission (CR), disease-free survival, overall survival and 30-day treatment-related mortality have been comparable to those seen with more intensive therapies, prompting further ongoing phase III comparative studies in older patients.",
"     </li>",
"     <li>",
"      In a phase II trial that included patients up to age 65, the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/43/40630?source=see_link\">",
"       idarubicin",
"      </a>",
"      , infusional intermediate-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      and the histone deacetylase inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/29/27093?source=see_link\">",
"       vorinostat",
"      </a>",
"      reported a CR rate of 76 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/49\">",
"       49",
"      </a>",
"      ]. Excess toxicity attributable to vorinostat was not seen.",
"     </li>",
"     <li>",
"      A phase II trial adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      , a putative inhibitor of myeloid leukemia stem cells, to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      in patients aged 60 to 75 years showed a CR rate of 65 percent, with another 4 percent CR with incomplete platelet recovery with acceptable toxicity [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A case series reported on two older adults with AML, each demonstrating trisomy 13 as the sole cytogenetic abnormality, who achieved morphologic and cytogenetic CR lasting nine months each after induction with high-dose single-agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/51\">",
"       51",
"      </a>",
"      ]. This regimen was also used in an unselected population of older patients with previously untreated AML [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/52\">",
"       52",
"      </a>",
"      ]. Ten of 33 patients (30 percent) achieved CR with or without complete normalization of peripheral blood counts. A second phase II trial of high-dose single-agent lenalidomide in 37 older adults with newly diagnosed AML with del(5q) reported an overall response rate of 14 percent with a median overall survival of two months [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/53\">",
"       53",
"      </a>",
"      ]. Adverse events were common and only 38 percent of patients were able to complete the 28-day induction phase.",
"     </li>",
"     <li>",
"      Randomized trials have not shown any benefit when inhibitors of the anthracycline and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      drug efflux mechanism mediated by MRD1 (p-glycoprotien) were added to conventional chemotherapy for older AML patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/54,55\">",
"       54,55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trials under way or being considered are trying to clarify the role of agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/29/27093?source=see_link\">",
"     vorinostat",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/5/33879?source=see_link\">",
"     clofarabine",
"    </a>",
"    in the induction chemotherapy of AML in older patients. Many new agents are currently in development for older patients with AML. The pharmaceutical industry sees this as an important unmet medical need. A milder side effect profile is an important goal for these novel agents. (See",
"    <a class=\"local\" href=\"#H27\">",
"     'Clinical trials'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1358202\">",
"    <span class=\"h2\">",
"     Response evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of remission induction chemotherapy is the rapid restoration of normal bone marrow function and attainment of complete remission. An initial evaluation to assess the antileukemic efficacy is typically performed seven days after the final doses of induction chemotherapy with a unilateral bone marrow aspirate and biopsy. Remission criteria are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=see_link&amp;anchor=H2#H2\">",
"     \"Remission criteria in acute myeloid leukemia and monitoring for residual disease\", section on 'Definition of complete remission (CR)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Post remission therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While a substantial percentage of older adults will attain a complete remission (CR) with induction chemotherapy, virtually all of these patients will relapse within a median of four to eight months unless given additional cytotoxic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/56\">",
"     56",
"    </a>",
"    ]. Even with post-remission therapy, relapses are common. Only about 10 percent of older adults, and generally only those with favorable or intermediate risk disease, attain long-term survival after the administration of post-remission therapy. Even in prospective studies, there is considerable selection bias among those patients who receive post-remission therapy; they are already a more favorable subgroup because they have survived induction therapy and entered remission.",
"   </p>",
"   <p>",
"    Post-remission therapy aims to destroy leukemia cells that survived induction chemotherapy but are undetectable by conventional studies. There are two generally accepted options for post-remission therapy: consolidation chemotherapy and allogeneic hematopoietic cell transplantation (HCT). There is a paucity of data regarding the efficacy of these approaches. Consolidation chemotherapy is less intensive and has a lower early mortality rate, but allogeneic HCT provides a potential graft-versus-tumor effect that may decrease relapse rates. Evidence regarding the therapeutic benefit of any consolidation therapy in older patients with AML is limited and its value has remained uncertain. In particular, the prospective studies that have been performed are limited by selection bias due to the fact that only a minor fraction of patients in these trials that achieve a CR proceed to receive post-remission treatment. A detailed description of these options in younger adults is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=see_link\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Post-remission therapy in older adults is complicated by high rates of treatment-related toxicity. Older adults are generally not candidates for a fully myeloablative allogeneic HCT, but a subset may be able to undergo nonmyeloablative HCT after reduced intensity conditioning regimens. A choice among these strategies is generally made based upon the risk stratification of the patient's tumor and the patient's performance status and comorbidities that might affect tolerance of intensive therapy.",
"   </p>",
"   <p>",
"    For older adults with favorable or intermediate risk AML in first CR, we suggest the use of consolidation chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    plus an anthracycline or with intermediate or high dose cytarabine (eg, 2",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over four hours daily for five days) rather than HiDAC (eg, 5 to 36",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    or allogeneic HCT. This preference places a high value on avoiding toxicity and a low value on the potential, yet unproven, benefit of a graft-versus-leukemia effect. Alternatively, patients with unfavorable risk AML should be considered for nonmyeloablative allogeneic HCT within the context of a clinical trial since results with chemotherapy alone have been poor. While initial results with this approach appear promising, only a highly selected subgroup of older patients with AML will be eligible for HCT. Comparative studies are needed to determine the best therapy in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=see_link&amp;anchor=H17#H17\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\", section on 'Nonmyeloablative HCT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Consolidation chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;High dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    (HiDAC) is the standard consolidation chemotherapy for younger adults with AML of a favorable risk, but is associated with unacceptably high rates of severe toxicity and early death in older adults that counteract any improvement in efficacy over standard dose cytarabine. Instead, consolidation therapy with two cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    (30 to 45",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for two days) and cytarabine (ara-C, 100 to 200",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day for five days) for older adults is preferred. An alternative is the use of an intermediate dosing of cytarabine (eg, 1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily for five days) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/6\">",
"     6",
"    </a>",
"    ]. Intermediate dose cytarabine has not been directly compared with standard dose cytarabine plus daunorubicin. The use of consolidation chemotherapy in younger adults is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=see_link&amp;anchor=H5#H5\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\", section on 'Favorable risk disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following studies have investigated consolidation chemotherapy in older adults:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A French study randomly assigned 164 older patients who had achieved CR to receive either a second intensive induction (four days of an anthracycline plus seven days of continuous infusion",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      ) or six monthly courses of outpatient chemotherapy (one day of anthracycline and five days of subcutaneous cytarabine per course). On an intent-to-treat basis at two years post attainment of CR, the following observations were made [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/57\">",
"       57",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The cumulative rate of death in CR was 5 versus zero percent for those receiving intensive or outpatient consolidation, respectively.",
"     </li>",
"     <li>",
"      Patients who received outpatient consolidation had significantly superior overall (56 versus 37 percent) and disease-free (28 versus 17 percent) survival rates. Outpatient consolidation was also associated with significantly shorter periods of rehospitalization as well as a lower utilization of red cell and platelet transfusions.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The CALGB conducted a randomized trial of consolidation therapy using standard or intermediate doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      (100 or 400",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day by continuous intravenous infusion for five days) or HiDAC (3",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every 12 hours on days 1, 3, and 5) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/9\">",
"       9",
"      </a>",
"      ]. Among patients over 60 years of age, the toxic death rate was higher in the HiDAC arm, which contributed to the overall failure to improve outcome. There was also a higher incidence of cerebellar ataxia (&gt;30 percent in patients &ge;60 years), which was irreversible in some patients.",
"     </li>",
"     <li>",
"      The CALGB conducted another trial in which 163 patients in CR over age 60 were randomized to standard dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      versus a combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      and intermediate dose cytarabine [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/20\">",
"       20",
"      </a>",
"      ]. No differences were seen with respect to disease-free survival.",
"     </li>",
"     <li>",
"      In a study of 110 patients over the age of 60, 51 percent achieved a complete remission (CR) and were eligible for HiDAC-based consolidation chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/58\">",
"       58",
"      </a>",
"      ]. Median remission duration for all eligible patients was nine months and the actuarial survival was 14 percent after a median follow-up of 17 months.",
"     </li>",
"     <li>",
"      A randomized trial of 489 older adults with AML who underwent induction with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      plus either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37368?source=see_link\">",
"       mitoxantrone",
"      </a>",
"      administered one additional cycle of daunorubicin or mitoxantrone after attainment of CR followed by randomization to no further treatment or eight cycles of low-dose cytarabine (10",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every 12 hours for 12 days every six weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/14\">",
"       14",
"      </a>",
"      ]. The administration of low-dose cytarabine for maintenance of remission prolonged disease-free survival but had no significant effect on overall survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Nonmyeloablative transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allogeneic hematopoietic cell transplantation (HCT) is the preferred treatment for younger adults with unfavorable risk AML because of its graft-versus-leukemia effect. However, HCT is associated with a very high treatment-related mortality rate in older patients that precludes its general use [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/59\">",
"     59",
"    </a>",
"    ]. Instead, various reduced intensity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/60\">",
"     60",
"    </a>",
"    ] or nonmyeloablative [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/61\">",
"     61",
"    </a>",
"    ] HCT regimens have been employed in fit older adults. However, the comparable efficacy of this approach remains to be proven. The use of HCT in younger adults is presented separately, as is additional information on nonmyeloablative HCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=see_link&amp;anchor=H5#H5\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\", section on 'Favorable risk disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=see_link&amp;anchor=H13#H13\">",
"     \"Preparative regimens for hematopoietic cell transplantation\", section on 'Nonmyeloablative and reduced intensity preparative regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have reported promising data on the use of reduced intensity or nonmyeloablative preparative regimens prior to HCT in older adults with AML or myelodysplastic syndrome (MDS) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/62-65\">",
"     62-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By far the largest was an international study of 1080 patients ages 40 to 79 who underwent reduced intensity or nonmyeloablative HCT for AML in first complete remission (545 patients) or MDS (535 patients) between 1995 and 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/66\">",
"     66",
"    </a>",
"    ]. The following outcomes reported for patients with AML appeared to be independent of the age at the time of transplant:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rate of non-relapse mortality at 100 days (6 to 13 percent), one year (18 to 30 percent), and two years (22 to 34 percent).",
"     </li>",
"     <li>",
"      Rate of acute (33 to 35 percent) or chronic (41 to 53 percent) graft versus host disease (GVHD).",
"     </li>",
"     <li>",
"      Overall survival rate at two years (34 to 50 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factors that predicted a decreased overall survival rate at two years included a worse performance status (KPS &lt;80) (",
"    <a class=\"graphic graphic_table graphicRef72901 graphicRef58785 \" href=\"UTD.htm?42/57/43932\">",
"     table 2A-B",
"    </a>",
"    ), greater HLA disparity, and unfavorable risk cytogenetics. These data must be interpreted with caution given the highly selected patient population. In addition, there has been relatively short patient follow-up. Risk of transplant-related mortality can be expected to continue through the fourth and fifth years post transplant.",
"   </p>",
"   <p>",
"    The development of less toxic and better tolerated nonmyeloablative regimens capable of inducing a state of mixed chimerism may allow HCT to be performed in patients with AML and advanced age or co-morbidity, with the hope that such regimens would result in lower rates of treatment-related mortality without sacrificing relapse-free and overall survival, and with a reasonable balance between GVHD and the graft-versus-tumor effect.",
"   </p>",
"   <p>",
"    A retrospective study compared the outcomes of older adults (age 60 to 70 years) with AML in first CR receiving reduced intensity conditioning (94 patients) with the outcomes following postremission chemotherapy (96 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/67\">",
"     67",
"    </a>",
"    ]. Treatment groups were well balanced for cytogenetic risk groups and inclusion of therapy-related leukemia. Patients undergoing HCT were younger (median age 63 versus 65 years) and had a longer time from diagnosis to first CR (44 versus 38 days). When compared with consolidation chemotherapy, HCT was associated with a lower risk of relapse (32 versus 81 percent), higher non-relapse mortality (36 versus 4 percent), and longer leukemia-free survival (32 versus 15 percent) at three years. While there was a trend towards increased overall survival (37 versus 25 percent at three years), this did not reach statistical significance. Additional experience with this approach is awaited [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1358852\">",
"    <span class=\"h2\">",
"     Post-consolidation management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the completion of post-remission therapy, patients are seen at periodic intervals to monitor for treatment complications and assess for possible relapse. This is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=see_link&amp;anchor=H18#H18\">",
"     \"Post-remission therapy for acute myeloid leukemia in younger adults\", section on 'Post-consolidation management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     LESS INTENSIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;For older patients with indolent AML, severe comorbidity, or unfavorable risk disease, we suggest either supportive care alone or less intensive chemotherapy rather than conventional remission induction chemotherapy. Supportive care can include the use of red blood cell and platelet transfusions, antibiotics, and control of leukocytosis with agents such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    . Less intensive therapy uses",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    or low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1358586\">",
"    <span class=\"h2\">",
"     DNA hypomethylating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;DNA hypomethylating agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    ) target the aberrant DNA methylation seen in AML [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/69\">",
"     69",
"    </a>",
"    ]. Both azacitidine and decitabine are pyrimidine nucleoside analogs of cytidine that strongly inhibit DNA methylation and are commonly used for the treatment of myelodysplastic syndromes (MDS). Clinical trials have shown the ability of the hypomethylating agents azacitidine and decitabine, used as single agents, to induce remissions and potentially prolong survival in a fraction of older patients with newly diagnosed AML or advanced MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/43,44,47,70-77\">",
"     43,44,47,70-77",
"    </a>",
"    ]. Neither agent has been approved by the United States Food and Drug Administration for the treatment of AML. The European Medicines Agency (EMA) has approved decitabine for the treatment of AML and azacitidine for the treatment of AML that has developed from MDS. While they have each demonstrated superior response rates when compared with conventional supportive care alone, they have not been directly compared with each other in a randomized trial.",
"   </p>",
"   <p>",
"    Given the prospective trials demonstrating a potential benefit with each of these agents, and the lack of a randomized trial comparing these agents with one another, either agent may be used. Some clinicians prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    because it is given intravenously over fewer days. Other clinicians prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    because of its ability to be administered subcutaneously as an outpatient, requiring less time in an infusion center. The use of DNA hypomethylating agents in MDS is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link&amp;anchor=H2447218#H2447218\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'DNA hypomethylating agents'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9049?source=see_link&amp;anchor=H48546561#H48546561\">",
"     \"Treatment of high or very high risk myelodysplastic syndromes\", section on 'DNA hypomethylating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1358593\">",
"    <span class=\"h3\">",
"     Azacitidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     Azacitidine",
"    </a>",
"    (5-azacytidine, 5-aza, Vidaza) is commonly used for the treatment of myelodysplastic syndrome (MDS) and has demonstrated activity in patients with AML. Studies in AML suggest that, when compared with supportive care alone, azacitidine improves symptoms and quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/47,70,71\">",
"     47,70,71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A phase III study (AZA-001) randomly assigned therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"       azacitidine",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day for seven days every 28 days) or a &ldquo;conventional care regimen&rdquo; (ie, best supportive care, low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , or AML induction chemotherapy as selected by the investigators before randomization) in 358 patients with higher-risk MDS by French-American-British (FAB) criteria [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/78\">",
"       78",
"      </a>",
"      ]. Of these, 113 patients would be considered to have AML by World Health Organization (WHO) criteria (ie, a bone marrow blast percentage &gt;20 percent). When compared with the conventional care regimens, treatment with azacitidine resulted in longer median overall survival (median, 24.5 versus 15 months) and less toxicity (eg, grade 3 to 4 cytopenias and length of hospitalization) in the group as a whole [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/44,72\">",
"       44,72",
"      </a>",
"      ]. A subset analysis suggested that the survival benefit was also seen among patients with AML.",
"     </li>",
"     <li>",
"      In another phase III study (CALGB 9221), 191 patients with high risk MDS by FAB criteria were randomly assigned therapy with best supportive care or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"       azacitidine",
"      </a>",
"      at the dose and schedule described above [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/73\">",
"       73",
"      </a>",
"      ]. Of these, 45 patients would be considered to have AML by WHO criteria. Patients assigned to supportive care were permitted to receive azacitidine at the time of disease progression. No responses were seen with supportive care. In contrast, 60 percent of patients receiving azacitidine demonstrated a response, with 7 percent achieving a complete response. Response rates were similar in those with MDS and those with AML. Azacitidine was associated with improvements in physical function, symptoms, and psychological state. A survival analysis was limited by the cross-over study design.",
"     </li>",
"     <li>",
"      In another study, 82 patients with AML received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"       azacitidine",
"      </a>",
"      as part of a compassionate use program [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/47\">",
"       47",
"      </a>",
"      ]. Complete response or complete response with incomplete blood count recovery was seen in 11 of the 35 (31 percent) previously untreated patients. The median overall response duration was 13 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these studies suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    can produce remissions and improve symptoms in patients with AML.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1358600\">",
"    <span class=\"h3\">",
"     Decitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    (5-aza-2'-deoxycytidine, Dacogen) in patients with AML has been evaluated in open-label prospective trials. Complete response (CR) or complete response without platelet recovery (CRp) is attained in 18 to 47 percent with a median survival of five to eight months [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/43,44,74-76\">",
"     43,44,74-76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As an example, in a multicenter, open-label, phase III trial, 485 older adults (&ge;65 years) with newly diagnosed de novo or secondary AML were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"       decitabine",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      intravenously over a one-hour period once daily for five consecutive days; cycles were repeated every four weeks) or to a therapy of their choice: either supportive care alone or subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day for 10 consecutive days; cycles were repeated every four weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/74\">",
"       74",
"      </a>",
"      ]. When compared with the other therapies, decitabine was associated with a significantly higher rate of CR and CRp (18 versus 8 percent) with a median time to best response of 4.3 months. Patients assigned to decitabine had a trend towards increased median overall survival (7.7 versus 5.0 months), that did not reach statistical significance. Decitabine resulted in higher rates of febrile neutropenia (24 versus 14 percent) and pneumonia (20 versus 15 percent).",
"     </li>",
"     <li>",
"      Another multicenter, open-label, phase II trial evaluated the same five-day",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"       decitabine",
"      </a>",
"      regimen in 55 older adults (&gt;60 years) with newly diagnosed AML [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/43\">",
"       43",
"      </a>",
"      ]. CR was seen in 21 and 24 percent of patients with intermediate- and poor-risk AML, respectively. The median overall survival was 7.7 months. The most common toxicities were myelosuppression, febrile neutropenia, and fatigue.",
"     </li>",
"     <li>",
"      In another multicenter phase II trial, 227 older adults (median 72 years) with newly diagnosed AML ineligible for intensive induction chemotherapy were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"       decitabine",
"      </a>",
"      (135",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      total dose infused over 72 hours every six weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/76\">",
"       76",
"      </a>",
"      ]. A CR was attained in 30 patients (13 percent). Partial remission, stable disease, and progressive disease were seen in 30, 57, and 19 patients, respectively. Median survival was 5.5 months and the overall survival rates at one- and two-years were 28 and 13 percent, respectively.",
"     </li>",
"     <li>",
"      A phase II single institution study of 53 patients with a median age of 74 years suggested that a better response rate (47 percent CR) may be obtained when",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"       decitabine",
"      </a>",
"      was administered daily for 10 days [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these trials suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    can produce remissions in patients with AML. When given to patients with AML, decitabine significantly reduces global methylation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/69\">",
"     69",
"    </a>",
"    ]. Whether the mechanism of action resulting in improved outcomes is direct cytotoxicity or via an epigenetic mechanism is not yet known. The duration of these remissions and whether these patients need to continue monthly maintenance therapy is not yet known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Low-dose cytarabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of trials have investigated the use of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    in older subjects with AML, both for induction and later for maintenance of remission [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/4,14,23,24,79-81\">",
"     4,14,23,24,79-81",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multicenter phase III trial, 217 patients with AML or high risk MDS who were not considered fit for intensive treatment were randomly assigned to receive low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      (20 mg twice daily for 10 days) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/82\">",
"       82",
"      </a>",
"      ]. When compared with hydroxyurea, low-dose cytarabine resulted in a higher remission rate (18 versus 1 percent) and improved overall survival (odds ratio 0.60; 95% CI 0.44-0.81). Toxicity was generally mild with the most common severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities being cardiac (10 percent),",
"      <span class=\"nowrap\">",
"       nausea/emesis",
"      </span>",
"      (6 percent), and diarrhea (4 percent).",
"     </li>",
"     <li>",
"      Investigators in France randomly assigned 87 patients &gt;65 to receive either intensive chemotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      and rubidazone (a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      analogue) or low-dose subcutaneous cytarabine (10",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every 12 hours for 21 days) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/83\">",
"       83",
"      </a>",
"      ]. Although the number of complete remissions was greater with intensive chemotherapy, the early death rate was also higher. As a result, there were no differences in survival or remission duration between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other supportive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other measures of supportive care include the use of leukocyte-depleted, irradiated red blood cell and platelet transfusions as needed, and the use of antibiotics to treat infections. As described above, patients treated with supportive care alone spend a similar amount of time in the hospital compared with those who receive intensive chemotherapy. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Selection of therapy'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link&amp;anchor=H14#H14\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Supportive care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;AML can be cured in some older patients, but many questions remain and considerable challenges need to be overcome in order to improve outcomes. Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial.",
"   </p>",
"   <p>",
"    However, only a minority of newly diagnosed older adults with AML are currently enrolled in clinical trials in the United States. Examples of the magnitude of this problem include the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adults 65 years of age or older represent 63 percent of the United States population of patients with cancer. However, they accounted for only 27 percent of patients enrolled in leukemia clinical trials sponsored by the Southwest Oncology Group [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a Swiss study, in which only 45 percent of 170 newly-diagnosed patients with AML were included in a phase III trial, the most common causes for noninclusion were ineligibility due to advanced age or the presence of significant comorbidity [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/\">",
"     www.clinicaltrials.gov",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732965\">",
"    <span class=\"h2\">",
"     Gemtuzumab ozogamicin (GO)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/3/1078?source=see_link\">",
"     Gemtuzumab ozogamicin",
"    </a>",
"    (GO) is a recombinant, humanized anti-CD33 antibody linked to the cytotoxic agent calicheamicin. GO is internalized by CD33+ cells, resulting in cell death. GO was initially approved by the US FDA for use in patients age 60 or older with CD33+ AML in first relapse not considered candidates for cytotoxic chemotherapy. The recommended dose was 9",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    given by two-hour IV infusion, with a second dose two weeks later [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. GO has since been removed from the market in the US because preliminary results from a subsequent randomized trial in newly diagnosed AML patients less than 60 years old did not confirm a clinical benefit from the combination of gemtuzumab ozogamicin with chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. Serious adverse reactions, including fatal anaphylaxis, prolonged thrombocytopenia, and hepatic injury including sinusoidal obstruction syndrome (also called hepatic veno-occlusive disease) have been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=see_link&amp;anchor=H70421931#H70421931\">",
"     \"Treatment of relapsed or refractory acute myeloid leukemia\", section on 'Clinical trials'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Subsequent studies have investigated the use of different dosing schedules of GO in newly diagnosed AML. Initial results suggest that there may be a survival advantage when GO is added to induction chemotherapy for patients with favorable and intermediate risk cytogenetics. In addition, concerns regarding an increase in treatment-related mortality with GO have not been confirmed in these trials.",
"   </p>",
"   <p>",
"    Three studies illustrate this concept:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The phase III MRC AML 15 trial in 1113 patients (median age 49, 14 percent &gt;60 years) with newly diagnosed AML randomly assigned patients to one of three induction regimens with or without GO with a second randomization to consolidation with or without GO [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/90\">",
"       90",
"      </a>",
"      ]. GO did not improve response rates or survival in the group as a whole. However, a preplanned subset analysis of the 137 patients with favorable cytogenetics noted significantly improved five-year survival rates for those assigned to GO (79 versus 51 percent).",
"     </li>",
"     <li>",
"      The randomized MRC AML 16 trial of 1115 patients (age 51 to 84 years) in the UK showed a survival advantage and longer relapse-free survival for older patients who received a single dose of GO at 3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1 of induction together with standard",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/91\">",
"       91",
"      </a>",
"      ]. No major increase in toxicity, including 30- and 60-day mortality, occurred in the GO arm.",
"     </li>",
"     <li>",
"      A meta-analysis of the 2228 patients enrolled on the MRC AML 15 and MRC AML 16 trials suggested that the addition of GO to standard chemotherapy resulted in improved relapse-free survival (hazard ratio [HR] 0.82; 95% CI 0.72-0.93) and overall survival (HR 0.88; 95% CI 0.79-0.98) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/91\">",
"       91",
"      </a>",
"      ]. This benefit was most evident in patients with favorable risk cytogenetics (HR 0.47; 95% CI 0.28-0.77) and less pronounced in those with intermediate risk cytogenetics (HR 0.84; 95% CI 0.73-0.97). There did not appear to be a benefit for patients with adverse cytogenetics (HR 1.02; 95% CI 0.81-1.27).",
"     </li>",
"     <li>",
"      In another phase III trial, 280 older adults (age 50 to 70 years) with newly diagnosed AML underwent induction chemotherapy with seven days of continuous infusion",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      (200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day) plus three once-daily doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      at 60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      and were randomly assigned to receive GO (3",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       ,",
"      </span>",
"      maximum dose 5 mg, on days 1, 4, and 7) or not as part of induction therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/92\">",
"       92",
"      </a>",
"      ]. Those who were randomized to GO continued to receive GO together with consolidation chemotherapy for two courses. Treatment in the two arms resulted in similar rates of complete remission with or without incomplete platelet recovery (81 versus 75 percent). After a median follow-up of 20 months in survivors, the addition of GO resulted in significantly higher rates of event-free survival (41 versus 17 percent; hazard ratio 0.58; 95% CI 0.43-0.78) and overall survival (53 versus 42 percent; hazard ratio 0.69; 95% CI 0.49 to 0.98) at two years. On a subset analysis, the clinical benefit appeared restricted to patients with favorable or intermediate risk cytogenetics and no benefit was observed in patients with unfavorable cytogenetics. GO was associated with significantly higher rates of persistent thrombocytopenia (16 versus 3 percent), but no increase in treatment related mortality.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These and other studies have demonstrated no benefit from GO as part of the induction regimen for patients with unfavorable risk cytogenetics, but there is some evidence of a benefit for patients with favorable and intermediate cytogenetics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/29/29146/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/4/14402?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=see_link\">",
"       \"Patient information: Leukemia in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Older adults with acute myeloid leukemia (AML) have been variably defined in clinical trials to include those patients over age 55, 60, or 65. When compared with younger adults, older adults have more complications with chemotherapy and a diminished survival rates. Even so, approximately half of older adults achieve complete remission, and some older adults can attain long term remissions with intensive therapy. Treatment decisions should be individualized and take into account the age and performance status of the patient (",
"      <a class=\"graphic graphic_table graphicRef72901 graphicRef58785 \" href=\"UTD.htm?42/57/43932\">",
"       table 2A-B",
"      </a>",
"      ) and the presence of known adverse risk factors such as cytogenetics (",
"      <a class=\"graphic graphic_table graphicRef71278 \" href=\"UTD.htm?21/40/22156\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43768?source=see_link&amp;anchor=H6273162#H6273162\">",
"       \"Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults\", section on 'Outcomes in older compared with younger patients'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The pretreatment assessment of an older adult with AML includes those studies used to evaluate younger adults in addition to more specific investigations of physical functioning and comorbid conditions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43768?source=see_link&amp;anchor=H15843336#H15843336\">",
"       \"Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults\", section on 'Pretreatment evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Older adults should be encouraged to participate in clinical trials whenever available. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Clinical trials'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For otherwise healthy (ECOG performance status of two or less and with few comorbidities), older adults with newly diagnosed AML, we suggest remission induction treatment with a combination of an anthracycline and \"standard\" dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      rather than other chemotherapy regimens or supportive care alone&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A reasonable standard regimen for many older patients who are medically fit is seven days of continuous infusion cytarabine (ara-C, 100 or 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day) plus three days of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      (60 or 90",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per day). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Induction chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Randomized trials have found no benefit to the routine use of myeloid growth factors during remission induction chemotherapy for older patients with AML, although they may be beneficial for supportive care in patients with neutropenia and sepsis. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Use of growth factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For older patients with indolent AML, severe comorbidity, poor physical function, or unfavorable risk disease, we suggest the use of supportive care alone or less intensive chemotherapy rather than induction chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This supportive care can include the use of red blood cell and platelet transfusions, antibiotics, and control of leukocytosis, if needed, with agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      . Less intensive treatment with DNA hypomethylating agents or low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      may prolong survival in some older patients with low rates of toxicity. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Less intensive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For otherwise healthy, older adults in first complete remission, we suggest the use of consolidation chemotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      plus an anthracycline or with intermediate dose cytarabine alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). High dose cytarabine and myeloablative allogeneic HCT both result in unacceptable toxicity in this patient population. Alternatively, older patients in first remission, and especially those with unfavorable risk AML, should be considered for nonmyeloablative allogeneic HCT using reduced intensity conditioning within the context of a clinical trial. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Consolidation chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/1\">",
"      Schiffer CA. \"I am older, not elderly,\" said the patient with acute myeloid leukemia. J Clin Oncol 2010; 28:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/2\">",
"      Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113:4179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/3\">",
"      L&ouml;wenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989; 7:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/4\">",
"      Vey N, Coso D, Bardou VJ, et al. The benefit of induction chemotherapy in patients age &gt; or = 75 years. Cancer 2004; 101:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/5\">",
"      Friedman HD, Landaw SA. Recent-onset myelodysplastic syndrome mimicking acute leukemia during infection. Ann Hematol 1996; 72:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/6\">",
"      L&ouml;wenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009; 361:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/7\">",
"      Wahlin A, Markev&auml;rn B, Golovleva I, Nilsson M. Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol 2001; 115:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/8\">",
"      Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/9\">",
"      Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/10\">",
"      Pr&eacute;bet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol 2009; 27:4747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/11\">",
"      Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood 2010; 116:4422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/12\">",
"      Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009; 361:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/13\">",
"      Burnett AK, Milligan D, Goldstone A, et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 2009; 145:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/14\">",
"      L&ouml;wenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. J Clin Oncol 1998; 16:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/15\">",
"      Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/16\">",
"      Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98:1302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/17\">",
"      Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998; 91:3607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/18\">",
"      Uyl-de Groot CA, L&ouml;wenberg B, Vellenga E, et al. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br J Haematol 1998; 100:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/19\">",
"      Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995; 332:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/20\">",
"      Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001; 98:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/21\">",
"      Amadori S, Suciu S, Jehn U, et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005; 106:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/22\">",
"      Ferrara F, Annunziata M, Copia C, et al. Therapeutic options and treatment results for patients over 75 years of age with acute myeloid leukemia. Haematologica 1998; 83:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/23\">",
"      Leoni F, Ciolli S, Nozzoli C, et al. Idarubicin in induction treatment of acute myeloid leukemia in the elderly. Haematologica 1997; 82:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/24\">",
"      Juliusson G, H&ouml;glund M, Karlsson K, et al. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. Br J Haematol 2003; 123:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/25\">",
"      Letendre L, Noel P, Litzow MR, et al. Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C. Am J Clin Oncol 1998; 21:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/26\">",
"      Manoharan A, Baker RI, Kyle PW. Low-dose combination chemotherapy for acute myeloid leukemia in elderly patients: a novel approach. Am J Hematol 1997; 55:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/27\">",
"      Feldman EJ, Seiter K, Damon L, et al. A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia 1997; 11:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/28\">",
"      Stein RS, Vogler WR, Winton EF, et al. Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial. Leuk Res 1990; 14:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/29\">",
"      Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002; 99:4343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/30\">",
"      Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 2002; 100:3869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/31\">",
"      Giles FJ, Kantarjian HM, Cortes JE, et al. Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia. J Clin Oncol 2003; 21:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/32\">",
"      Ossenkoppele GJ, Graveland WJ, Sonneveld P, et al. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood 2004; 103:2908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/33\">",
"      Faderl S, Verstovsek S, Cortes J, et al. Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older. Blood 2006; 108:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/34\">",
"      Sudan N, Rossetti JM, Shadduck RK, et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 2006; 107:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/35\">",
"      Giles F, Rizzieri D, Karp J, et al. Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol 2007; 25:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/36\">",
"      Lancet JE, Gojo I, Gotlib J, et al. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 2007; 109:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/37\">",
"      Clavio M, Vignolo L, Albarello A, et al. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol 2007; 138:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/38\">",
"      Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007; 110:2302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/39\">",
"      Faderl S, Ravandi F, Huang X, et al. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 2008; 112:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/40\">",
"      Baer MR, George SL, Caligiuri MA, et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol 2008; 26:4934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/41\">",
"      Harousseau JL, Martinelli G, Jedrzejczak WW, et al. A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 2009; 114:1166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/42\">",
"      Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010; 28:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/43\">",
"      Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010; 28:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/44\">",
"      Fenaux P, Mufti GJ, Hellstr&ouml;m-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010; 28:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/45\">",
"      Agura E, Cooper B, Holmes H, et al. Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity. Oncologist 2011; 16:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/46\">",
"      Baer MR, George SL, Sanford BL, et al. Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia 2011; 25:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/47\">",
"      Maurillo L, Venditti A, Spagnoli A, et al. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer 2012; 118:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/48\">",
"      Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010; 28:2389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/49\">",
"      Garcia-Manero G, Tambaro FP, Bekele NB, et al. Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome. J Clin Oncol 2012; 30:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/50\">",
"      Attar EC, Johnson JL, Amrein PC, et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol 2013; 31:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/51\">",
"      Fehniger TA, Byrd JC, Marcucci G, et al. Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood 2009; 113:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/52\">",
"      Fehniger TA, Uy GL, Trinkaus K, et al. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 2011; 117:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/53\">",
"      Sekeres MA, Gundacker H, Lancet J, et al. A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605. Blood 2011; 118:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/54\">",
"      Chauncey TR, Gundacker H, Shadman M, et al. Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. Br J Haematol 2010; 148:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/55\">",
"      Baer MR, George SL, Dodge RK, et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 2002; 100:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/56\">",
"      Cassileth PA, Harrington DP, Hines JD, et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 1988; 6:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/57\">",
"      Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007; 109:5129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/58\">",
"      Schiller G, Lee M. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for older patients with acute myelogenous leukemia. Leuk Lymphoma 1997; 25:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/59\">",
"      Wallen H, Gooley TA, Deeg HJ, et al. Ablative allogeneic hematopoietic cell transplantation in adults 60 years of age and older. J Clin Oncol 2005; 23:3439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/60\">",
"      Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/61\">",
"      Champlin R, Khouri I, Shimoni A, et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/62\">",
"      Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003; 21:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/63\">",
"      Valc&aacute;rcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol 2008; 26:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/64\">",
"      Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010; 28:2859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/65\">",
"      Lioure B, B&eacute;n&eacute; MC, Pigneux A, et al. Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study. Blood 2012; 119:2943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/66\">",
"      McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol 2010; 28:1878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/67\">",
"      Farag SS, Maharry K, Zhang MJ, et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011; 17:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/68\">",
"      Estey E, de Lima M, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood 2007; 109:1395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/69\">",
"      Yan P, Frankhouser D, Murphy M, et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood 2012; 120:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/70\">",
"      Al-Ali HK, Jaekel N, Junghanss C, et al. Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma 2012; 53:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/71\">",
"      Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 2011; 29:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/72\">",
"      Fenaux P, Gattermann N, Seymour JF, et al. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C. Br J Haematol 2010; 149:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/73\">",
"      Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/74\">",
"      Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012; 30:2670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/75\">",
"      Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A 2010; 107:7473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/76\">",
"      L&uuml;bbert M, R&uuml;ter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 2012; 97:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/77\">",
"      Quint&aacute;s-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012; 120:4840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/78\">",
"      Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/79\">",
"      Estey E. Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 2007; 25:1908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/80\">",
"      Faderl S, Wetzler M, Rizzieri D, et al. Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial. J Clin Oncol 2012; 30:2492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/81\">",
"      Faderl S, Ravandi F, Huang X, et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 2012; 118:4471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/82\">",
"      Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007; 109:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/83\">",
"      Tilly H, Castaigne S, Bordessoule D, et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 1990; 8:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/84\">",
"      Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/85\">",
"      Mengis C, Aebi S, Tobler A, et al. Assessment of differences in patient populations selected for excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 2003; 21:3933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/86\">",
"      Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/87\">",
"      Gemtuzumab for relapsed acute myeloid leukemia. Med Lett Drugs Ther 2000; 42:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/88\">",
"      Petersdorf S, Kopecky K, Stuart RK, et al. Preliminary results of Southwest Oncology Group Study S0106: An international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia (abstract 790). Blood 2009; 114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/89\">",
"      Ravandi F, Estey EH, Appelbaum FR, et al. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol 2012; 30:3921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/90\">",
"      Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011; 29:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/91\">",
"      Burnett AK, Russell NH, Hills RK, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol 2012; 30:3924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/92\">",
"      Castaigne S, Pautas C, Terr&eacute; C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012; 379:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/29/29146/abstract/93\">",
"      Delaunay J, Recher C, Pigneux A, et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study (abstract 79). Blood 2011; 118:37.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4530 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-2F5800EE8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_29_29146=[""].join("\n");
var outline_f28_29_29146=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SELECTION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      INTENSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Induction chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Use of growth factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Other chemotherapy programs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1358202\">",
"      Response evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Post remission therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Consolidation chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Nonmyeloablative transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1358852\">",
"      Post-consolidation management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      LESS INTENSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1358586\">",
"      DNA hypomethylating agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1358593\">",
"      - Azacitidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1358600\">",
"      - Decitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Low-dose cytarabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other supportive measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      CLINICAL TRIALS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H732965\">",
"      Gemtuzumab ozogamicin (GO)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4530\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4530|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/40/22156\" title=\"table 1\">",
"      Karyotype risk AML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 2A\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 2B\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/11/28858?source=related_link\">",
"      Initial treatment of acute promyelocytic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/4/14402?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/30/34275?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=related_link\">",
"      Patient information: Leukemia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/55/17274?source=related_link\">",
"      Post-remission therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/34/25130?source=related_link\">",
"      Preparative regimens for hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/47/43768?source=related_link\">",
"      Pretreatment evaluation and prognosis of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12073?source=related_link\">",
"      Remission criteria in acute myeloid leukemia and monitoring for residual disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/42/10922?source=related_link\">",
"      Systemic chemotherapy for cancer in elderly persons",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/53/9049?source=related_link\">",
"      Treatment of high or very high risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=related_link\">",
"      Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/51/29498?source=related_link\">",
"      Treatment of relapsed or refractory acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_29_29147="Features of AKI versus CKD in children";
var content_f28_29_29147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features differentiating acute kidney injury from chronic kidney disease in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Finding",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acute kidney injury (AKI)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Chronic kidney disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum BUN and Cr",
"       </td>",
"       <td>",
"        Progressive rise in BUN and Cr",
"       </td>",
"       <td>",
"        Stable elevated BUN and Cr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Historical clues",
"       </td>",
"       <td>",
"        Positive history for AKI etiology (eg, recent streptococcal infection: poststreptococcal glomerulonephritis)",
"       </td>",
"       <td>",
"        History of chronic hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Growth",
"       </td>",
"       <td>",
"        Normal growth",
"       </td>",
"       <td>",
"        Impaired growth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bone status",
"       </td>",
"       <td>",
"        Normal bones",
"       </td>",
"       <td>",
"        Evidence of renal osteodystrophy: History of fractures, abnormal tibial torsion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine sediment",
"       </td>",
"       <td>",
"        No broad urinary casts",
"       </td>",
"       <td>",
"        Broad waxy urinary casts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematocrit",
"       </td>",
"       <td>",
"        Anemia usually mild",
"       </td>",
"       <td>",
"        Anemia usually severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal ultrasound",
"       </td>",
"       <td>",
"        Normal or enlarged kidney size",
"       </td>",
"       <td>",
"        Small shrunken kidneys",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BUN: blood urea nitrogen, Cr: creatinine",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_29_29147=[""].join("\n");
var outline_f28_29_29147=null;
var title_f28_29_29148="Treatment for severe pediatric lead poisoning";
var content_f28_29_29148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52132&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment for children with symptomatic lead poisoning or blood lead level 70 mcg/dL or greater",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Symptomatic or asymptomatic with blood lead level &ge;70 mcg/dL (3.38 micromol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        a)",
"       </td>",
"       <td>",
"        The children should be hospitalized immediately.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        b)",
"       </td>",
"       <td>",
"        Report to appropriate health authorities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        c)",
"       </td>",
"       <td>",
"        Perform history, physical examination and laboratory examinations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        d)&nbsp;",
"       </td>",
"       <td>",
"        Administer BAL 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        deep IM, then continue with 75 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /dose at four-hour intervals for&nbsp;five days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        e)&nbsp;",
"       </td>",
"       <td>",
"        After BAL is started, and once urine output is established, begin CaNa",
"        <sub>",
"         2",
"        </sub>",
"        EDTA 1000-1500 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /day as a continuous infusion in 0.9 percent saline, daily for&nbsp;five days. The concentration of CaNa",
"        <sub>",
"         2",
"        </sub>",
"        EDTA should not exceed 0.5 percent in parenteral fluids. Children with encephalopathy may receive this medication IM (250 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        /dose at&nbsp;four hour intervals). Monitor renal and hepatic function and electrolytes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        f)",
"       </td>",
"       <td>",
"        Wait&nbsp;two days after completion, recheck Pb levels, and administer a second course if Pb levels &gt;45 mcg/dL (2.17 micromol/L). A third course may be necessary if Pb levels remain elevated &gt;45 mcg/dL (2.17 micromol/L)&nbsp;five to seven&nbsp;days after the second course.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        g)&nbsp;",
"       </td>",
"       <td>",
"        Succimer may be used for the second or third course of chelation in patients who are asymptomatic and whose lead levels are between 45 (2.17 micromol/L) and 70 mcg/dL&nbsp;(3.38 micromol/L)&nbsp;if they are cooperative and good compliance is anticipated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        h)",
"       </td>",
"       <td>",
"        Provide parents with educational and nutritional counseling.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        i)",
"       </td>",
"       <td>",
"        Do not discharge until environmental investigation is completed and recommendations on care at home are made. Patients must be discharged to a lead-safe environment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        j)",
"       </td>",
"       <td>",
"        Monitor lead level every&nbsp;two weeks x 3, then repeat every&nbsp;one month x 3-4, then&nbsp;every&nbsp;three to four&nbsp;months for one year. Continue to check lead levels until &lt;30 mcg/dL (1.45 micromol/L).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    BAL: British anti-Lewisite (dimercaprol); IM: intramuscular; CaNa2EDTA: calcium disodium edetate; Pb: lead.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_29_29148=[""].join("\n");
var outline_f28_29_29148=null;
var title_f28_29_29149="G6PD mutations and class";
var content_f28_29_29149=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F66818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F66818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Location of point mutations in the glucose-6-phosphate dehydrogenase molecule and associated DNA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 267px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    G6PD deficiency Distribution along the glucose-6-phosphate dehydrogenase (G6PD) sequence of point mutations causing G6PD deficiency in three groups of patients: class 1 (severe deficiency with nonspherocytic hemolytic anemia), class II (severe deficiency with intermittent hemolysis), and class III (moderate to mild deficiency). The three classes tend to have different distributions. In particular, class I mutants tend to be clustered in the region of the putative glucose-6-phosphate binding site (cDNA nucleotides 613-615; amino acid 205) and the putative NADP-binding site (nucleotides 1156-1161; amino acids 386 and 387).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Beutler, E, Blood 1994; 84:3613.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_29_29149=[""].join("\n");
var outline_f28_29_29149=null;
var title_f28_29_29150="Resumption of the steady state in primary aldosteronism";
var content_f28_29_29150=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62044&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Resumption of the steady state in primary aldosteronism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 341px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The combination of aldosterone administration and the ingestion of a high Na+ diet leads initially to Na+ retention, volume expansion, and a rise in systemic blood pressure. After several days, however, there is a spontaneous diuresis, resulting in the return of Na+ balance toward normal but persistent hypertension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Hall JE, Granger JP, Smith MJ Jr, Premen AJ, Hypertension 1983; 6(2 Pt 2):I-183. By permission of the American Heart Association, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_29_29150=[""].join("\n");
var outline_f28_29_29150=null;
var title_f28_29_29151="Sigmoid loops examples";
var content_f28_29_29151=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75180&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Magnetic 3-D imaging colonoscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Examples of common and uncommon sigmoid loops seen during colonoscopy (AP views). (A) Intubation to the mid-descending colon with a sigmoid 'N' spiral loop. (B) Sigmoid alpha loop with endoscope inserted to splenic flexure. (C) (Atypical) Reverse alpha loop with endoscope tip in descending colon. (D) Atypical counter-clockwise (reverse sigmoid) spiral loop with the endoscope tip in the proximal sigmoid colon. (E) Complex sigmoid spiral loop with endoscope inserted to the proximal sigmoid colon.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher B Williams BM, FRCP, FRCS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_29_29151=[""].join("\n");
var outline_f28_29_29151=null;
